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Abstract 
 
The spreading of bacterial resistance is promoting global research efforts toward the 
development of new therapeutic alternatives. Antivirulence therapy seems to be a 
valid, new avenue for discovering innovative medicines. In this context, anti-adhesive 
drugs, which block the first step of bacterial colonization of the host’s tissues are 
particularly attractive, as they do not kill the pathogens, and thus do not contribute to 
the selection of resistant strains. 
 
Urinary tract infections (UTIs) are among the most frequent reasons for antibiotic 
intake, thus playing a pivotal role in spreading bacterial resistance. Moreover, their 
recurrent nature reduces consistently patient’s quality of life. As the most common 
pathogen involved in UTIs is E. coli (about 80% in otherwise healthy patients), an 
anti-adhesive therapy against it would be highly valuable. E. coli uses filamentous 
structures called pili to adhere to the host’s tissues. In UTIs concerning the lower 
urinary tract (cystitis), type 1 pili are mainly involved. At the tip of type 1 pili, the 
lectin FimH is expressed, which recognizes mannosylated glycoproteins, abundant in 
the urinary bladder. A large body of literature is dedicated to antagonizing FimH. 
Despite nanomolar antagonists have been long discovered, suitable clinical candidates 
are lacking. One important determinant for a successful drug is the target occupancy 
time. Using surface plasmon resonance, we demonstrated that our lead structures have 
excellent kinetic profiles, when tested against the FimH lectin domain (paper 1). 
However, one crucial limiting factor was the poor pharmacokinetic profile of these 
antagonists. We therefore successfully tailored the physicochemical properties of a set 
of promising lead structures (paper 2).  
 
In order to support therapy, a detection system for FimH-expressing E. coli is of great 
importance. Biosensors offer several advantages, including reliability, low cost, and 
ease of use. Using a FimH antagonist as recognition element and FimH as analyte, we 
developed a FimH sensitive biosensor, providing the first proof of concept of label-
free detection of a pathologically relevant protein, by field-effect, silicon 
nanoribbons-based sensors (SiNR-BioFET, paper 4).  
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However, most research efforts have until very recently focused on the isolated lectin 
domain of FimH, which exists in a high-affinity state. To finally clarify if the high-
affinity state is the appropriate therapeutic target, a study based on crystallography, 
molecular dynamics, and kinetics was undertaken on the full-length FimH protein, 
which exists prevalently in a low-affinity state (paper 3). The results support the use 
of the full-length protein as the most appropriate model for anti-adhesive therapy, thus 
opening a completely new research path for medicinal chemistry studies. 
 
In UTIs involving the human upper urinary tract (pyelonephritis), E. coli type P pili 
have been shown to play an important role. The adhesive properties of these pili arise 
from the PapG-II adhesin, which recognizes the tetrasaccharide epitope of tetraosyl 
galactosyl globosides (GbO4). Although the incidence of upper UTIs as compared to 
cystitis is rather low, the risk of serious organ damage is high. Moreover, the 
increasing frequency of resistant strains requires new therapeutic alternatives. 
Medicinal chemistry has so far focused on the modification of the minimal binding 
epitope, i.e. Galα(14)Gal. However, the best published lead compound exhibits 
affinity only in the mid-micromolar range. Based on a critical analysis of the present 
literature on antagonists of PapG-II and of the closely related PapG-I, a new, not yet 
explored sub-binding site was identified and explored. Disappointingly, no 
improvement in affinity could be achieved (chapter 3.2.2), confirming the challenging 
nature of the target. 
 
Fragment-based approaches have been shown to have a great potential for hard-to-
drug targets. In our group, second-site ligand search using fragments had been 
successfully applied on other lectin targets. The same strategy was applied to PapG-II, 
albeit with scarce success (manuscript 1).  
 
The observation that the hexasaccharide epitope of the sialosyl galactosyl globoside 
shows 5-fold increased affinity for PapG-II as compared to the epitope of GbO4, from 
which it differs by an added disaccharid units at the non-reducing end, led us to study 
the details of the interaction. Crystallographic and thermodynamic investigations 
suggested that the improvement in affinity arises from an entropic contribution, due to 
the non-binding, terminal saccharidic units (paper 5). 
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The data collected during the development of this thesis added important information 
on PapG-II and will assist further medicinal chemistry research toward the 
development of high-affinity antagonists. 
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DIPEA   Diisopropylethylamine 
DMAP 4-(Dimethylamino)pyridine 
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DME Dimethoxyethane 
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DMSO  Dimethylsulfoxide 
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DPBS Dulbecco’s phosphate buffer saline 
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DSE Donor-strand Exchange 
EA Ethanolamine 
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ELSD Evaporative light scattering 
EM Electron microscope 
ESI-MS   Electrospray ionization mass spectrometry 
Et2O Diethyl ether 
EtOAc Ethyl acetate 
EtOH Ethanol 
FBDD Fragment-based drug design 
FBS Fetal bovine serum 
FCS Fetal calf serum 
FET Field effect transistor 
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FP Fluorescence polarization 
FSC Forward scatter 
Gal   D-galactose 
GalNAc  D-N-acetylgalactosamine 
GbO3 Globotriasyl ceramide 
GbO4 Globotetraosyl ceramide 
GbO5 Globopentaosyl ceramide 
Glc  D-glucose 
HBTU N,N,N’,N’-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HEPESd18 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid-d18 
HIV Human immunodeficiency virus 
HM Heptyl α-D-mannoside 
HMBC Heteronuclear multiple-bond correlation 
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HPLC High performance liquid chromatography 
HSQC  Heteronuclear single quantum coherence 
IBC Intracellular bacterial colony 
IC50 Median inhibition cocentration 
IPGT Isopropyl β-D-thiogalactopyranoside 
ISFET Ion-sensitive field effect transistor 
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MAC90 Minimal antiadhesion concentration to inhibit 90% adhesion 
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NMR Nuclear magnetic resonance 
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OD600 Optical Density at 600 nm 
PAA Polyacrylamide 
PAMPA Parallel artificial membrane permeation assay 
PapG-IILD Lectin domain of PapG-II protein 
Papp Apparent permeability 
PBS Phosphate buffer saline 
PD Pharmacodynamic 
Pd/C Palladium on charcoal 
PDB Protein data bank 
PDMS Polydimethylsiloxane 
PE Petrol ether 
Pe Effective permeability 
PEG Polyethylene glycol 
PK Pharmacokinetic 
PMB 4-Methoxybenzyl 
Po Per os 
PPB Plasma protein binding 
PRE Paramagnetic relaxation enhancement 
PTFE Polytetrafluoroethylene 
PyBOP (Benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate) 
QSAR Quantitative structure-activity relationship 
r.t. Room temperature 
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RLM Rat liver microsomes 
RP-C18 Reverse phase silica gel 
SAM Self-assembled monolayer 
SAR Structure-activity relationship 
Satd Saturated 
SBDD Structure-based drug design 
Sc Subcutaneous 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SGG Sialosyl galactosyl globoside 
SiNR Silicon nanoribbons 
SiNW Silicon nanowire 
SMX Sulfamethoxazole 
SNR Signal-to-noise ratio 
SOI Silicon on insulator 
SPR Surface plasmon resonance 
SSC Side scatter 
STD Saturation transfer difference spectroscopy 
t1/2 Half-life 
TBABr Tetrabutylammonium bromide 
TBAF Tetrabutylammonium fluoride 
TBDMS tert-Butyldimethylsilyl 
TBDPSCl tert-Butyldiphenylsilyl Chloride 
TCR T-cell Receptor 
TEER Transepitelial electrical resistance 
TEMPO 2,2,6,6-Tetramethylpiperidine-N-oxyl 
TEMPO-COOH 4-Carboxy-2,2,6,6-tetramethylpiperidine-1-oxyl 
TFA Trifluoroacetic acid 
TfN3 Trifluoromethanesulfonyl azide 
THF Tetrahydrofuran 
TLC Thin layer chromatography 
TMAH Tetramethylammonium hydroxide 
TMP Trimethoprim 
TMS Trimethylsilyl 
TMSOTf Trimethylsilyl trifluoromethanesulfonate 
TOCSY Total correlation spectroscopy 
Triflyl Trifluoromethanesulfonyl 
Tris 2-Amino-2-(hydroxymethyl)-1,3-propanediol 
TsOH/pTsOH p-Toluene sulfonic acid 
TSPd4 2,2,3,3-Tetradeutero 3-(Trimethylsilyl)propionic acid sodium salt 
UPEC Uropathogenic Escherichia coli 
UPIa Uroplakin Ia 
UTI Urinary tract infection 
UV Ultraviolet light 
Vz Volume of distribution in terminal phase 
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1.1   Introduction 
 
The urinary tract infections (UTI) are among the most common bacterial infections 
and are classified as lower or upper, depending on the affected organs (urethra and the 
urinary bladder or the kidneys), and either as uncomplicated or complicated. 
Uncomplicated UTIs concern non-pregnant, non-instrumented hosts, without 
structural or functional abnormalities of the urinary tract. All other UTIs are 
considered complicated [1].  
UTIs affect prevalently women. It was estimated that about 60% of all women 
experience a UTI, with 5% of them suffering recurrent episodes at some point during 
their life [2,3]. Among young women with a first UTI, 21% suffer a second infection 
within 6 months [4]. In men, UTIs are most often associated with other comorbidities 
or abnormalities [5]. Most UTIs resolve within a few days and are rarely associated 
with long-term sequelae [6-8]. However, the very high incidence and the propensity to 
recur result in very high annual direct and indirect costs (1.6 billion dollars only in the 
USA, in 1995 [3]). Moreover, the recurrence in some patients contributes importantly 
to the reduction of life quality.  
The most common cause of uncomplicated UTI are uropathogenic E. coli (UPEC), 
which in otherwise healthy women aged 18-39 years accounts for 80% of infections 
[9]. Complicated UTIs are caused by a broader spectrum of microorganism, due to 
host factors that can allow less virulent organisms to colonize the urinary tract [10].  
Common ways to induce a UTI are the movement of pathogens from the gut [11] or 
vagina [10] to the urethra, sexual direct or indirect transmission, and at least in case of 
nosocomial infections, contact with contaminated surfaces (e.g. personnel’s hands) 
[1,12]. Some studies suggest the possibility of water, food or person-to-person 
transmission during travels [13]. 
The treatment of UTIs relies intensively on antibiotics [1]. Due to the very high 
incidence, acute uncomplicated cystitis is still the most common reason for antibiotic 
prescription [14-16]. Considering also the recurrent nature of UTIs, it is not surprising 
that their treatment plays an important role in selecting resistant organisms, not only 
among uropathogenic ones, but also in the normal macrobiota [17,18]. 
1.1   Introduction 
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Despite the rather large arsenal of antibiotics, the rapid spread of resistance requires 
innovative solutions [19,20]. Vaccines are emerging as a viable alternative, although 
hurdles as pathogens heterogeneity and low immunogenicity have to be addressed. A 
different and appealing strategy involves the inhibition of pathogen’s adhesion to the 
host. Uropathogenic E. coli adhere to target tissues thanks to organelles called pili 
[21]. Type 1 pili, expressing the FimH adhesin, are playing a crucial role in bladder 
invasion [22] whereas the P pili, expressing the PapG adhesin are highly correlated 
with kidney infections [23-26]. Therefore, two promising therapeutic strategies are 
currently under development, namely the inhibition of pilus biogenesis with small 
molecules (pilicides) [27-30], and the inhibition of the pilus adhesive properties 
(antiadhesives) [31].  
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2.1 Introduction 
 
2.1.1 Infection Cycle 
 
The infection cycle has been characterized in animal models of UTI and in human 
tissue [32,33]. The type 1 pili, expressed in almost every isolate from patients with a 
UTI [34], are involved in the initial step of the infection. They bind to mannosylated 
glycoproteins on the surface of the bladder epithelium. The main receptor in humans 
is uroplakin-Ia (UPIa) [35]. The strong adhesion to the epithelium prevents bacteria 
from being washed off by the urine flow and is followed by invasion of the urothelial 
cells [36]. Once inside the cells, bacteria start to replicate and form intracellular 
bacterial communities (IBCs), biofilm-like structures that protect them from the host’s 
immune response [32]. Although cell-death and exfoliation reduce the number of 
infecting bacteria, this mechanism also leaves uncovered the immature cells in the 
deeper layers of the urothelium, which can also be invaded [32].  
After sufficient maturation 
the IBCs can evade from the 
cells and further disseminate 
infective bacteria. Single rod-
shaped cells as well as 
filamentous colonies are 
released [36]. Part of the 
bacteria form quiescent 
colonies - intrinsically less 
sensitive to antibiotics - that 
are probably responsible for 
recurrent infections (figure 1) 
[36]. 
Figure 1. The infection cycle of uropathogenic E. coli in the 
urinary bladder (adopted from ref. [103] with permission). 
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2.1.2 Type 1 pilus 
 
The type 1 pilus (fimbria) is a highly 
specialized and efficient adhesion 
organelle. On their surface, bacteria 
commonly bear 200 to 500 type 1 
pili [37]. From a structural point of 
view, a pilus is composed of a rod 
and a tip fibrillum; the former 
consists of 500-3000 copies of the 
protein FimA arranged in a right-
handed helix, the latter of one copy 
of the protein FimH and several 
copies of the subunits FimG and 
FimF. The whole structure measures 
about 7 nm in diameter and 1-2 µm 
in length  (figure 2) [38,39]. The 
type-1 pilus biogenesis follows the 
chaperone/usher pathway [40-43]. Each subunit shows an incomplete 
immunoglobuline-like fold (the so-called “pilin” fold), in which the 7th, C-terminal β-
sheet is missing, leaving a hydrophobic pocket uncovered. In the assembled pilus, this 
space is filled by the N-terminal domain (Nte) of the following subunit [42], in a 
process called Donor Strand Complementation (DSC) [44,45]. The whole process of 
pilus assembly has been recently reviewed [43].  
 
 
2.1.3 FimH Adhesin 
 
The FimH adhesin at the tip of type 1 pili is responsible for the adhesion to the host’s 
tissues [46]. It consists of two domains presenting Ig-like folds, the so-called lectin 
domain and pilin domain (figure 3).  
 
Figure 2. Representation of the type 1 pilus and its 
assembly. Top part: assembled pilus. Bottom part: 
chaperone-usher machinery (adopted from ref. [39] 
with permission). 
2.1 Introduction 
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FimH pilin domain 
FimC 
FimH lectin domain 
α-D-mannose 
The former is responsible for the adhesive properties; the latter connects FimH to the 
FimG subunit [45].  
The crystal structure of the FimH:FimC 
complex was published in 1999 [45], and 
shortly after the first FimH:FimC:manno-
side complex, which furnished valuable 
information on the binding site [47]. FimC 
was necessary to keep FimH in the active 
conformation. A step forward was made 
when the lectin domain of FimH alone — 
a truncated version of FimH locked in the 
high-affinity state — was crystallized 
[48], facilitating the discovery of high-
affinity antagonists.  
The main natural target of FimH in the 
human urinary tract are uroplakins, 
especially UPIa [35,49], on which a 
heterogeneous pattern composed of 
moieties ranging from Man6GlcNAc2 to Man9GlcNAc2 residues was evidenced [35]. 
Other targets are the surface-expressed integrins α3 and β1 [50,51], and the Tamm-
Horsfall protein (THP) [52], also decorated with high-mannose glycans. The latter is a 
soluble glycoprotein, which acts as a natural antagonist of FimH [53,54]. 
The FimH adhesin is able to increase its affinity for mannosylated substrates under 
tensile mechanical force [55], a property called “catch-bond” behavior [56]. The 
details of the allosteric regulation mechanism were recently disclosed by solving the 
crystal structure of the full-length FimH protein in the context of the whole fimbrial 
tip [57].  
The majority of E. coli expresses low-affinity FimH adhesins presenting catch-bond 
behavior, suggesting an evolutionary advantage [58]. Probably this property favors 
rapid host colonization and bacterial survival. It was suggested that in fact low-
affinity variants could be resistant to soluble antagonists [59] and able to colonize 
surfaces more rapidly [60]. 
Figure 3. Crystal structure of the 
FimH:FimC:mannose  ternary complex (PDB 
code 1KLF) [47]. FimH is represented in green, 
FimC in orchid. The mannose is depicted in 
sticks, with oxygen atoms in red and carbon 
atoms in gray. 
2.1.4 FimH antagonists 
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2.1.4 FimH antagonists 
 
The idea of blocking the interaction between the FimH adhesin and its natural target 
inspired a number of medicinal chemistry studies. Owing to the relatively high 
affinity (millimolar–micromolar range) of the rather simple methyl α-D-mannoside 
for FimH [48,61,62], most efforts were directed towards the modification of the 
aglycone part. Already in the 1980s, aromatic aglycones were known to enhance the 
inhibitory potency of mannose on yeast agglutination by E. coli, by a factor of 400 to 
1000 [63]. In 2005, Bouckaert et al. reported the 5 nM antagonist n-heptyl 
mannopyranoside [48]. Later, the higher potential of mannopyranosides with 
extended aromatic portions was recognized [64], resulting in a number of biphenyl 
[64-66], indolinylphenyl [67], and squaric acid derivatives [68-70].
 
  
2.1.5 Fluorescence Polarization 
 
The first report on fluorescence polarization in liquid samples was published by 
Perrin in 1926 [71]. When polarized light is passed through a solution of a fluorescent 
molecule, the solution emits only partially polarized light. The depolarization is due 
to a number of factors, mainly rotational diffusion and fluorescence lifetime. 
Molecules with high rotational diffusion during the lifetime of the fluorescence will 
lose polarization faster. It follows that small and flexible molecules will experience 
more depolarization than larger and stiffer ones [72]. The polarization P is expressed 
as: 
 
P = ୍∥ି఼୍
୍∥ା఼୍
      eq. 1 
 
The measured polarization is related to the tumbling of the fluorescent molecules in 
solution and can be used to determine interactions of small ligands with large 
receptors. A fluorescent small molecule probe in solution exhibits low polarization 
value. Upon binding to a macromolecular target (i.e. a protein), the value increases, as 
2.1 Introduction 
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a consequence of the slower tumbling. A great advantage of FP over other traditional 
binding assays (radiolabeling, ELISA, etc.) is that no separation step and no 
immobilization is needed. The measurement is done at the equilibrium, the crucial 
parameter being the fraction of fluorescent ligand bound to the target. The 
mathematical resolution of free from bound fluorescent probe was derived by Weber 
in 1952 [73], based on the additivity of the polarization of different species: 
 
ቀ ଵ
୔౥ౘ౩
− ଵ
ଷ
ቁ
ିଵ
=  ∑ f୧ ቀ
ଵ
୔౟
− ଵ
ଷ
ቁ
ିଵ
      eq. 2 
 
However, changes in the intensity of the fluorescence emitted by the fluorophore in 
the free and bound states must be corrected by the term ℊ, as in equation 3 [74]: 
fୠ =  
(ଷି୔ౘ)(୔౥ౘ౩ି୔౜)
(ଷି୔౥ౘ౩)(୔ౘି୔౜)ା(ℊିଵ)(ଷି୔౜)(୔ౘି୔౥ౘ౩)
      eq. 3 
The value for fb can then be used to obtain the KD for the ligand:target interaction:  
 
fୠ =
[୔୰୭୲ୣ୧୬]
[୔୰୭୲ୣ୧୬]ା୏ీ
            eq. 4 
A plot of fb vs. concentration of protein can be fitted with equation 4. The FP 
measurement can be designed as competitive binding assay, in which a known 
fluorescently-labeled molecule is titrated with a competitor ligand [75,76]. The 
obvious advantage lies in the possibility to screen a number of competitors with a 
single fluorescently-labeled, known binder. Thanks to the improvements in 
instrumentation, FP assays are now widely applied in medicinal chemistry and life 
sciences, and offer the advantages of high-throughput, homogeneity (“mix and 
measure assay”), automation, reliability, reproducibility [72]. Because of that, we 
envisioned the application of a competitive FP assay for screening FimH antagonists  
[75]. For the establishment of a competitive FP assay, several parameters must be 
considered.  
2.1.5.1 Probe design 
The establishment of a competitive FP assay starts from the design of a suitable 
fluorescently-labeled binder. First of all, the fluorescent lifetime τ must be long 
enough for observing a difference between bound and free states (equation 5) [72]. 
ଵ
୔
− ଵ
ଷ
= ቀ ଵ
୔బ
− ଵ
ଷ
ቁ ቀ1 + ଷத
஡
ቁ          eq. 5 
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Secondly, the fluorescent probe should not retain too much flexibility when bound to 
the test molecule, because residual local motion results in lower polarization. In the 
case of a competitive FP assay, the probe must be linked to a known binder, without 
changing its binding mode and ideally without influencing the affinity [72,77]. 
Moreover, neither the linking, nor the complex formation with the target should result 
in complete fluorescence quenching.  
2.1.5.2 Assay design 
After a suitable reporter compound has been designed, appropriate assay conditions 
have to be identified. This involves finding the proper probe and protein 
concentrations, buffer composition, plate type, etc. [76,77]. In general, it is important 
that the probe concentration does not exceed too much 2KD, to avoid stoichiometric 
titration, and that the fraction of bound probe is in the range 0.5-0.8 [76]. 
The assay we developed for the screening of FimH antagonist is detailed in paper 2. 
 
 
2.1.6 Nanowires-based Field-Effect Biosensors 
 
The sensitive and specific detection and quantification of biological and chemical 
species are crucial in a number of fields, including research in life science, healthcare, 
and medicinal chemistry. Most standard techniques involve optical readouts of 
fluorescently-labeled analytes [78,79]. As this commonly involves sample 
manipulation and often target labeling, i.e. a chemical modification that could 
influence target’s properties, these methods are not ideal [80].  
An alternative approach is the use of biosensors [81], devices that are “capable of 
providing specific quantitative or semi-quantitative information using a biological 
recognition element retained in direct spatial contact with an electrochemical 
transduction element” [82]. Field-effect based biosensors (BioFETs) based on silicon 
nanowires are promising tools for label-free detection of biomolecules, as they have 
shown high sensitivity and scalability. Thanks to the recent advances in the 
fabrication processes, device characteristics can be controlled at the micro/nano-scale, 
thus achieving multiplexing and selective addressing. Analytical devices relying on 
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this technology could perform point-of-care multicomponent analysis with minimal 
sample consumption.  
A BioFET consists of the following parts: a source (S), a drain (D), and a channel 
connecting S and D, composed of doped semiconducting materials (traditionally, S 
and D have opposite doping than the channel, but this is not always the case, as 
shown in manuscript 2); a gate insulator covering the channel and composed of SiO2, 
Si3N4, Al2O3, or other insulating materials, which contacts the liquid sample; a gating 
circuit, connected to a reference electrode; a functionalization layer, consisting of a 
biomolecule and interacting with the analyte [83]. A BioFET is therefore conceptually 
an ion-sensitive field-effect transistor (ISFET) interfaced with a biomolecule that 
recognizes biological analytes. In an ISFET, when a sufficient voltage is applied to 
the gate, an inversion layer is induced in the channel, thus influencing its conductance 
and therefore the current flowing from S to D (figure 4). The presence of charges 
close to the surface can modify the surface potential (and consequently the number of 
charge transporters in the inversion layer), generating a measurable electric signal. It 
follows that every (bio-)chemical reaction that modifies the charges at the interface 
gate oxide/liquid sample can in theory be measured by an ISFET interfaced with a 
bioreceptor. Many examples of BioFETs are described in literature, ranging from 
enzyme- (EnFET) to antibody-modified sensors (ImmunoFET), and from DNA- 
(GenFET) to cell- and even beetle-modified ones [83]. More recently, sensors based 
on nano-sized structures, such as nanowires [84] (SiNW-BioFET) and nanoribbons 
[85] (SiNR-BioFET) have been produced. The main advantages of this new 
generation of sensors are the readily conceivable massive production [86], the ultra-
high sensitivity, and the possibility of multiplexing [87-90]. Real-time and label-free 
detection of DNA [91-94], RNA [95], proteins [96] (including cancer markers [97]), 
and viruses [98,99] has been demonstrated.  
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Figure 4. The schemes of a pH-sensitive ISFET (A) and a BioFET (B) with n-type channels and p-type 
source and drain are depicted, working in inversion mode. The binding of positively charged species 
reduces the number of charge carriers, thus reducing the conductance (A). Negatively charged species 
have opposite effect (B). 
 
So far, studies on quantifying binding affinities and kinetic data have primarily 
focused on DNA [91] and biotin-streptavidin interactions [100]. However, as a model 
system for protein-small molecule interactions and for the benchmarking of the limit 
of detection (LOD), the use of the biotin-streptavidin pair is questionable, due to the 
extremely strong binding (dissociation constant KD ≈ 10−14 M, one of the strongest 
non-covalent interactions known in nature) [101].  
In our work (manuscript 2), we demonstrate real-time, label-free detection of the 
clinically relevant protein FimH with gold-coated silicon nanoribbons (SiNR). SiNR 
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are easier than SiNW to produce and have shown comparable sensitivity [85]. Our 
results are an important step toward the study of protein-ligand interactions by FET 
nanosensors, and demonstrate that SiNR-BioFETs are excellent candidates to 
compete with surface plasmon resonance, the golden standard for such application 
[102]. 
 
 
2.1.7 Aims of this Project 
 
This project is aiming at the development of FimH antagonists with excellent 
pharmacodynamic and pharmacokinetic profiles for treating UTIs in humans. This 
thesis’ aims in the context of this project were: 1) the contribution to the kinetic 
characterization of FimH interaction with FimH antagonists (paper 1); 2) the design 
of a fluorescently-labeled compound with suitable properties for FP-based high-
throughput screening of new FimH antagonists (paper 2) and which was used for the 
characterization of FimH high- and low-affinity states (paper 3); 3) the demonstration 
of the proof-of-concept of direct protein measurement on nanoribbons-based sensors, 
using FimH as analyte and a FimH antagonist as recognition element (paper 4).  
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2.2.1 Outline 
 
For a successful therapeutic application of FimH antagonists, several parameters have 
to be adjusted, among them the receptor occupancy time is of paramount importance. 
By means of surface plasmon resonance experiments, the dissociation rate constants 
koff for biphenyl and indolyl α-D-mannosides were measured. The unexpectedly long 
occupancy times for all tested compounds suggest a high potential for in vivo 
treatment of UTIs (paper 1). However, the pharmacokinetic profiles of these 
molecules were not optimal. In fact, for oral treatment good water solubility, 
permeability, and limited first-pass metabolism are very important. Moreover, in 
order to reach the target renal excretion of the non-metabolized molecule must also be 
achieved. By applying bioisosteric substitutions on the lead compounds 1 and 2, a 
suitable candidate was developed (compound 3), which demonstrated high efficacy in 
an in vivo model of UTI (paper 2). 
 
 
Figure 1. Structures of the lead compounds that were modified by bioisosteric substitutions of the 
carboxy group (compounds 1 and 2) and of the optimized candidate (compound 3). 
 
The FimH protein exists in different affinity stages. Very promising results from our 
and other groups in targeting FimH were generated studying a truncated version of the 
FimH protein (FimHLD) as a model system, which exists only in high affinity state. 
However, more studies were needed to understand which affinity state is the most 
therapeutically relevant in vivo. With the help of crystallographic and kinetic data, 
molecular dynamic simulations, and cell-tracking experiments we confirmed that the 
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low affinity state is the most relevant target for medicinal chemistry (paper 3), thus 
opening a new avenue for the development of FimH antagonists.  
 
However, the FimHLD is an excellent study system for long-lived interactions 
involving carbohydrates. Moreover, FimH represents a pathologically relevant 
protein. The available compound 2 and FimHLD were selected as a model for the 
development of a label-free protein detection system based on silicon nanoribbons 
configured as field-effect transistors (SiNR-BioFET). In this area most research had 
focused so far on biotin-streptavidin as a model system, a rather questionable choice, 
due to the extremely low KD. Our results constitute the first successful proof-of-
concept for the detection of a pathologically relevant protein by SiNR-BioFETs 
(paper 4). 
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2.2.2 Paper 1  
Kinetic Properties of Carbohydrate–Lectin Interactions: FimH 
Antagonists 
 
 
This paper describes the kinetic characterization of FimH antagonists. The binding to 
FimH of a set of biphenyl and indolyl α-D-mannosides was measured by surface 
plasmon resonance. The results highlighted the unexpectedly long off-rate constants 
exhibited by the test molecules after binding to the lectin domain of FimH, suggesting 
high potential for in vivo treatment of UTIs. 
 
 
Contribution to the project: 
Giulio Navarra synthesized compounds 2 and 3b. 
 
 
This paper was published in ChemBioChem: 
 
Meike Scharenberg, Xiaohua Jiang, Lijuan Pang, Giulio Navarra, Said Rabbani, 
Florian Binder, Oliver Schwardt, and Beat Ernst 
 
Reprinted with permission from Sharenberg et al. ChemMedChem 2013, 1, 78-83.  
Copyright 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 
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Kinetic Properties of Carbohydrate–Lectin Interactions:
FimH Antagonists
Meike Scharenberg, Xiaohua Jiang, Lijuan Pang, Giulio Navarra, Said Rabbani,
Florian Binder, Oliver Schwardt, and Beat Ernst*[a]
The lectin FimH is terminally expressed on type 1 pili of uropa-
thogenic Escherichia coli (UPEC), which is the main cause of uri-
nary tract infections (UTIs). FimH enables bacterial adhesion to
urothelial cells, the initial step of infection. Various mannose
derivatives have been shown to antagonize FimH and are
therefore considered to be promising therapeutic agents for
the treatment of UTIs. As part of the preclinical development
process, when the kinetic properties of FimH antagonists were
examined by surface plasmon resonance, extremely low disso-
ciation rates (koff) were found, which is uncommon for carbohy-
drate–lectin interactions. As a consequence, the corresponding
half-lives (t1/2) of the FimH antagonist complexes are above
3.6 h. For a therapeutic application, extended t1/2 values are
a prerequisite for success, since the target occupancy time di-
rectly influences the in vivo drug efficacy. The long t1/2 value of
the tested FimH antagonists further confirms their drug-like
properties and their high therapeut ic potential.
Urinary tract infections (UTIs) are among the most prevalent in-
fections and affect millions of people each year. In 70–95% of
all cases, the UTI is caused by uropathogenic Escherichia coli
(UPEC).[1] These bacteria express type 1 pili with a terminally lo-
cated adhesive protein called FimH. FimH-mediated adhesion
to the surface of urothelial cells by binding to oligomannoside
residues of the glycoprotein uroplakin Ia (UPIa)[2–5] is a prerequi-
site for the invasion of the host cells leading to a UTI.[2,3] There-
fore, efforts have been made to identify orally available FimH
antagonists to interfere with the attachment of UPEC to uro-
thelial cells. From these studies, a-d-mannopyranosides have
emerged providing a novel therapeutic opportunity for pre-
vention and treatment of UTIs as an alternative to antibiot-
ics.[6–8] To date, several mannose-based FimH antagonists have
been validated in various in vitro and in vivo studies.[9–20]
As part of their pharmacodynamic characterization, not only
equilibrium dissociation constants (KD) or half-maximal inhibito-
ry concentrations (IC50) but also the kinetics of the binding pro-
cess are studied.[21–23] One crucial factor for a sustained in vivo
efficacy is the half-life (t1/2) of the drug–receptor complex, es-
pecially when drugs compete with endogenous ligands.
The t1/2 of a drug–receptor complex depends on the dissoci-
ation rate (koff). Slow off-rates are beneficial for the in vivo effi-
cacy, as prolonged occupancy of the target by the drug results
in an extended duration of the pharmacological effect. Conse-
quently, lower drug concentrations are required to obtain high
efficacy, decreasing the risk of off-target toxicity.[21–23] The im-
portance of long target occupancy is reflected in the long t1/2
of many drugs reaching the market, such as the HIV-1 protease
inhibitor Darunavir (t1/2> 240 h),[24] the CCR5 receptor antago-
nist Maraviroc (t1/2= 10.5 h),[25] or the viral neuraminidase inhib-
itor Zanamivir (t1/2> 33 min), which was developed from a car-
bohydrate-based lead structure.[26]
For carbohydrate–lectin interactions, only a few studies de-
scribing the kinetic properties are available. For the lectins,
myelin-associated glycoprotein (MAG),[27,28] E-, L- and P-selec-
tin,[29–31] galectin-1 and -3,[32] mannose-binding protein
(MBP),[33] concanavalin A (ConA),[34] and calreticulin[35] surface
plasmon resonance (SPR) experiments revealed fast association
and dissociation kinetics with koff rates between 2.6” 10 3 and
> 10 s 1, resulting in short t1/2 values ranging from 266 to
0.07 seconds (Table 1). These fast binding kinetics, typical for
carbohydrate–lectin interactions, strongly hamper the develop-
ment of carbohydrate-derived drugs. The determination of the
kinetic parameters of FimH antagonists is therefore of utmost
importance for successful lead optimization.
Beside KD values, dissociation rates (koff) of the complex be-
tween the antagonist and the target protein FimH are of spe-
cial interest. To study these parameters, SPR is widely applied,
including for carbohydrate–lectin[37] and carbohydrate–anti-
body[36] interactions. For the lectin domain of FimH, different
affinity states are known.[38] In this study, the lectin domain in
the high-affinity state was used.[39] Immobilization attempts by
standard amine coupling failed, presumably due to accessible
amino groups in and close to the ligand binding site. Thus, the
N-terminal phenylalanine is part of the binding site. Immobili-
zation via a C-terminal His-tag onto a nickel(II)–nitrilotriacetate
(Ni-NTA) chip or indirect coupling via an anti-His-tag antibody
failed due to instability of the base line, resulting from a slow
detachment of the noncovalently immobilized FimH. Further-
more, harsh regenerating condit ions (50 mm NaOH), necessary
for the dissociation of the antagonist–lectin complex, caused
the inactivation of the protein. Consequently, we immobilized
FimH antagonists functionalized with an amino- (1 and 2) or
N-hydroxy- (3a,b) succinimide via an amine-coupling proce-
dure on CM4 dextran sensor surface chips (Scheme 1).
To determine the kinetic parameters of the FimH–antagonist
interaction, a direct binding assay was performed. FimH was
[a] Dr. M. Scharenberg, Dr. X. Jiang, L. Pang, G. Navarra, Dr. S. Rabbani,
Dr. F. Binder, Dr. O. Schwardt, Prof. Dr. B. Ernst
Institute of Molecular Pharmacy, Pharmacenter, Universit y of Basel
Klingelbergstrasse 50, 4056 Basel (Switzerland)
E-mail : beat.ernst@unibas.ch
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cmdc.201300349.
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passed at concentrations be-
tween 0–200 nm over the flow
cells (CM4 chip) equipped with
covalently linked antagonists
(Figure 1a). A reference cell
without antagonist but treated
with N-hydroxysuccinimide
(NHS)/N-(3-dimethylaminoprop-
yl)-N-ethylcarbodiimide hydro-
chloride (EDC) and ethanolamine
(EA) was used to account for
nonspecific binding of the pro-
tein to the dextran matrix. The
kinetic parameters kon and koff
were obtained by applying
a global fit to the sensorgrams,
using a 1:1 (Langmuir-type)
binding-model (Scrubber 2.0c).
The fitted sensorgrams of com-
pounds 1, 2, 3a and 3b are
shown in Figure 1b.
Mass transfer limitations,
which might occur when using
proteins as analytes (FimH:
MW= 18.6 kD), can falsify the
measured kinetic parameters.
They depend on the cell dimen-
sion, the flow rate, and the diffu-
sion coefficient of the analyte.
Proteins having smaller diffusion
coefficients than low-molecular-
weight compounds are prone to
show mass transfer limitations.
To rule out these limitations, we
used high flow rates (20–
30 mLmin 1) and a low surface
antagonist density (usage of
CM4 chips instead of CM5
chips). Furthermore, we immobi-
lized antagonist 1 at three differ-
ent immobilization levels (differ-
Table 1. Typical kinetic binding parameters of carbohydrate–protein interact ions.
Protein Ligand KD [mM] kon [m 1/s 1] koff [s 1] t1/2 [s] Ref.
L-selectin GlyCAM1 108 > 105 > 10 0.07 [30]
E-selectin ESL 1 62 4” 104 3.0 0.2 [29]
P-selectin PSGL 1 0.3 4” 106 1.4 0.5 [31]
GSLA-2 mAB sialyl Lewisa 4.3 1.1” 105 8” 10 1 0.9 [36]
MAG d-Neu5Ac derivative 2.8 3.5” 105 0.8” 10 1 0.9 [27]
Galectin-1 d-Lactose derivative 1010 1.9” 102 2.1” 10 1 3.3 [32]
Galectin-3 d-Lactose derivative 280 7.3” 102 2.0” 10 1 3.4 [32]
CG-1A (avian galectin) d-Lactose derivative 83.5 2.5” 103 2.1” 10 1 3.3 [32]
Calreticulin Glc1Man9-GlcNAc2 2 3.9” 104 8” 10 2 8.6 [35]
Con A d-Man derivative 65 1.43” 102 9.4” 10 3 73.7 [34]
MBP d-Man16/BSA 13.3 3.47” 104 2.6” 10 3 266.6 [33]
Abbreviations: myelin-associated glycoprotein (MAG); concanavalin A (Con A); mannose-binding protein (MBP).
Scheme 1. Synthesis of the amino- or N-hydroxyl-succinimide-functionalized FimH antagonists 1–3. Reagents and
conditions: a) H2 (1 atm), PtO2, morpholine, EtOAc/MeOH (1:1), RT, 1 h (97%); b) 8-(Fmoc-amino)-3,6-dioxa-octanoic
acid, PyBOP, DIPEA, DMF, RT, overnight ; c) NaOMe, MeOH, RT, 2 h (47% over two steps); d) EBE, COMU, DIPEA,
DMF, 08C! RT, overnight (20%); e) EDC, NHS, H2O, RT, 30 min (3a: 98%); f) EDC, NHS, MES buffer (pH 5.6), RT,
30 min (3b : 99%).
2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 78–83 79
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resulting from off-target toxicity.[21,22] However, carbohydrate–
lectin interactions often exhibit low affinities and fast off-
rates—properties that hamper the development of carbohy-
drate-derived drugs. Therefore, as part of the preclinical devel-
opment process of FimH antagonists, we examined their kinet-
ic characteristics by surface plasmon resonance (SPR). In this
study, the lectin domain of FimH in the high-affinity state was
used. The surprisingly small dissociation rates for FimH–antag-
onist complexes resulting in long t1/2 values in the range of
several hours (> 3.6 h) are indicators for high in vivo efficacy.
This is a further indication that the corresponding ester pro-
drugs not only have a beneficial pharmacokinetic profile,[46]
but also fulfill the pharmacodynamic requirements for thera-
peutic application, that is, high affinity and long residence
time. However, whether the investigated high-affinity state of
FimH investigated in our study[39] is the only pathophysiologi-
cally relevant state remains to be demonstrated. Therefore,
studies with FimH lectin in other affinity states are planned.
Experimental Section
Synthesis: For synthesis and spectroscopic details of antagonists
1, 2 and 3a,b, see the Supporting Information. The synthesis and
characterization of compounds 9–13 are described in Ref. [46] .
Chemical abbreviations used in Scheme 1 and elsewhere: (benzo-
triazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate
(PyBOP), (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylami-
no-morpholino-carbenium hexafluorophosphate (COMU), N,N-diiso-
propylethylamine (DIPEA), N-(3-dimethylaminopropyl)-N-ethylcar-
bodiimide hydrochloride (EDC), 2,2’-(ethylenedioxy)bis(ethylamine)
(EBE), ethanolamine (EA), 2-[4-(2-hydroxyethyl)piperazin-1-yl]etha-
nesulfonic acid (HEPES), N-hydroxysuccinimide (NHS), 2-(N-morpho-
lino)ethanesulfonic acid (MES).
FimH-CRD-6His protein expression : The FimH carbohydrate rec-
ognition domain (CRD) with a thrombin cleavage site linked to
a 6His tag (FimH-CRD-Th-6His) was expressed in E. coli strain
HM125 and purified by affinity chromatography as described by
Rabbani et al.[39]
Surface plasmon resonance (SPR) analysis: SPR measurements
were performed on a Biacore 3000 SPR-based optical biosensor
(Biacore, GE Healthcare, Uppsala, Sweden). Sensor chips (CM4), im-
mobilization kits, maintenance supply and HBS-P buffer were pur-
chased from GE Healthcare (Uppsala). The amino-functionalized
monovalent compounds 1 and 2 were covalently attached to the
activated dextrane matrix on CM4 chips by the standard amine-
coupling method (GEHealthcare, Uppsala). The surface was activat-
ed by NHS and EDC. To obtain different ligand densities on the
chip, compound 1 (1 mm in borate buffer) was mixed with EA (1m)
in different molar ratios prior to the coupling process (1/EA ratios:
1:0, 1:10, and 1:100). Pure compound 2 (1 mm in borate buffer)
was coupled to the chip. After coupling, the matrix was capped
with EA. For the coupling of the N-hydroxy-succinimide-functional-
ized compounds 3 and 4, the free carboxyl groups on the chip
were activated with NHS and EDC and reacted with 1,2-diamino-
ethane (0.1m in borate buffer, pH 8.5) to give free amino groups.
The next steps were followed as described above. A reference cell
without immobilized ligand was prepared and the system equili-
brated with HEPES-buffered saline (HBS)-P buffer (10 mm HEPES,
150 mm NaCl, 0.005% P20, pH 7.4). The activity of the chips was
confirmed by FimH binding at a constant concentration of 50 nm
in HBS-P buffer. All binding experiments were performed at 258C
at a flow rate of 20 or 30 mLmin 1 using HBS-P buffer. For kinetic
studies, a dilution series of FimH with concentrations ranging from
0–200 nm in HBS-P buffer was used. Contact time was 120 s, and
the dissociation time was 1200 s. The surface was regenerated
with a single injection of 50 mm NaOH for 120 s. Data processing
as well as kon, koff, and KD determinations were accomplished with
the Scrubber software (BioLogic Software, Version 2.0c, Campbell,
Australia). Double referencing (subtraction of reference and blank
injection) was applied to correct for bulk effects and other system-
atic artifacts.
In-solution affinity inhibit ion experiments: FimH (10–15 nm in
HBS-P buffer) was inhibited with a series of test compound solu-
tions of increasing concentrations (0–1 mm) overnight at RT to
allow the equilibration of the system. The mixtures were run over
a sensor surface coated with compound 1, and the resonance
units (RU) after an association time of 110 s were detected. The
non-inhibited FimH concentration ([FimHfree]) in the protein–com-
pound mixtures was determined by means of a FimH calibration
curve using free FimH concentrations ranging from 0–120 nm. The
KD values of the compounds were calculated by plotting [FimHfree]
versus [compound] , and fitting the curve with the in-solution affin-
ity fit.
Acknowledgements
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Table 3. KD values of FimH antagonists[46] determined by an in-solution
affinity assay.
Entry Compd R KD [nm][a] rKD[b]
1 8 – 5.21 1.6 1
2 7b Cl 0.71 0.01 0.13
0.5 0.05[c] 0.10[c]
3 9 F 1.63 0.9 0.32
4 10 OCH3 1.08 0.18 0.21
5 11 CH3 0.44 0.22 0.09
6 12 Cyclopropyl 2.19 0.1 0.42
7 13 CF3 1.1 0.34 0.21
[a] Determined on chip 1 (CM4 chip functionalized with compound 1).
Data represent the mean SD of n= 3 independent experiments per-
formed in triplicate. [b] The relative KD (rKD) values were calculated by di-
viding the KD of the antagonist of interest by the KD of n-heptyl a-d-man-
nopyranoside (8). [c] Determined on chip 2 (CM4 chip functionali zed with
compound 2, n= 3).
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2.2.3 Paper 2 
FimH Antagonists: Bioisosteres To Improve the in Vitro and in Vivo 
PK/PD Profile 
 
 
In this paper the optimization of the pharmacokinetic profile of FimH antagonists 
based on the biphenyl α-D-mannoside structure, by means of bioisosteric 
substitutions, is described. For the rapid and reliable evaluation of the binding affinity 
of the new compounds, a fluorescence polarization assay was developed. The 
molecule exhibiting the best parameters for oral administration was tested in an in 
vivo model of UTI and showed high efficacy, reducing the bacterial count in the 
bladder by about 1000-fold.  
 
 
Contribution to the project: 
Giulio Navarra designed, synthesized, and characterized the fluorescent compounds 
22, 23, and 24, and wrote the corresponding parts of the experimental section. 
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sides) to mannose receptors of the human host system have
recently been ruled out.33
The high affinities of the monovalent α-D-mannopyranosides
are based on optimal interactions with the main structural
features of the CRD:34−37 first, the mannose binding pocket
accommodating the mannose moiety by means of an extended
hydrogen bond network and,second, theentranceto thebinding
site composed of three hydrophobic amino acids (Tyr48,
Tyr137, and Ile52) and therefore referred to as “tyrosine gate”
hostingaliphaticandaromaticaglycones.Asanexample,n-heptyl
α-D-mannopyranoside (1) exhibits nanomolar affinity due to
hydrophobiccontactsof thealkyl aglyconewith thehydrophobic
residuesof thetyrosinegate.15 Furthermore, aromatic aglycones,
suchaspresent in mannosides2and3 (Figure1),providestrong
π−πstacking interactionswith thetyrosinegate.Thisinteraction
is further favored by the addition of an electron withdrawing
substituent on theterminal ring of thebiaryl portion (→4).18,19
Recent in vivo PK studiesin miceproved thehigh potential of
the biphenyl α-D-mannosides 5−8 for an oral treatment,
although high doses (≥50 mg/ kg) were necessary to achieve
theminimal concentrationsrequired for theantiadhesiveeffect in
theurinary bladder.19−21 Moreover, the therapeutic effect could
only be maintained for a few hours, i.e., 4 h for a po (per os)
single-dose application of 7 (50 mg/ kg), because of rapid
elimination by glomerular filtration and low reabsorption from
theprimary urine in the renal tubules.20
To date, the physicochemical properties affecting the rate of
renal excretion, i.e., lipophilicity and plasma protein binding
(PPB), or metabolic liabilities promoting nonrenal elimination
pathways have been barely investigated for FimH antagonists.
Thegoal of thepresent study wasto optimizethebiphenyl α-D-
mannoside with respect to oral bioavailability and renal
excretion. Starting from antagonist 919 (Figure 2) , we
synthesized new biphenyl derivatives, characterized their affinity
to the CRD, structurally investigated their binding mode, and
determined physicochemical and pharmacokinetic parameters
predictive for intestinal absorption and renal elimination.
Furthermore, we determined in vivo PK (pharmacokinetics) of
themost promisingnewantagonistsinamousemodel.After oral
administration, the compound with the best PK profile proved
effectivein reducing thebacterial loadsupon bladder infection in
amouse model of UTI.
■RESULTSAND DISCUSSION
Aspreviously reported, thecarboxylatesubstituent present in the
biphenyl mannoside9 (itselectron withdrawing potential being
essential for an enhanced drug target interaction) strongly
decreases the lipophilicity of theantagonist (log D7.4 < −1.519)
in comparison to the n-heptyl (→1, log P = 1.7 19) or the
unsubstituted biphenyl aglycone(→3, logP= 2.122). Since low
lipophilicity is amajor reason for low intestinal absorption and
rapid renal excretion of thesystemically availableantagonist,19,23
we aspired to improve oral bioavailability as well as renal
excretion by replacing the carboxylate in 9 with various
bioisosteric groups39 (Figure 2).
Synthesis. Iodide 11 was prepared from peracetylated
mannose and 4-iodophenol in thepresence of BF3·Et2O.22 In a
palladium-catalyzed Miyaura−Suzuki coupling40 with the
boronic acid or boronate derivatives 12a−g, the biphenyl
derivatives 13a−g were obtained in good to excellent yields.
Final deprotection yielded the test compounds 10a−g. When
microwave-assisted reaction conditions41 were utilized, the
conversion of arylnitrile 13g to tetrazole 14 proceeded rapidly
and with good yield. After deprotection of 14 using Zemplén
conditions, the test compound 10h was obtained (Scheme1).
Thecyanobenzamide derivative10i (Scheme2) wasobtained
from 9 by peracetylation (→15) followed by conversion of the
Figure 1. Monovalent FimH antagonists 1−4 acting asreference compounds and 5−8 which have been orally explored in in vivo disease models.
Figure 2. Bioisosteric replacement of thecarboxylic acid substituent of
biphenyl α-D-mannopyranoside 9.
Journal of Medicinal Chemistry Article
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carboxylic acid into its acid chloride with 1-chloro-N,N,2-
trimethyl-1-propenylamine.42 Without isolation, the acid
chloride was reacted with sodium hydrogen cyanamide in
DMF followed by deacetylation under Zemplén conditions to
yield the test compound 10i.
Finally, to further improve thepharmacokinetic properties of
mannoside 10g18 (see Table 3), a chloride substituent was
introduced to theortho-position of thearomatic ringadjacent to
the anomeric oxygen. For its synthesis, peracetylated α-D-
mannose (16) was coupled with 2-chloro-4-iodophenol (17)
usingBF3·Et2O aspromotor (→18,76%).After theintroduction
of thesecond aromatic ringby Miyaura−Suzuki coupling (→19,
75%), deprotection yielded mannoside 10j (Scheme 3).
Binding Affinity. Thebindingaffinityof heptyl mannoside1,
the biphenyl mannosides 3, 9, 20,18 and the bioisosteres 10a−j
wasdetermined in acompetitive fluorescence polarization assay
(FP assay) and with isothermal titration calorimetry (ITC). A
protein construct consisting of the CRD with aC-terminal His-
tag with a thrombin cleavage site (FimH-CRD-Th-His6) was
used for all experiments.43
Competitive Fluorescence Polarization Assay. For the
rapid evaluation of bindingaffinity, weestablished acompetitive
Scheme 1a
a(a) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C, 4 h (13a−g, 44−99%); (b) NaOMe, MeOH, rt, 4 h (10a−h, 29−86%); (c) TMSN3, Bu2Sn(O),
DME, 150 °C, microwave, 10 min (81%).
Scheme 2a
a(a) (i) Ac2O, DMAP, pyridine, 0 °C to rt, overnight; (ii) sat. NaHCO3 aq, DCM, rt, 2 h (15, 53%); (b) 1-chloro-N,N,2-trimethyl-1-propenylamine,
toluene, 0 °C to rt, 2 h; (c) NaH, NH2CN, DMF, 0 °C to rt, overnight; (d) NaOMe, MeOH, rt, 4 h (10i, 21%for three steps).
Scheme 3a
a(a) BF3·Et2O, CH2Cl2, 40 °C (76%); (b) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C (75%); (c) NaOMe, MeOH, rt, 4 h (48%).
Journal of Medicinal Chemistry Article
DOI:10.1021/jm501524q
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optimal sensitivity and signal-to-noise ratio, three main
parameters need to be considered: (i) the affinity of the
competitor should not be impaired by the fluorescent label; (ii)
the conformational flexibility of the label upon binding of the
competitor to the CRD should be low; (iii) the fluorescence
properties of the label should not be affected by the connected
ligand.46−48Achangein fluorescencepropertieswasobserved for
reporter ligand 22 in which the label was linked to thebiphenyl
agylconeby an amidebond. Theabsorption spectrum revealed a
lack of the characteristic fluorescein absorption peak at 494 nm
(Scheme4), likely dueto an extension of theconjugated system
to the biphenyl moiety of the ligand. The elongated saturated
spacer groups in competitors 23 and 24 ensured that the
expected spectral properties of the dye were retained (Scheme
4).
For the determination of their binding affinity, fixed
concentrationsof thereporter ligands23 and 24 wereincubated
for 24hwithalinear dilutionof theFimH-CRD (0−100nM).FP
was measured using a plate reader, with polarized excitation at
485nmandemission at 528nmmeasured through appropriately
oriented polarizers. Fitting the single-site binding function of
Cooper49 to theobserved FPdataresulted for compound 23 in a
dissociation constant (KD = 1.7nM,Figure3A) similar to that of
the unlabeled parent compound 21,19 whereas 24 showed a 5-
fold lower affinity (9.9nM) (Scheme4). Therefore, thereporter
ligand 23 fulfillsall characteristics asan optimal competitor and
wasused for the FP assay.
For the test compounds 1, 3, 9, 20, and 10a−j, a 24 h
incubation timewasapplied beforeFPwasmeasured becauseof
thelongresidencetimeof FimH antagonists(t1/ 2 > 3.5 h, Figure
3B50).The24hincubation periodwasempirically determined to
be necessary to reach equilibrium between reporter ligand and
compound of interest. IC50 values were obtained by nonlinear
least-squares regression (standard four-parameter dose−re-
sponse curve) and converted to KD values using a modified
Cheng−Prusoff equation.45 This equation accounts for the
ligand depletion effect in competitive titrations involving high-
affinity interaction partners present in similar concentrations.
Under theseconditions, the freeconcentration of an interacting
species cannot be assumed to equal the total concentration.
TheKD valuesdetermined for thetest compounds1, 3, 9, 20,
and 10a−j aresummarized in Table1. Against our expectations,
thebiphenyl mannosides3 and 9 exhibit similar affinities(Table
1), despite thepresence of an electron withdrawing carboxylate
substituent in antagonist 9. According to thecrystal structure of
FimH cocrystallized with thesulfonamidederivative10e(Figure
4A), theouter aromatic ringof thebiphenyl aglyconeformsπ−π
interactions with the electron rich Tyr48, which is part of the
tyrosine gate of FimH.15 A reduction of electron density of the
aglycone by the electron withdrawing carboxylate wasexpected
to enforcetheseπ−πstacking interactions and lead to improved
affinity. However, thisbeneficial effect might becompensated by
an entropic penalty originating from theimproved π−πstacking
toTyr48that might leadto thereduced flexibility of bothprotein
and antagonist. Furthermore, abeneficial enthalpy effect might
bepartially compensated byanenthalpy penaltyoriginatingfrom
the desolvation of the charged carboxylate in 951 (see also
Experimental Section). Although this substituent is solvent
exposed, at least a partial desolvation may be necessary upon
antagonist binding. To prove this assumption, we replaced the
carboxylateby thecorrespondingmethyl ester (→20)18 in order
to reduce the desolvation penalty and, as predicted by the
Hammett constant σp,52 to further improve the π−π stacking.
Table 1. Affinities (KD) of FimH Antagonists to FimH-CRD-
Th-His6b
aThe KD value of 10j was approximated to be in the subnanomolar
range. The IC50 value obtained in the competitive FP assay was equal
to the lowest value that can be resolved by the assay, indicating
stoichiometric titration of 10j due to itshigh affinity. Consequently, its
KD must be below the KD of competitor 23. bDissociation constants
(KD) weredetermined in acompetitive fluorescence polarization assay.
Journal of Medicinal Chemistry Article
DOI:10.1021/jm501524q
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revealed the flexibility of the aglycone in the FimH-CRD/ 10e
structure, since theelectron density toward thesolvent-exposed
sulfonamide indicates that there is not one single orientation.
Therefore, the aglycone was modeled in two distinct poses. In
contrast, in the FimH-CRD/ 10j structure the amino acid side
chain of Y48canbemodeled in twodistinct rotamers, suggesting
flexibility also of the receptor.
Physicochemical Properties and in Vitro Pharmacoki-
netics. Intestinal absorption and renal excretion are prereq-
uisites for a successful oral treatment of UTI with FimH
antagonists. Furthermore, reabsorption of antagonist from the
renal ultrafiltrate is desirable for maintaining the minimal
antiadhesive concentration in the target organ, namely, the
bladder, over an extended period of time. To estimate the
influence of the bioisostere approach on oral bioavailability and
therateof renal excretion, wedetermined lipophilicity by means
of the octanol−water distribution coefficient (log D7.4),59
aqueous solubility, and membrane permeability in the artificial
membrane permeability assay (PAMPA)60 and the colorectal
adenocarcinoma (Caco-2) cell monolayer model.61
Table 2. Thermodynamic Parameters from ITC for Selected FimH Antagonists Binding to FimH-CRD-Th-His6d
a95%confidence interval from fitting in parentheses. bGlobal fit including two direct titration measurements. cITC data were previously published
with an n-value of 0.82.37 dn, stoichiometric correction factor.
Journal of Medicinal Chemistry Article
DOI:10.1021/jm501524q
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9.9.88 The global minimum structures were used as input for the
AMSOL 7.1 program89 to obtain the free energy of desolvation ΔGdes
(Table 5) with the SM5.4A solvation model90 and the AM191 level of
theory (used keywords “AM1 SM5.4A SOLVNT=WATER TRUES”).
Determination of the MAC90 by Flow Cytometry. TheMAC90
was determined in principle as in the previously published flow
cytometry assay79 but with some modifications. The human epithelial
bladder carcinomacell line5637(DSMZ, Braunschweig, Germany) was
grown in RPMI 1640 medium, supplemented with 10%fetal calf serum
(FCS),100U/ mL penicillin, and 100μg/ mL streptomycin at 37°C,5%
CO2.All solutionswerepurchased fromInvitrogen (Basel,Switzerland).
The cells were subcultured 1:6 twice per week [using trypsin/ EDTA
(Sigma-Aldrich) for thedetachment] . Two daysbefore infection, 1.8 ×
105 cells were seeded in each well of a 24-well plate in RPMI 1640
containing 10% FCS without antibiotics. The cell density was
approximately (3−5) × 105 cells/ well at theassay day.
For infection, the GFP-expressing clinical E. coli isolate UTI8992
(UTI89 wt) and the GFP-expressing FimA-H knockout strain UTI89
ΔfimA-H wereused(strainswereprovided byProf.UrsJenal,Biocenter,
University of Basel, Switzerland).79 Bacteriawerecultivated at 37 °C in
10 mL Luria−Bertani (LB) broth (Becton, Dickinson and Company)
overnight, harvested by centrifugation (3800rpm, 10min), and washed
three times in phosphate buffered saline (PBS, Sigma-Aldrich), and a
bacterial solution of OD600 of 0.75 in RPMI + 10%FCSwasprepared.
For thedetermination of theMAC90 value, the IC90, linear dilutions of
theFimH antagonist wereprepared in5%DMSO andPBS.Bacteriaand
antagonists were preincubated for 10 min at 37 °C, before cells were
infected witheither only200μL of bacterial solution of UTI89or UTI89
ΔfimA-H (positive and negative controls), or 225 μL of the
preincubated bacteria−antagonist mixture. Infection lasted for 1.5 h.
Duringthistimeinfected cellswereincubated at 37°C.Then, cellswere
washed with PBSand detached from wellsby theaddition of 150 μL of
trypsin and incubation at 37 °C for 10 min, before flushing from wells
PBScontaining 2%FCSand transferred to tubes. To dilutethetrypsin,
cellswere centrifuged at 13000 rpm, 1 min, 600 μL of thesupernatant
wasdiscarded, and thepellet wasresuspended in theremaining 300 μL
of PBS containing 2% FCS. Samples were stored on ice until
measurement. Before analysis with the flow cytometer (Becton
Dickinson, FACSCanto II), thesamples weregently mixed and filtered
using a35 μm nylon mesh (Corning Life Sciences) to prevent cellular
aggregation. Cells were gated with linear scaling for sidescatter (SSC)
and forward scatter (FSC) and GFPintensity of livecellswasevaluated.
IC90 values were determined by plotting the concentration of the
antagonist in alogarithmic modeversusthemean fluorescenceintensity
(MFI) of living cells and by fitting a dose−response curve (variable
slope, four parameters) with thePrism software (GraphPad Prism).
X-ray Analysis of the Antagonists 10e and 10j Cocrystallized
with FimH-CRD. FimH-CRD/10e Cocrystallization. Initial FimH-
CRD (18 mg/ mL in 20 mM HEPES, pH 7.4) crystalswereobtained in
complex with 4-(5-nitroindolin-1-yl)phenyl α-D-mannopyranoside (5
mM).23 Crystals were grown in sitting-drop vapor diffusion at 20 °C
with 200 nL of protein−antagonist mixture together with 200 nL of
precipitant solution in well D3 (0.2 M sodium phosphate monobasic
monohydrate, 20% w/ v PEG 3,350) of the PEG/ Ion HT screen
(Hampton Research, CA,USA). Cubiccrystalsappeared within 1week,
which served as cross-seeding crystals. A solution of FimH-CRD (20
mg/ mL) and 10e (5 mM) was mixed with 0.2 M sodium phosphate
monobasic monohydrate, 20% w/ v PEG 400 with 0.5 μL of each
solution. Streak-seeding wasperformed after 1day of incubation. Cubic
FimH-CRD/ 10ecrystalsformed within 24h.Crystalswereflash cooled
to 100 K with perfluoropolyether cryo oil (Hampton Research, CA,
USA) ascryoprotectant. Datawerecollected withsynchrotron radiation
(λ = 0.99999Å) at thePXIII beamline, SwissLight Source, Switzerland.
FimH-CRD/10j Cocrystallization. Cocrystals were initially grown in
sitting-drop vapor diffusion at 20 °C with 0.5 μL of amixture of FimH-
CRD (20 mg/ mL) and 10j (5 mM) together with 0.5 μL of 0.1 M
HEPES,pH 7.5,2M ammoniumsulfate.Platelikecrystalsformed within
2 weeks and were used as seeds for subsequent crystallization.
Diffraction quality crystals were grown by streak-seeding in 0.5 μL of
FimH-CRD (10 mg/ mL) with 10j (2.5 mM) and 0.5 μL of 0.1 M
HEPES, pH 7.5, 1.25 M ammonium sulfate. The drops were covered
with perfluoropolyether cryo oil prior to flash cooling to 100 K. Data
werecollected with synchrotron radiation (λ = 1.00003Å) at thePXIII
beamline, Swiss Light Source, Switzerland.
Structure Determination and Refinement. Data were indexed and
integrated with the XDS package93 for the FimH-CRD/ 10e cocrystal
structure, andwithmosflm94 for theFimH-CRD/ 10j cocrystal structure
(Table6).Scalingwasperformed with XDSand SCALA included in the
CCP4 suite, respectively.95 Structures were solved by molecular
Figure 8. 4-Methoxybiphenyl scaffold of aglycons.
Table 5. Aqueous Free Energy of Desolvation
R ΔGdes [kJ/ mol]
neutral
H 15.6
CONHCH3 39.9
COOCH3 23.0
SO2NHCH3 65.5
SO2CH3 56.4
4-morpholineamide 45.3
CN 22.0
deprotonated
COO− 298.2
SO2-N−-Me 342.0
Table6. DataCollection and Refinement Statistics for FimH-
CRD/ 10e and FimH-CRD/ 10j Cocrystals
FimH-CRD/ 10e FimH-CRD/ 10j
PDB code 4CSS 4CST
space group P212121 P212121
no. of molecules in
the asymmetric
unit
1 1
Cell Dimensions
a, b, c(Å) 48.38, 56.23, 61.59 48.84, 55.89, 61.00
α, β, γ (deg) 90, 90, 90 90, 90, 90
DataCollection
beamline SwissLight SourcePXIII SwissLight Source PXIII
resolution range
(Å)a
30.0−1.07 (1.13−1.07) 23.5−1.10 (1.12−1.10)
unique
observationsa
72000 (9354) 66470 (2500)
average
multiplicitya
10.9 (3.7) 5.4 (2.4)
completeness (%) 96.1 (78.0) 97.2 (76.5)
Rmerge a 0.056 (0.57) 0.051 (0.305)
mean I/ σ(I) a 21.5 (2.22) 15.5 (2.9)
Refinement
resolution range
(Å)
15.7−1.07 23.5−1.10
R, Rfree 11.2, 13.2 11.4, 13.0
rmsdeviation from
ideal bond length
(Å)
0.010 0.010
rmsdeviation from
ideal bond angle
(deg)
1.170 1.420
aValues in parentheses are for highest-resolution shell.
Journal of Medicinal Chemistry Article
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2.2.4 Paper 3 
Catch-bond mechanism of the bacterial adhesin FimH 
 
 
This paper describes the in-depth study of the molecular mechanism that regulates the 
catch-bond behavior of the lectin protein FimH. The full-length protein, 
complemented with a synthetic donor strand, proved to be an excellent model system. 
Crystallography, molecular dynamics, and kinetic studies revealed the details of the 
allosteric regulation, which enables FimH to react to shear stress. Using cell-tracking 
experiments, the importance of the dynamic switching between a low and high 
affinity state for cell motility was demonstrated. Moreover, a road-map for studying 
other catch-bond interactions was outlined. 
 
 
 
Contribution to the project: 
Giulio Navarra designed, synthesized, and characterized the fluorescent tracer GN-
FP-4 and wrote the corresponding parts of the supporting information. 
 
 
This paper was published in Nature Communications: 
 
Maximilian M. Sauer, Roman P. Jakob, Jonathan Eras, Sefer Baday, Deniz Eriş, 
Giulio Navarra, Simon Bernèche, Beat Ernst, Timm Maier, Rudi Glockshuber 
 
Reproduced under Creative Common License CC BY from Sauer et al. Nature 
Communications 2016, 7, 1-13.  
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2.2.5 Paper 4 
Label-Free FimH Protein Interaction Analysis Using Silicon Nanoribbon 
BioFETs 
 
 
In this paper the label-free detection of FimH protein with biosensors based on silicon 
nanoribbons (SiNRs) is described. SiNRs configured as ion-sensitive field-effect 
transistors (ISFETs) are of great interest for diagnosis. The performance of the system 
was compared to the well-established commercial instrument Biacore T-200. The 
results highlighted some crucial elements for achieving successful label-free detection 
of pathologically relevant proteins with ISFETs and provided the first proof of 
concept for this application. 
 
 
Contribution to the project: 
Giulio Navarra designed, synthesized, and characterized the mannose-based ligands 
that were used in the study. He established the surface functionalization methods and 
prepared protein samples for the measurements. He additionally performed the 
Biacore experiments. 
 
This paperwas published in ACS Nano: 
 
Mathias Wipf, Ralph L. Stoop, Giulio Navarra, Said Rabbani, Beat Ernst, Kristine 
Bedner, Christian Schönenberger, and Michel Calame 
 
 
 
Reprinted with permission from Wipf et al. ACS Sensors 2016, 1, 781-788.  
Copyright 2016 Americal Chemical Society.  
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3.1 Introduction 
3.1.1 Pyelonephritis 
 
Pyelonephritis is a UTI that involves the renal parenchyma and the renal pelvis [1]. In 
the USA approximately 250,000 cases, predominantly women, are registered every 
year, 100,000 of which require hospitalization [2,3]. The estimated cost due to 
pyelonephritis in the year 2000 was 2.14 billion USD [4]. In immunocompetent 
patients, in absence of urinary tract abnormalities, the infection is considered 
uncomplicated. In presence of host factors such as immunosuppression, diabetes 
mellitus, pregnancy, sickle cell anemia, obstruction, renal stones or any structural or 
functional abnormalities of the urinary tract, pyelonephritis is considered as 
complicated [4]. 1-2% of all pregnancies are complicated by pyelonephritis [5]. 
 
 
3.1.2 Pathogenesis  
 
In most of the infections reaching the kidneys bacteria ascend from the lower urinary 
tract. Descending infections with hematic origin are rare and limited to chronically ill 
or immunosuppressed patients [1]. The main etiological agent is E. coli, which 
accounts for 70-80% of all uncomplicated infections [6,7]. Untreated pyelonephritis 
can lead to serious organ damage and even death [8].  
 
 
3.1.3 UPEC with kidney tropism 
 
Uropathogenic E. coli are highly specialized bacteria that evolved an arsenal of 
virulence factors (VFs), supporting colonization of the urinary tract. Among them, 
Type 1 and type P pili have been ascribed pivotal roles in the establishment of UTIs 
[9,10]. Type 1 pili bind in fact to glycoproteins bearing terminal mannose residues 
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[11], which are widely expressed in the bladder [12,13] and less abundant to 
completely absent in the upper urinary tract [14,15]. Type P pili are instead expressed 
in most UPEC isolates from pyelonephritis patients [16] and bind to glycolipids 
exposing Galα(1-4)Galβ (galabiose) moieties [17], which are abundant in the human 
kidney [18]. Although type-1 pili have been shown to clearly play a role in bladder 
colonization as well as in the establishment of recurrent infections, their function in 
the invasion of the upper urinary tract is not fully understood. The adhesive properties 
of type-P pili have been shown to facilitate bacterial invasion of the kidneys in some 
studies [19-21], but others could not find any differences among the infectivity of 
UPEC possessing functional or non-functional pili [22]. However, care should be 
used in extrapolating the results from mouse models to humans, due to large anatomic 
differences. Studies in primates and in humans [21] suggest the involvement of the 
type P pili in the infection, especially in the early stage [19].  
 
 
3.1.4 Type P pilus 
 
The type P-pilus is similar to the type-1 pilus already described in chapter 2. It 
consists of a right-handed helical rod [23,24] of nearly 10 nm diameter [25] composed 
of ≈ 1000 copies of the major subunit PapA and a flexible tip-fibrillum [25,26]. The 
latter is formed by one copy of PapK, followed by 5–10 copies of PapE, one copy of 
PapF and one copy of the adhesin PapG (figure 1) [27], and has a diameter of about 3 
nm [26]. The total length of the pilus is about 1 µM [25]. The biogenesis follows the 
chaperone/usher pathway. The subunits are secreted from the cytosol through the 
secYEG translocon [27]. In the periplasmic space, the chaperone PapD [28,29] bind 
them by donor stand complementation (DSC) [30,31], and afterwards the complex is 
captured by the usher PapC [32]. The next subunit binds to the usher and undergoes 
donor stand exchange (DSE) [33]. The reiteration of this process allows the assembly 
of the whole pilus.  
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3.1.5 PapG Adhesins 
The PapG adhesins are located 
at the tip of the P pili [27] and 
are the only subunits of the 
whole pilus responsible for 
binding [17]. Four isoforms 
have been identified, which can 
be grouped into three binding 
subtypes (I-III). All adhesins 
recognize glycolipids 
containing the galabiose core. 
However, the residues flanking 
the galabiose have different 
influence on each of the three 
classes.  
 
 
 
 
 
3.1.6 Natural Ligands of PapG Adhesins 
 
The minimal binding epitope for all PapG adhesins is galabiose [17]. Nevertheless, 
the single adhesins’ subtypes bind preferentially to specific ligand; class I adhesins 
prefer GbO3, while class II bind more strongly to GbO4, and class III to GbO5 [16], 
although these sharp differences have been questioned, due to the high variability of 
the phenotypic assays with which they were determined [34]. Moreover, all PapG 
adhesins bind well to the isolated GbO5 pentasaccharide, but only class III adhesins 
do so also when it is bound to the cellular membrane [18]. In 1998, Stapleton et al. 
demonstrated that all P adhesins bind avidly to the isolated hexasaccharide of sialosyl 
galactosyl globoside (SGG), which is expressed on kidney and vaginal epithelial cells 
Figure 1. Comparison of type-1 (a) and type-P pili (b) 
(adapted from ref. [33]). Extracellular space (E), periplasm 
(P), outer membrane (OM), inner membrane (IM). The red 
cross over the last arrow of the assembly cycle of the type-P 
pilus symbolizes PapH function, i.e. cycle stop and pilus 
anchoring. 
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of nonsecretors. They correlated this behavior with the increased risk of contracting 
UTIs in these patients’ population [35].  
The different affinity for Gal(1-4)Gal isoreceptors exhibited by class I-III adhesins 
(table 1) has been suggested to play a role in host specificity [18]. 
 
Table 1. Binding of 35S-labelled recombinant E.coli strains expressing G adhesins I-III, to globosides 
immobilized on a thin plate [18,36]. +++*, “very strong” binding; + +, “strong” binding; +, “moderate” 
binding; (+), “weak” binding; -, no binding at all. *SGG was measured in a separate experiment and 
compared to GbO3 and GbO4, where it showed stronger binding than all other glycolipids to all 
adhesins’ classes [35]. 
 
In fact, dog UTI isolates express mainly class-III adhesins and bind cells expressing 
GbO5 (abundant in dog urinary tract) [18], whereas human isolates from patients with 
a normal urinary tract produce mainly class-II adhesins [18,36], recognizing 
preferentially GbO4, one of the major globosides expressed in humans [18].  
 
  
Name Structure       Binding  
 I         II       III 
GbO3 Galα1-4Galβ1-4Glcβ1-1Cer ++ ++ - 
GbO4 GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer ++ ++ + 
GbO5 GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer ++ ++ ++ 
SGG* NeuAcα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-
1Cer 
+++ +++ +++ 
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3.1.7 PapG class-II Adhesin 
 
PapG-II is of particular 
medical interest, because 
of its strong association 
with pyelonephritis in hu-
mans [17,18,37,38]. PapG-
II presents two domains, a 
receptor-binding N-termi-
nal domain (lectin domain) 
and a C-terminal domain 
that links it to the rest of 
the pilus (pilin domain) 
[30]. The lectin domain is 
formed mainly by β-sheet 
structures, organized in 
two regions; region 1 consists of a large β-barrel, formed by seven strands. Region 2 
is formed by a large β-sheet, flanked on one side by two double-stranded small β-
sheets and on the other by an α-helix, and it comprises the binding pocket (figure 2) 
[39]. The pilin domain shows an incomplete Ig-like fold, with a missing strand that is 
complemented by the chaperone PapD (during pilus biogenesis) or by the subunit 
PapF (in the assembled pilus) [40].  
The binding specificity of PapG-II has been studied and its natural target in the human 
urinary tract identified. It binds preferentially to GbO4 [41], which contains the 
minimal galabiose core, flanked by a GalNAc residue at the non-reducing end and a 
glucose unit at the reducing terminus, and is abundant in the human upper urinary 
tract [35]. PapG adhesins have been suggested to play a role also in bacteremia [42]. 
 
 
 
 
Figure 2. PapG-II lectin 
domain (PDB code 
1J8R) [39]. The arrows 
delimit-tate regions 1 and 
2. β-sheets are marked in 
alphabetical order, star-
ting from the N-termi-
nus. The protein is repre-
sented in cartoon style 
(cyan β-sheets, purple α-
helix). The ligand (GbO4 
tetra-saccharide) is re-
presented in ball and 
sticks with green carbon, 
red oxygen, and blue 
nitrogen atoms). 
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3.1.7.1 Binding Pocket of PapG-II 
 
The binding site of PapG-II is located on one side with respect to the main axis of the 
protein (figure 2). In the first published crystal structure, the tetrasaccharide of GbO4 
is in a pocket formed by strands j, g, and k, helix A, and the loop connecting strand o 
to helix A (figure 3) [41]. The ligand is bound in a V shape, with one arm comprising 
GalNAc and the adjacent Gal (rings A and B respectively), and the other arm Gal and 
Glc (rings C and D). Ring D forms a water-mediated H-bond between the anomeric 
oxygen and Nε1 of Trp107 and two charge-assisted H-bonds between 3-OH and 
Arg170. The α-face [43] of ring D is partially involved in apolar contacts with 
Trp107. The β-face [44] of ring C stacks on Trp107 (strand k). The 3-OH of ring C is 
involved in an H-bond with Gly104, whilst 6-OH is H-bonded to Glu59 and water-
bridged to the backbone carbonyl of Lys106. Ring B forms a dense network of H-
bonds: 2-OH forms a water-mediated H-bond to Glu59, the oxygen in position 3 
accepts a H-bond from Lys172, 4-OH binds to Glu91, and 6-OH binds to the NH of 
Gly104 and is water-bridged to Lys103. 
 
Figure 3. Binding pocket of PapG-II with the natural tetrasaccharide epitope of GbO4. The protein is 
represented in cartoon style in white color. The β-sheets are labeled with low case according to ref. 
[41]. The ligand is in ball and sticks, with carbon atoms in green, hydrogen in white, oxygen in red, and 
nitrogen in blue. Water molecules are shown as wires. Amino acids are labeled in one-letter code and 
numbered according to the PDB file 1J8R. Each monosaccharide unit is labeled with purple capital 
letter. Hydrogen bonds are highlighted by magenta dashed lines. 
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The apolar part of C1 and C2 of residue B lies on top of a hydrophobic patch formed 
by the hydrophobic portions of Lys172, Ile61 (g strand), and Leu102 (k strand). 
The GalNAc (ring A) is involved in more loose interactions; the polar groups are 
involved in water-mediated contacts: the acetyl group with Glu59, 4-OH with Lys172, 
and 6-OH with the hydroxyl group of Tyr175 and with the backbone NH of Arg92.  
The location of the binding site on one side of PapG-II has some implications on 
target recognition. As the GbO4 tetrasaccharide is thought to assume a close-to-90° 
orientation relative to the lipid chains [45], the adhesin has to orient parallel to the 
epithelium for reaching its target. The tip fibrillum could provide enough flexibility, 
as suggested by electron microscope (EM) analysis [41]. The positively charged patch 
on the surface of PapG-II, in close proximity to the binding site, might help the 
docking, thanks to the interaction with the polar head groups of the lipid bilayer of the 
cellular membranes [41]. 
 
 
3.1.7.2 Catch-bond or slip-bond? 
 
Nilsson et al. investigated the binding behavior of PapG-II by means of stick-and-roll 
experiments. The results suggested catch-bond behavior at shear-stress ≤4.3 pN/µm2 
[44]. However, further investigations with force-measuring optical tweezers, in which 
the single pilus can be studied, support a slip-bond character for the interaction 
between PapG-II and galabiose [46]. This is in agreement with the rigid body-type 
interaction already described by Dodson et al. [41] Interestingly, despite the rather 
low affinity of this interaction [41], the mechanical strength of the bond is enough to 
allow the unfolding of the pilus subunits under tensile force [47], probably an 
evolutionary optimization of the adhesion organelle, which allows better adaptation to 
the colonized niche [41,48]. 
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3.1.7.3 PapG Antagonists 
 
The correlation of PapG adhesins and UTI inspired researchers to develop molecules 
able to inhibit its binding to the host’s ligands [41,48-56]. Starting from the natural 
targets, an impressive number of mimetics was tested. As the core motif is the 
Gal(1-4)Gal disaccharide, its modification was initially investigated.  
Table 2. Data from ref. [50]. Inhibition of hemagglutination by E. coli bearing class I adhesins. 
aCompound 25 was assayed with a different batch of bacteria. bValues were calculated using compound 
1 as reference. 
 
 
 
 
Cpd R1 R2 R3 R4 R5 R6 R7 R8 
IC50 
(mM) rIC50b 
1 OH OH OH OH OH OH OH OMe 0.18 1.0 
2 H OH OH OH OH OH OH OMe 0.3 1.7 
3 OH H OH OH OH OH OH OMe 0.98 5.4 
4 OH Me OH OH OH OH OH OMe 0.37 2.1 
5 OH Et OH OH OH OH OH OMe 3.4 18.9 
6 OH OMe OH OH OH OH OH OMe 1.6 8.9 
7 OH OH H OH OH OH OH OMe 4.2 23.3 
8 OH OH F OH OH OH OH OMe 9.2 51.1 
9 OH OH OMe OH OH OH OH OMe >25 − 
10 OH OH OH H OH OH OH OMe 2.3 12.8 
11 OH OH OH OH H OH OH OMe 6.4 35.6 
12 OH OH OH OH OMe OH OH OMe 0.082 0.5 
13 OH OH OH OH OH H OH OMe 10 55.6 
14 OH OH OH OH OH F OH OMe 3.3 18.3 
15 OH OH OH OH OH epi OH OMe 5.0 27.8 
16 OH OH OH OH OH OH H 
1.0 
OMe 3.6 20.0 
17 OH OH OH OH OH OH F OMe 0.33 1.8 
18 OH OH OH OH OH OH OH OEt 0.13 0.7 
19 OH OH OH OH OH OH OH OiBu 0.082 0.5 
20 OH OH OH OH OH OH OH OCH2CH2SiMe3 0.046 0.3 
21 OH OH OH OH OH OH OH OCH2CH(OH)SiMe3 0.12 0.7 
22 OH OH OH OH OH OH OH O-4GlcβOCH2CH2SiMe3 0.26 1.4 
23 OH OH OH OH OH OH OH αOMe 2.1 11.7 
24 OH OH OH OH OH OH OH αβOH 1.3 7.2 
25 OH OH OH OH OH OH OH SEt −a 0.5a 
 
O
O
O
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Kihlberg et al. systematically replaced each hydroxy group of the disaccharide by H, 
F, or OMe and tested the modified disaccharides with PapG-I (table 2). Additional 
modifications, e.g. at the reducing end were tested as well (table 2, compounds 5, 15, 
and 20-25). The results furnished the first mapping of the binding site. Whereas most 
modifications reduced or even abolished the binding, the introduction of lipophilic 
aglycones and the methylation of the 3’-OH were beneficial (table 2) [50]. However, 
affinities for PapG-II were tested only at a leater point in time [51]. When Striker et 
al. examined the binding epitope of PapG-II [51], they reported that the substitution 
of 3-OH by either hydrogen or a methyl group slightly improved the affinity as 
compared to methyl galabiose 1 (table 3). 
 
Table 3. Data from ref. [51]. Inhibition of hemagglutination by E. coli bearing class II adhesins. 
aStatistically significantly better inhibitor. bStatistically significantly worse inhibitor.  
 
  
 
 
Cpd R1 R2 R3 R4 R5 R6 R7 MIC (mM) 
Inhib. 
Power (%) 
1 OH OH OH OH OH OH OH 7.4 ± 2.3 100 
2 H OH OH OH OH OH OH 17.1 ± 11.9 51 
3 OH H OH OH OH OH OH 4.8 ± 2.2 143 
4 OH Me OH OH OH OH OH 3.8 ± 2.8 191a 
5 OH Et OH OH OH OH OH ≥ 25.1 ≤ 25 
7 OH OH H OH OH OH OH ≥ 33.5b ≤ 22 
10 OH OH OH H OH OH OH ≥ 25.9 ≤ 30 
11 OH OH OH OH H OH OH ≥ 34.4 ≤ 21 
13 OH OH OH OH OH H OH ≥ 33.8 ≤ 21 
16 OH OH OH OH OH OH H ≥ 35.4 ≤ 20 
 
Moreover, the presence of a glucose unit at the reducing end of galabiose strongly 
increased affinity. When Nilsson et al. investigated the isosteric replacement of the 
ring oxygen atom of the galactose moiety with sulfur, they observed a loss of affinity. 
As possible reasons small conformational changes or the disruption of a cooperative 
H-bond were discussed [57]. In 1998, Hansen et al. published the synthesis and 
evaluation of amino and carboxy analogs of galabiose and showed that 2’-OH of the 
galabiose can be efficiently replaced by an amino group, increasing the affinity for 
PapG-I, whilst the other modifications reduced the affinity [53]. However, no data for 
the binding to PapG-II were provided. The first study with both PapG-I and PapG-II 
O
O
O
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was published by Ohlsson et al in 2002. The most potent inhibitors to date are 
presented in figure 4 [55]. 
An SPR investigation of 
PapG-II binding to a small 
set of natural and synthetic 
inhibitors was published 
shortly after by Larsson et 
al. [54] Hydroxy groups in 
the 2’- and 3’-position were 
suggested as possible anchor 
points for improving the 
affinity. The docking results 
of the reported compound 27 
in the PapG-II binding 
pocket was also disclosed, suggesting that the phenyl ring could be involved not only 
in hydrophobic interactions, but also in a π-cation interaction with Arg170. It is 
interesting to observe the drop in affinity of the thioglycoside 28 (figure 5, KD = 488 
µM) as compared to the isosteric compound 27 (figure 4, KD = 170 µM); proposed to 
result on conformational changes [52]. Ohlsson et 
al. tested a large number of synthetic inhibitors for 
binding to the PapG-II adhesin, and developed a 
small set of QSAR models [56]. However, no 
improved binders as compared to compound 26 
were discovered. In one SPR study, multivalent 
compounds were synthesized and their inhibitory power against bacterial adhesion to 
galabiose-coated BSA was measured. Surprisingly, only PapG-I was inhibited. The 
most potent compound showed 2 µM IC50 [57].  
 
3.1.8 Aims of this Project 
 
This project is aiming at a deeper understanding of PapG-II binding to its cellular 
target and at the development of improved antagonists. To reach these goals structure-
based as well as fragment-based approaches were used, with support from 
O
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Figure 4. Strongest inhibitors of hemagglutination by E. coli 
bearing PapG-II adhesins, which are described in literature. 
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crystallography, isothermal titration calorimetry, and NMR techniques. The collected 
data will help to develop further drug-like PapG-II inhibitors. 
 
 
  
3.1 Introduction 
90 
 
References 
 
[1]  K. Ramakrishnan, D.C. Scheid. Diagnosis and Management of Acute 
Pyelonephritis in Adults. Am. Fam. Phys. 2005, 71(5), 933-942. 
 
[2]  W. E. Stamm, T. M. Hooton, J. R. Johnson. Urinary tract infections: from 
pathogenesis to treatment. Infect. Dis. 1989, 159(3) 400-406. 
 
[3]  K. L. Klemstine, P. D. Brown, B. Foxman. Acute pyelonephritis in US 
hospitals in 1997: hospitalization and in-hospital mortality. Ann Epidemiol. 
2003, 13(2), 144-150. 
 
[4]  P. Brown, M. Ki, B. Foxman. Acute Pyelonephritis Among Adults Cost of 
Illness and Considerations for the Economic Evaluation of Therapy. 
Pharmacoeconomics 2005, 23(11), 1123-1142. 
 
[5]  L. C. Gilstrap, S. M. Ramin. Urinary tract infections during pregnancy. Obstet. 
Gyn. Clin. N. Am. 2001, 28(3), 581-91. 
 
[6]  W. E. Stamm, T. M. Hooton. Management of urinary tract infections in adults. 
 N. Engl. J. Med. 1993, 329, 1328-34. 
 
[7]  D. J. Farrell, I. Morrissey, D. DeRubeis, M. Robbins, D. Felmingham. A UK 
multicenter study of the antimicrobial susceptibility of bacterial pathogens 
causing urinary tract infection. J. Infect. 2003, 46(2), 94-100 
 
[8]   G. B. Piccoli, V. Consiglio, M. C. Deagostini, M. Serra, M. Biolcati, F. Ragni, 
A. Biglino, A. De Pascale, M. F. Frascisco, A. Veltri, and F. Porpiglia. The 
clinical and imaging presentation of acute “non complicated” pyelonephritis, 
A new profile for an ancient disease. Nephrology 2011, 12, 68 
 
[9]  M. A. Mulvey. Adhesion and entry of uropathogenic Escherichia coli. Cell 
Microbiol. 2002, 4(5), 257–271. 
 
[10]  M. A. Mulvey, J. D. Schilling, J. J. Martinez, S. J. Hultgren. Bad bugs and 
beleaguered bladders: interplay between uropathogenic Escherichia coli and 
innate host defenses. Proc. Natl. Acad. Sci. USA 2000, 97(16), 8829–8835. 
 
[11]  K. A. Krogfelt, H. Bergmans, P. Klemm. Direct evidence that the FimH 
protein is the mannose-specific adhesin of Escherichia coli type 1 fimbriae. 
Infect. Immun. 1990, 58, 6, 1995-1998. 
 
[12]  X. R. Wu, T. T. Sun, J. J. Medina. In vitro binding of type 1-fimbriated 
Escherichia coli to uroplakins Ia and Ib: relation to urinary tract infections. 
Proc. Natl. Acad. Sci. USA 1996, 93(18), 9630-9635. 
 
[13]  B. Xie, G. C. Zhou, C. Shiu-Yung, E. Shapiro, X. P. Kong, X. R. Wu, T. T. 
Sun, C. E. Costello. Distinct glycan structures of uroplakins Ia and Ib: 
References 
 91
structural basis for the selective binding of FimH adhesin to uroplakin Ia. J. 
Biol. Chem. 2006, 281(21), 14644-14653. 
 
[14]  R. Romih, P. Koro, W. de Mello Jr, K. Jezernik. Differentiation of epithelial 
cells in the urinary tract. Cell Tissue Res. 2005, 320(2), 259-268. 
 
[15]  F.-X. Liang, M. C. Bosland, H. Huang, R. Romih, S. Baptiste, F.-M. Deng, 
X.-R. Wu, E. Shapiro, T.-T. Sun. Cellular basis of urothelial squamous 
metaplasia: roles of lineage heterogeneity and cell replacement. J. Cell. Biol. 
2005, 171(5), 835-844. 
 
[16]  H. Leffler, C. Svanborg-Eden. Chemical identification of a glycosphingolipid 
receptor for Escherichia coli attaching to human urinary tract epithelial cells 
and agglutinating human erythrocytes. FEMS Microbiol. Lett. 1980, 8(3), 
127–134. 
 
[17]  B. Lund, F. Lindberg, B. I. Marklund, S. Normark. The PapG protein is the 
alpha-D-galactopyranosyl-(1–4)-beta-D-galactopyranose-binding adhesin of 
uropathogenic Escherichia coli. Proc Natl Acad Sci USA 1987, 84(16), 5898–
5902. 
 
[18]  N. Stromberg, B.I. Marklund, B. Lund, D. Iliver, A. Hamers, W. Gaastra, K.A. 
Karlsson, S. Normark. Host-specificity of uropathogenic Escherichia coli 
depends on differences in binding specificity to Gal alpha 1-4Gal-containing 
isoreceptors. EMBO J. 1990, 9(6), 2001-2010. 
 
[19]  J. A. Roberts, B. I. Marklund, D. Ilver, D. Haslam, M. B. Kaack, G. Baskin, 
M. Louis, R. Möllby, J. Winberg, S. Normark. The Gal(alpha 1-4)Gal-specific 
tip adhesin of Escherichia coli P-fimbriae is needed for pyelonephritis to occur 
in the normal urinary tract. Proc Natl Acad Sci USA 1994, 91(25), 11889-
11893 
 
[20]  C. C. Tseng, J. J. Huang, M. C. Wang, A. B. Wu, W. C. Ko, W. C. Chen, J. J. 
Wu. PapG II adhesin in the establishment and persistence of Escherichia coli 
infection in mouse kidneys. Kidn. Int. 2007, 71(8), 764-770. 
 
[21]  B. Wullt, G. Bergsten, H. Connell, P. Röllano, N. Gebretsadik, R. Hull, C, 
Svanborg. P fimbriae enhance the early establishment of Escherichia coli in 
the human urinary tract. Mol. Biol. 2000, 38(3), 456-464. 
 
[22]  H. L. T. Mobley, K. G. Jarvis, J. P. Elwood, D. I. Whittle, C. V. Lockatell, R. 
G. Russell, D. E. Johnson, M. S. Donnenberg, J. W. Warren. Isogenic P-
fimbrial deletion mutants of pyelonephritogenic Escherichia coli: the role of α 
Gal(1–4)β Gal binding in virulence of a wild-type strain. Mol. Biol. 1993, 
10(1), 143-155. 
 
[23]  M. Gong, L. Makowski. Helical structure of P pili from Escherichia coli. 
Evidence from X-ray fiber diffraction and scanning transmission electron 
microscopy. J. Mol. Biol. 1992, 228(3), 735–742. 
 
3.1 Introduction 
92 
 
[24]  E. Bullitt, L. Makowski. Structural polymorphism of bacterial adhesion pili. 
Nature 1995, 373(6510), 164–167. 
 
[25]  M. J. Kuehn, J. Heuser, S. Normark, S. J. Hultgren. P pili in uropathogenic E. 
coli are composite fibres with distinct fibrillar adhesive tips. Nature 1992, 
356(6366), 252-255. 
 
[26]  C. H. Jones, J. S. Pinkner, R. Roth, J. Heuser, A. V. Nicholes, S. N. Abraham, 
S. J. Hultgren. FimH adhesin of type 1 pili is assembled into a fibrillar tip 
structure in the Enterobacteriaceae. Proc. Natl. Acad. Sci. USA 1995, 92(6), 
2081–2085. 
 
[27] C. H. Jones, P.N. Danese, J.S. Pinkner, T.J. Silhavy, S.J.Hultgren. The 
chaperone-assisted membrane release and folding pathway is sensed by two 
signal transduction systems, EMBO J. 1997, 16(21), 6394–6406.  
 
[28]  S. J. Hultgren, F. Lindberg, G. Magnusson, J. Kihlberg, J. M. Tennent, S. 
Normark. The PapG adhesin of uropathogenic Escherichia coli contains 
separate regions for receptor binding and for the incorporation into the pilus. 
Proc. Natl. Acad. Sci. USA 1989, 86(12), 4357-4361. 
[29]  F. Lindberg, J. M. Tennent, S. J. Hultgren, B. Lund, S. Normark. PapD, a 
periplasmic transport protein in P-pilus biogenesis. J. Bact. 1989, 171(11), 
6052-6058. 
[30]  F. G. Sauer, K. Futterer, J. S. Pinkner, K. W. Dodson, S. J. Hultgren, G. 
Waksman. Structural basis of chaperone function and pilus biogenesis. 
Science 1999, 285(5430), 1058–1061. 
 
[31]  D. Choudhury, A. Thompson, V. Stojanoff, S. Langermann, J. Pinkner, S. J. 
Hultgren, S. D. Knight. X-ray structure of the FimC–FimH chaperone–adhesin 
complex from uropathogenic Escherichia coli. Science 1999, 285(5430), 
1061–1066. 
 
[32]  H. Remaut, C. Tang, N. S. Henderson, J. S. Pinkner, T. Wang, S. J. Hultgren, 
D. G. Thanassi, G. Waksman, H. Li. Fiber formation across the bacterial outer 
membrane by the chaperone/usher pathway. Cell 2008, 133(4), 640-652. 
 
[33]  M. Båga, M. Norgren, S. Normark. Biogenesis of E. coli Pap pili: PapH, a 
minor pilin subunit involved in cell anchoring and length modulation. Cell 
1987, 49(2), 241-251. 
 
[33]  S. Geibel, G. Waksman. The molecular dissection of the chaperone-usher 
pathway. Bioch. Biophys. Acta 2014, 1843(8), 1559-1567.  
 
[34]  J. R. Johnson, J. L. Swanson, T. J. Barela, J. J. J. Brown. Receptor 
Specificities of Variant Gal( 1-4)Gal-Binding PapG Adhesins of 
Uropathogenic Escherichia coli as Assessed by Hemagglutination Phenotypes. 
Inf. Dis. 1997, 175(2), 373-381. 
 
References 
 93
[35]  A. E. Stapleton, M. R. Stroud, S. I. Hakomori, W. E. Stamm. The globoseries 
glycosphingolipid sialosyl galactosyl globoside is found in urinary tract tissues 
and is a preferred binding receptor In vitro for uropathogenic Escherichia coli 
expressing pap-encoded adhesins. Inf. Immun. 1998, 66(8), 3856-3861. 
 
[36]  C. C. Tseng, J. J. Huang, W. C. Ko, J. J. Yan, J. J. Wu. Decreased 
Predominance Of Papg Class II Allele In Escherichia Coli Strains Isolated 
From Adults With Acute Pyelonephritis And Urinary Tract Abnormalities. J. 
Urol. 2001, 166(5), 1643-1646. 
 
[37]  I.M. Johanson, K. Plos, B. I. Marklund, C. Svanborg. Pap, papG and prsG 
DNA sequences in Escherichia coli from the fecal flora and the urinary tract. 
Microb. Pathogenesis 1993, 15(2), 121-129. 
 
[38]  J. R. Johnson. papG Alleles among Escherichia coli Strains Causing 
Urosepsis: Associations with Other Bacterial Characteristics and Host 
Compromise. Infect. Immun. 1998, 66(9), 4568-4571. 
 
[39]  K. W. Dodson, J. S. Pinkner, T. Rose, G. Magnusson, S. J. Hultgren, G. 
Waksman. Structural basis of the interaction of the pyelonephritic E. coli 
adhesin to its human kidney receptor. Cell 2001, 105(6), 133-143. 
 
[40]  B. Ford, D. Verger, K. Dodson, E. Volkan, M. Kostakioti, J. Elam, J. Pinkner, 
G. Waksman, S. J. Hultgren. The structure of the PapD-PapGII pilin complex 
reveals an open and flexible P5 pocket. J. Bacteriol. 2012, 194(23), 6390-
6397. 
 
[41]  A. Larsson, J. Ohlsson, K. W. Dodson, S. J. Hultgren, U. Nilsson, J. Kihlberg, 
Quantitative studies of the binding of the class II PapG adhesin from 
uropathogenic Escherichia coli to oligosaccharides Bioorg. Med. Chem. 2003, 
11(10), 2255-2261. 
 
[42]  G. Otto, G. Magnusson, M. Svensson, J. H. Braconier, C. Svanborg. pap 
Genotype and P Fimbrial Expression in Escherichia coli Causing Bacteremic 
and Nonbacteremic Febrile Urinary Tract Infection. Clin. Infect. Dis. 2001, 
32(11), 1523-1531. 
 
[43]  I. A. Rose, K. R. Hanson, K.D. Wilkinson, M. J. Wimmer. A suggestion for 
naming faces of ring compounds. Proc. Natl. Acad. Sci. USA 1980, 77(5), 
2439-2441. 
 
[44]  L. M. Nilsson, W. E. Thomas, E. Trintchina, V. Vogel, E. V. Sokurenko. 
Catch bond-mediated adhesion without a shear threshold: trimannose versus 
monomannose interactions with the FimH adhesin of Escherichia coli. J. Biol. 
Chem. 2006, 281(24), 16656-16663. 
 
[45]  I. Pascher, M. Lundmark, P. G. Nyholm, S. Sundell. Crystal structures of 
membrane lipids. Bioch. Bioph. Acta 1992, 1113(3-4), 339-373. 
 
 
3.1 Introduction 
94 
 
[46]  O. Björnham, H. Nilsson, M. Andersson, S. Schedin. Physical properties of 
the specific PapG-galabiose binding in E. coli P pili-mediated adhesion. Eur. 
J. Bioph. 2009, 38(2), 245-254. 
 
[47]  R. Lugmaier, S. Schedin, F. Kühner, M. Benoit. Dynamic restacking of 
Escherichia coli P-pili. Eur. J. Bioph. 2008, 37(2), 111-120. 
 
[48]  R. Striker, U. Nilsson, A. Stonecipher, G. Magnusson, S. J. Hultgren. 
Structural requirements for the glycolipid receptor of human uropathogenic 
Escherichia coli. Molec. Biol. 1995, 16(5), 1021-1029.  
 
[49]  J. Kihlberg, S. J. Hultgren, S. Normark, G. Magnusson. Probing of the 
combining site of the PapG adhesin of uropathogenic Escherichia coli bacteria 
by synthetic analogs of galabiose. J. Am. Chem. Soc. 1989, 111(16), 6364-
6368. 
 
[50]  J. Ohlsson, A. Sundin, U. J. Nilsson. Conformational studies on phenyl 
thioglycosides: a remote effect on disaccharide linkage by phenyl aglycons 
attenuates recognition of galabiosides by a bacterial adhesin. Chem. Comm. 
2003, 3, 384-5. 
 
[51]  U. Nilsson, R. T. Striker, S. J. Hultgren, G. Magnusson. PapG adhesin from E. 
coli J96 recognizes the same saccharide epitope when present on whole 
bacteria and as isolated protein. Bioorg. Med. Chem. 1996, 4(11), 1809-1817. 
 
[52]  H. C. Hansen, G. Magnusson. Synthesis of some amino and carboxy analogs 
of galabiose; evaluation as inhibitors of the pilus protein PapGJ96 from 
Escherichia coli. Carbohyd. Res. 1998, 307(3-4), 233-242. 
 
[53]  J. Ohlsson, J. Jass, B. E. Uhlin, J. Kihlberg, U. J. Nilsson. Discovery of potent 
inhibitors of PapG adhesins from uropathogenic Escherichia coli through 
synthesis and evaluation of galabiose derivatives. ChemBioChem 2002, 3(8), 
772-779. 
 
[54]  J. Ohlsson, A. Larsson, S. Haataja, J. Alajääski, P. Stenlund, J. S. Pinkner, S. 
J. Hultgren, J. Finne, J. Kihlberg, U. J. Nilsson. Structure-activity relationships 
of galabioside derivatives as inhibitors of E. coli and S. suis adhesins: 
nanomolar inhibitors of S. suis adhesins. Org. Biomol. Chem. 2005, 3(5), 886-
900. 
 
[55]  U. Nilsson, R. Johansson, G. Magnusson. Synthesis, Conformational Analysis 
and Comparative Protein Binding of a Galabioside and Its Thioglycoside 
Analogues. Chem. Eur. J. 1996, 2(3), 295-302. 
 
[56]  H. C. Hansen, G. Magnusson. Synthesis of selected aminodeoxy analogues of 
galabiose and globotriose. Carbohyd. Res. 1999, 322(3-4), 166-180. 
 
[57]  A. Salminen, V. Loimaranta, A. F. J. Joosten, S. A. Khan, J. Hacker, R. J. 
Pieters, J. Finne. Inhibition of P-fimbriated Escherichia coli adhesion by 
References 
 95
multivalent galabiose derivatives studied by a live-bacteria application of 
surface plasmon resonance. J. Antimicrob. Chemother. 2007, 60(3), 495-501. 
 
 
 
  
3.2 Results 
96 
 
3.2 Results  
3.2.1 Outline 
 
The PapG-II adhesin has been the target of extensive medicinal chemistry efforts for 
over 30 years. Several attempts to generate glycomimetics with improved affinity as 
compared to the natural ligands have failed. The best antagonist in term of affinity 
and structural simplicity is compound 1, discovered by Ohlsson et al., exhibiting an 
IC50 of 120 µM in hemagglutination experiments. 
 
Figure 1. The structure of the most binding efficient PapG-II antagonist known to date. 
 
By examining all reported small molecule antagonists of PapG-II and by molecular 
modeling, we identified a new promising exit vector, which had never been 
thoroughly exploited before.  
Figure 2. Modifications of compound 1. A small set of initial probe compounds (encircled in blue) 
highlighted the interesting thermodynamic signature of the benzyl-substituted analog. The benzyl series 
was later expanded (encircled in magenta). 
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Disappointingly, despite intensive synthetic effort, no improved binders were 
discovered, confirming PapG-II as a hard-to-drug protein (chapter 3.2.2).  
Furthermore, a fragment-based approach, which had been successfully applied to 
challenging targets, was explored. Thus, in our group, other lectins have been 
effectively targeted by linking a second-site fragment-sized ligand to a central 
glycomimetic core. However, the application of this strategy to PapG-II yielded only 
slightly improved binders (Manuscript 1).  
Finally, literature data indicate that the hexasaccharidic epitope of sialyl galactosyl 
globoside 2 has stronger affinity for PapG-II than the tetrasaccharidic epitope of 
GbO4 (figure 3), which is the major natural target, and from which it differs by the 
two saccharidic units at the non-reducing end. The determination of the exact KD for 
this interaction showed the surprisingly low value of 21.9 µM. Crystal structure and 
thermodynamic analyses suggested that the increased binding affinity originates from 
an entropy-driven contribution of the nonbinding saccharide moieties flanking the 
galabiose core (Paper 5). 
 
Figure 3. The structures and ITC-determined KDs of the hexasaccharidic epitope of sialyl galactosyl 
globoside 2 and of the tetrasaccharidic epitope of GbO4 3. 
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3.2.2 New Glycomimetics as Antagonists of the PapG-II Adhesin of E. 
coli 
 
 
 
Contributions to the project: 
Giulio Navarra designed and characterized all compounds used in this study except 
for compound 1 (commercial). He interpreted ITC, crystallography, and polymer-
assay results and wrote the chapter. For the synthesis of the compounds, Lisa Beretta 
Piccoli importantly collaborated in the frame of her master thesis (cited in the text, 
were appropriate). Crystallization experiments were conducted by Dr. Roland Preston 
and Dr. Roman P. Jakob. The protein PapG-II was produced by Dr. Katja Stangier, 
Dr. Roland Preston, and Dr. Said Rabbani. The polymer assay was run by Dr. Said 
Rabbani.  
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3.2.2 New Glycomimetics as Antagonists of the PapG-II Adhesin of E. 
coli 
 
 
Background 
 
Despite extensive medicinal chemistry efforts devoted to the targeting of PapG-II, no 
affinity improvement as compared to the natural ligand has been achieved. The 
minimal binding epitope for all PapG adhesins is the galabiose core (Gal1-4αGal) [1]. 
Magnusson’s and later Nilsson’s groups explored the chemical modification of each 
hydroxyl group on the Gal1-4αGal core [2-7]. The most obvious exit vectors, namely 
anomeric position 1 and the 3’-position of galabiose, were thoroughly explored. 
However, the best binder 2 [8], exhibits only mid-micromolar affinity [4].  
 
 
 
 
 
 
 
 
 
Figure 1. Structures of the tetrasaccharide epitope of GbO4 (natural ligand of PapG-II, 1) and of the 
best mimetic 2. The galabiose core is highlighted in blue.  
 
Furthermore, 6’-position has been only poorly investigated. Its dehydroxylation 
reduces the affinity for PapG-II by at least 79% [9], but no other modifications were 
explored. Previous studies on PapG-I (PapGJ96) had evidenced a comparable effect; 
however, the isosteric substitution of the 6’-OH with a fluorine atom reduced the 
affinity only by 50% [2]. As the binding pocket of both adhesins recognizes the same 
pattern of OH groups on the galabiose [9], we speculated that for PapG-II a similar 
effect is to be expected and could be related to the H-bond acceptor character of this 
moiety, as suggested by Kihlberg et al. for PapG-I [2]. In the crystal structure of the 
natural tetrasaccharide receptor in complex with the lectin domain of PapG-II (PapG-
O
HO
NHAc
OH
HO
O
O
O
HO
O
HO
HO
OH
O
OH
OH
O
OH
OH
HO OH
O
O
O
HO
HO
HO
HO
OH
O
OH
OH
OMe
1
2
3.2 Results 
100 
 
IILD, PDB: 18JR), the corresponding OH group of the β-galactosyl unit accepts an H-
bond from Gly104 and is involved in a water bridge to Lys103 [10]. For a deeper 
insight into the binding pocket, compound 2 [4] was synthesized and co-crystallized 
with PapG-IILD, thus providing a clear picture of its binding mode. A series of new 
candidates was then synthesized and tested for binding to PapG-IILD. Disappointingly, 
no improvement in affinity could be achieved. However, the results provided a better 
understanding of the binding event and will guide future medicinal chemistry efforts. 
 
 
Results and Discussion 
 
In the crystal structure of the complex PapG-IILD : 2, the galabiose core of compound 
2 forms the same interactions as described for the natural tetrasaccharide GalNAc1-
3βGal1-4αGal1-4βGlc (epitope of GbO4, compound 1) [10]. However, in each 
asymmetric unit cell two molecules of PapG-IILD are found (= chains A and B, 
respectively). The major difference among chains A and B involves the orientation of 
Lys103, which in chain A is forming a water bridge with the 6’-OH of 2, and in chain 
B is pointing away from it, as highlighted in Figure 2. The fact that this interaction is 
not always formed suggested that its contribution to the binding energy is limited, and 
that targeting the lysine with appropriate manipulations of group 6’-OH could be 
beneficial. Moreover, if Lys103 is pointing away from the ligand (thus relaxing to an 
all-anti conformation), it would uncover a lipophilic patch formed by the backbone of 
residues 102-104 and the β-ε carbons of Lys103.  
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Figure 2. Highlight of Lys103 and the bridged water molecule, as found in the co-crystal 2 : PapG-
IILD. Overlap of chains A (yellow) and B (turquoise) from the same asymmetric unit. In chain A, the 
lysine is involved in a water bridge to 6’-OH. In chain B, Lys103 points away from the ligand.  
 
To explore this hypothesis, “probe” compounds 13a-c, 19, and 25a were synthesized 
as described in schemes 1-3. Charged moieties were not explored to avoid the 
introduction of additional polarity. The glycosyl donors 7a-c were prepared starting 
from peracetylated α-D-galactose 3, which was reacted with thiophenol in presence of 
BF3Et2O, followed by removal of the acetyl groups with catalytic sodium methoxide 
in methanol. After regioselective protection of the 6-OH with tert-
butyl(chloro)diphenylsilane (TBDPSCl), compound 4 was obtained. Subsequent 
benzylation of the remaining hydroxyl groups and selective removal of the silyl 
protective group gave access to 6. Alkylation under basic conditions with the 
appropriate bromo- or iodoalkane provided the glycosyl donors 7a-c [11]. The 
synthesis of compound 10 from 3 was adopted from Ohlsson, et al. [12]. Finally, the 
disaccharides 13a-c were accessed through glycosylation of 10 with 7a-c, followed by 
removal of the benzyl and benzoyl groups. 
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Scheme 1. a) i. PhSH, BF3⸱Et2O, DCM, rt, 2 h, ii. MeONa, MeOH, rt, overnight, 74%; iii. TBDPSCl, 
imidazole, DMF, 0 °C  rt, 8 h, 92%; b) i. BnBr, NaH, DMF, rt, 3 h, 60%, ii. TBAF 1 M, AcOH, 0 °C 
 rt, 1h, 75%; c) Base, RX, 0 °C  rt, 44-96%; d) i. 4-methoxyphenol, BF3⸱Et2O, DCM, rt, 4 h, ii. 
MeONa, MeOH, rt, overnight, 72%; e) PhCH(OMe)2, p-TsOH, ACN, rt  0 °C, 30 min, 85%; f) i. 
BzCl, DMAP, pyridine, 0 °C  rt, overnight, ii. 2 N HCl/THF 1:7, 55 °C, 24 h, iii. BzCl, pyridine, -10 
°C, 75 min, 53%; g) i. 7a-c, NIS, TMSOTf, Et2O/DCM 2:1, -55 °C, 1-5 h, 78-27%; h) MeONa, MeOH, 
rt, 20-24 h, 96-84%; i) H2, Pd-C, AcOH, rt, 85-81%. 
 
The synthesis of 6’-O-arylmethyl compounds 19 (scheme 2) and 25a (scheme 3) 
required a different approach to avoid the cleavage of the 6’-O-benzyl group during 
the final hydrogenation step. The key glycosyl donor 14 was prepared from 4, through 
reaction with allyl bromide (scheme 2). Compound 16 was obtained by replacing the 
protective group in the 6-position and used for glycosylation of compound 10 ( 17). 
Full deprotection finally yielded compound 19. 
Scheme 2. a) i. PhSH, BF3⸱Et2O, DCM, rt, 2 h, ii. MeONa, MeOH, rt, overnight, 74%, iii. TBDPSCl, 
imidazole, DMF, 0 °C  rt, 8 h, 92%, iv. AllBr, NaH, DMF, rt, 30 min, 73%; b) i. TBAF 1 M, AcOH, 
0 °C  rt, overnight, 78%, ii. NaH, BnBr, DMF, 0 °C  rt, 1 h, 77%; c) 10, NIS, TMSOTf, 
Et2O/DCM 2:1, -55  30 °C, 4 h, 39%; d) DMBA, Pd(OAc)2, PPh3, MeOH/DCM 3:1, rt  40 °C, 5 h, 
78%; e) MeONa, MeOH, rt, 18 h, 67%. 
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A similar approach proved ineffective for synthesizing compound 25a and congeners. 
Therefore, the synthetic pathway in scheme 3 was designed. Compound 14 was 
glycosylated with 10, to obtain 20. The benzoyl groups of compound 20 were 
exchanged for allyl groups, and then the TBDPS group was removed, to yield 23. 
Alkylation of 23 with the appropriate halogenide and removal of the allyl groups 
provided access to compound 25a-g. 
 
 
Scheme 3. a) 10, NIS, TMSOTf, DCM, -45  -15 °C, 5 h, 67%; b) i. MeONa, MeOH, rt, 40 h, 75%, 
ii. AllBr, NaH, DMF, 0 °C  rt, 50 min, 62%; iii. TBAF 1M, AcOH, 0 °C  rt, overnight, 90%; c) 
ArCH2X, NaH, DMF, 0 °C  rt, 2-33 h, 74-50%; d) DMBA, Pd(OAc)2, PPh3, MeOH/DCM 3:1, rt  
40 °C, 7-24 h, 65-23%. 
 
The binding to PapG-IILD of the small set of probe compounds was investigated by 
isothermal titration calorimetry (ITC). As expected, the affinity of compound 13a, 
which bears the 6’-OMe group, drops to about 50% of the value for 2, due to a ΔΔG 
of 1.7 kJ/mol. This is in good agreement with previous studies on PapG-I [2]. 
The difference in Gibbs free energy between compound 2 and 13a is due to 8.0 
kJ/mol for ΔΔH and -6.2 kJ/mol for TΔΔS, which can be related to the loss of a 
hydrogen bond (improved entropy and reduced enthalpic contribution), only partially 
compensated by the lower desolvation penalty (improved enthalpy). Disappointingly, 
increasing the size of the 6’-O alkyl substituent (compounds 13b and 13c) proved 
detrimental. For compound 13b the reduction of affinity, compared to 13a, is due 
almost exclusively to entropy, with TΔΔS = 3.4 kJ/mol. This strongly suggests that 
the interaction with the protein is identical, but forces compound 13b, or the binding 
pocket’ side chains or both in an unfavorable conformation. Compound 13c, however, 
behaves differently, with an entropy term being more favorable for 13a (TΔΔS= -2.8 
kJ/mol), but an enthalpy importantly reduced (ΔΔH = 6.4 kJ/mol). A possible 
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explanation is a steric clash of the bulky 6’-substituent with the protein. Because of 
the loose interaction, residual movements – and therefore lower entropic cost – can be 
expected.  
 
Table 1. Thermodynamic signatures of PapG-IILD ligands. C values are not reported as in all cases they 
were < 0.01, thus requiring N to be fixed to 1. KD and ΔH values are average values of duplicate 
experiments at 95% c.i. 
 
  
Figure 3. Bar graph of the data from table 1. ΔG values are in green, ΔH in blue, and –TΔS in red. 
 
Compound 19 exhibits the most interesting thermodynamic profile. When compared 
to the reference compound 2, ΔΔH = -8.4 kJ/mol and TΔΔS = 12.8 kJ/mol were 
obtained. Desolvation alone does not explain this result, as according to the 
hydrophobic effect a more favorable entropy contribution is expected. A possible 
explanation is the formation of a π-cation interaction of the phenyl ring and Lys103. 
Entry Cpd KD (95% c.i.) N 
∆G°Obs 
[kJ/mol] 
∆H° [kJ/mol] 
(95% c.i.) 
-T∆S°  
[kJ/mol] 
A 2 102 µM (98 – 107) 1 (fix) -22.8 
-51.4 
(-50.1 - -52.7) 28.6 
B 13a 212 µM (203 – 223) 1 (fix) -21.0 
-43.4 
(-41.8 - -45.1) 22.4 
C 13b 677 µM (617 – 742) 1 (fix) -18.1 
-43.0 
(-39.2 - -47.2) 25.8 
D 13c 1.6 mM (970 – 3332) 1 (fix) -15.9 
-36.6 
(-20.3 - -89.7) 20.7 
E 19 598 µM (566 – 632) 1 (fix) -18.4 
-59.8 
(-56.7 - -63.2) 41.4 
F 25a 945 µM (846 – 1060) 1 (fix) -17.3 
-39.0 
(-34.5 - -52.7) 21.7 
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The entropy penalty would then result from freezing of Lys103 side chain and at least 
partially from conformational restriction of the disaccharide. If this holds true, it 
should be possible to optimize the interaction with Lys103 and thus compensate for 
the large entropy cost. Maintaining the aromatic moiety, compounds 25b-g were 
synthesized and tested for binding to PapG-IILD. Due to the high protein demand for 
ITC experiments, this new set of molecules was evaluated in a cell-free plate-based 
competitive assay [13]. Results are summarized in table 2. Disappointingly, none of 
compounds 25b-g showed an improved affinity compared to 2. Compound 25f was 
not evaluated due to low solubility. Interestingly, functionalization of the aromatic 
ring with one methoxy group (25b) or one fluorine atom (25d) in para-position, or the 
extension of the linker between the disaccharide and the aromatic ring (25e) all 
resulted in superior affinity, compared to compound 19. Especially the relatively high 
affinity of compound 25d was unexpected, suggesting that interactions other than π -
cation are involved. To explain the observations and guide further studies, three 
representative molecules, namely 13a, 19, and 25e, were selected for co-
crystallization with PapG-IILD. 
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Table 2. IC50 and rIC50 values for the series of benzylated compounds. *For compound 19 the relative 
KD is reported.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In Figure 4, crystal structures of various disaccharides bound to the protein are shown. 
The asymmetric crystal units contain two protein molecules; a close-up of the binding 
pocket of each is presented, in order to highlight small differences. Compound 13a 
binds as predicted, but compounds 19 and 25e show a surprising arrangement of the 
phenyl ring, which is stacking over the backbone amide bond connecting Ser89 and 
Trp88. Interestingly, Lys103 is pushed away from the disaccharide core because of 
the larger 6’-O substituent; although in the complex with compound 25e it still 
presents two conformations, in presence of compound 19 it is frozen in one single 
conformation.  
 
Cpd R IC50 rIC50 
2 OH 326.8 1 
19 
 
— 5.9* 
25c 
 
3500 10.7 
25d 
 
839.6 2.5 
25g 
 
6500 19.9 
25b 
 
715.2 2.2 
25e 
 
622.4 1.9 
O
O
F
F
F
F
F
O
F
N
O
O
OMe
O
3
3.2.2 New Glycomimetics as Antagonists of the PapG-II Adhesin of E. coli 
 107
Figure 4. Binding pocket of PapG-IILD in complex with compounds 13a (A1, B1), 19 (A2, B2), 25e 
(A3, B3), and 2 (A4, B4). The two slightly different crystal structures (A and B) identified in each unit 
cell are compared side-by-side for each complex. The most important residues are depicted as white 
sticks. The protein structure is in cartoon representation. H-bonds are highlighted with dashed purple 
lines. Conserved water molecules are shown as sticks. Water molecules close to position 6’-O of the 
galabiose are highlighted with ticker sticks and Goodwell coloring style. Ligand carbon atoms are in 
green. Oxygen and nitrogen atoms are in red and blue, respectively. 
 
The analysis of the scaled B-factors can provide insights into the local dynamics of 
proteins [14]. The direct comparison of B factors extracted from different structures is 
A1 B1 
A2 
A3 
A4 
B2 
B3 
B4 
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not possible, as they are scaled differently, according to the refinement procedure [14]. 
For the calculation of the scaled B-factors the unity-based scaling and the z-score 
normalization are often applied. As both were shown to provide comparable results 
[14], in our study only the unity-based scaling according to equation 1 was applied. 
 
𝐵௫ೞ೎ೌ೗೐೏(೔) =
ൣ஻ೣ(೔)ି஻ౣ౟౤(೔)൧
ൣ஻ౣ౗౮(೔)ି஻ౣ౟౤(೔)൧
+ 1          eq. 1 
 
An important parameter when extracting information on residue’s dynamics is the 
resolution. At low resolution (< 2.5Å) the B-factors become less informative [14]. In 
our case, all complexes have very high and comparable resolution, reinforcing our 
interpretation. However, the crystal structure of the apo form has only 2.5Å resolution 
and should be considered with care. In Figure 5 the scaled B-factors for the atoms of 
Lys103 are summarized in a bar graph. The highest values are found for the apo form, 
whilst the lowest in the complex with 2. The disruption of the water-mediated bond 
with Lys103 (complex with 13a) improves its movement.  
  
Figure 5. Scaled B-factors for the atoms of Lys103 from the crystals of PapG-IILD. Apo form (blue) 
and in complex with 2 (cyan), 13a (red), 19 (green), and 25e (violet).  N, C, O, H: nitrogen, carbon, 
oxygen, and hydrogen atoms involved in the amide bond in the backbone of the protein; CA to CE: 
carbon atoms α to ε of the lysine; NZ: nitrogen atom of the ε amine group; HA to HE: hydrogen atoms 
bound to carbons α to ε; HZ: hydrogen atoms of the ε amine group. 
 
However, the introduction of the larger side chains of 19 and 25e reduces the B-
factors. The smallest values are recorder in presence of compound 19. This structural 
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information explains the observed thermodynamic data for compound 19. The lower 
desolvation cost for the benzyl ether substituent as compared to the OH group in 
position 6’ reduces the enthalpic cost. The stacking on the backbone amide bond has 
suboptimal geometry and likely contributes poorly to the thermodynamic signature, as 
it shows a displacement value x of about 2.5Å (Figure 6). This value is almost 2-fold 
larger than in the minimum-energy arrangement of model systems [15].  
From the comparison of the complexes of PapG-IILD with 2 and 13a, the broken 
water-mediated bond is estimated to contribute -1.7 kJ/mol ΔΔG. The limitation of 
Lys103 motion contributes negative entropy (Figure 4, A4-B4 and A1-B1).  
The increased affinity of compound 25e compared to 19 is likely due to the increased 
motion of Lys103 (Figure 5) and to better stacking on the amide backbone. This 
compensates well for the perturbation of the H-bond between Gly104 and 6’-O 
(Figure 4).  
 
 
Figure 6. Stacking of the phenyl ring of the 6’-benzyl group in compound 19 on the backbone of the 
protein. Chain A (left) and chain B (right). Ribbons are in green, residue Ser88 and the backbone of 
Trp89 are shown as sticks (carbon in grey, oxygen in red, nitrogen in blue, hydrogen in white). The 
ligand is represented in sticks (carbon in green, oxygen in red, nitrogen in blue, hydrogen in white). 
Distances are shown in strawberry color and highlighted by dashed lines. Numbers are in angstroms. 
Distance between planes = d; distance between centroids = r; displacement = x. 
 
The improvement in affinity of compounds 25b and 25d is difficult to rationalize. 
When related to the different dipole moments [15], this effect would be of opposite 
sign for the p-fluoro and p-methoxybenzyl substituents. Polarizability has been used 
to explain the improved interaction energy among substituted benzene dimers, due to 
the increased dispersion component [16]. However, values calculated on model 
r r 
d d x 
x 
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systems are not consistently correlated with the observed affinities (not shown). A 
further possible explanation involves a different binding mode, in which the fluorine 
atom of 25d and the methoxy group of 25b are interacting with the amino group of 
Lys103. 
 
 
Conclusions 
 
Co-crystallization of compound 2 with the lectin domain of PapG-II finally disclosed 
the binding mode of this structurally simplified mimetic of the natural epitope of 
GbO4. Based on these results and the examination of all previously published 
antagonists, a new, promising exit vector on the galabiose core was suggested. A 
series of probe compounds was evaluated for binding to PapG-IILD. Compound 19 
was identified as a new lead structure. However, none of the analogs 25a-g showed 
better affinity, when compared to the reference compound 2. Co-crystallization of 19 
and 25g with PapG-IILD revealed a strained conformation of the side chain in position 
6’-O of the galabiose core, that can explain the lack of improvements in affinity. 
These observations will help in rationally designing new antagonists. 
 
 
Experimental 
  
General methods: 
NMR spectra were recorded on a Bruker Avance DMX-500 (500.1 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D 
methods (COSY, HSQC, HMBC). Chemical shifts are expressed in ppm using 
residual CHCl3, CHD2OD, or HDO as references. Optical rotations were measured 
using PerkinElmer polarimeter 341. Electron spray ionization mass spectra were 
obtained on a Waters micromass ZQ. Reactions were monitored by TLC using glass 
plates coated with silica gel 60 F254 (Merck) and visualized under UV light and/or by 
charring with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate 
dihydrate and ammonium molybdate tetrahydrate in 10% aqueous H2SO4), or by 
oxidation with a 5% aqueous KMnO4 solution. MPLC separations were carried out on 
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a CombiFlash Rf (Teledyne Isco) equipped with RediSep normal-phase or RP-C18 
reversed-phase flash columns. LC−MS separations were done on a Waters system 
equipped with sample manager 2767, pump 2525, PDA 2525, and Micromass ZQ, 
using a SUNFIRE Prep C18 OBD 5 µM, 19x150 mm column, and eluting with the 
appropriate water/ACN gradient, in presence of 0.2% HCOOH. Commercially 
available reagents were purchased from Fluka, Aldrich, Alfa Aesar, or Abcr GmbH & 
Co. KG (Germany). Solvents were purchased from Sigma-Aldrich or Acros and were 
dried prior to use where indicated. Methanol (MeOH) was dried on 3Å heat-activated 
molecular sieves for at least 48 h before use. Figures were generated with Maestro 
(Schrödinger Release 2012: Maestro, version 9.3.5, Schrödinger, LLC, New York, 
NY, 2012), VMD [17], and Prism 5 (GraphPad Software Inc., San Diego, U.S.A.) 
 
Synthesis 
 
Phenyl 6-O-tert-butyldiphenylsilyl-1-thio-β-D-galactopyranoside (4): 
From peracetylated galactose 3 (1.0 g, 2.6 mmol), phenyl 1-thio-β-D-
galactopyranoside was synthesized as described in Ref. [12]. The obtained compound 
(591 mg, 2.17 mmol) and imidazole (222 mg, 3.26 mmol) were dissolved in 2 mL of 
DMF and cooled to 0 °C. TBDPSCl (657 mg, 2.39 mmol) was added dropwise with 
stirring. The mixture was allowed to warm to rt, and the solution was stirred for 7 h. 
To drive the reaction to completion, additional 0.1 eq of TBDPSCl were added, and 
stirring was prolonged for additional 8 h. Methanol was added (1 mL) to quench the 
reaction, then the solvents were removed under vacuum and by co-evaporation with 
xylenes. Chromatographic separation (DCM/MeOH gradient) yielded 4 (1.016 g, 
92%). 
[α]D20 -13.8 (c 1.00, CHCl3). 
ESI-MS: m/z: Calcd for C28H34NaO5SSi [M+Na]+: 533.2, found 533.1.  
1H and 13C NMR data were in accordance with literature values [18]. 
 
Phenyl 6-O-tert-butyldiphenylsilyl-2,3,4-tris-O-benzyl-1-thio-β-D-galactopyra-
noside (5): 
Compound 4 (1016 mg, 1.99 mmol) was dissolved in 1 mL of dry DMF and added 
dropwise to a suspension of NaH (191 mg referred to dry NaH, 7.96 mmol; total 
amount of the 60% dispersion in mineral oil added: 318 mg) in 8 mL of dry DMF at 0 
3.2 Results 
112 
 
°C. A solution of benzyl bromide (1.285 g, 7.560 mmol) in 7 mL of DMF was added 
dropwise, then the mixture was allowed to warm to rt, and the mixture was stirred 
until disappearance of the starting material on TLC. On TLC, some decomposition 
was evident. The reaction was quenched with MeOH (1 mL), then diluted with Et2O 
and washed with water and satd aq. NH4Cl. The organic layer was evaporated and 
chromatographed on silica (PE/EtOAc gradient) to yield 5 (564 mg, 36%), 6 (243 mg 
23%), and 96 mg (7.6%) of perbenzylated phenylthiogalactoside. 
Phenyl 6-O-tert-butyldiphenylsilyl-2,3,4-tris-O-benzyl-1-thio-β-D-galactopyranoside 
(5): 
ESI-MS: m/z: Calcd for C49H52NaO5SSi [M+Na]+: 803.3, found 803.4  
1H and 13C NMR data were in accordance with literature values [19]. 
 
Phenyl 2,3,4,6-tetra-O-benzyl-1-thio-β-D-galactopyranoside:  
1H and 13C NMR data were in accordance with literature values [12]. 
 
Phenyl 2,3,4-tris-O-benzyl-1-thio-β-D-galactopyranoside (6): 
Compound 5 (564 mg, 0.722 mmol) was dissolved in TBAF (1M in THF, 2.15 mL, 
7.44 mmol) at 0 °C, then glacial acetic acid was added (0.14 mL, 2.38 mmol) under 
argon. The reaction was allowed to proceed at rt, while monitoring by TLC 
(PE/EtOAc, 2:1). After 2 h the mixture was diluted with EtOAc and washed three 
times with brine, dried over Na2SO4, filtered and concentrated. The residue was 
chromatographed on silica (PE/EtOAc gradient) to yield 6 (292 mg, 74.5%). 
[α]D20 -9.4 (c 1.00, CHCl3) [20].  
ESI-MS: m/z: Calcd for C33H34NaO5S [M+Na]+: 565.2, found 565.2  
1H and 13C NMR data were in accordance with literature values [20]. 
 
Phenyl 6-O-methyl-2,3,4-tris-O-benzyl-1-thio-β-D-galactopyranoside (7a): 
Compound 6 (243 mg, 0.432 mmol) was dissolved in 2 mL of dry DMF and added 
dropwise to a suspension of NaH (60% dispersion in mineral oil, 35 mg, 0.864 mmol) 
in 3 mL of dry DMF at 0 °C. MeI (122.6 mg, 0.864 mmol) was added, then the 
mixture was allowed to warm to rt, and the mixture was stirred until disappearance of 
the starting material on TLC (EtOAc/PE, 2:3). The reaction was then quenched with 
MeOH, evaporated, and taken up in DCM/water. The water phase was extracted 3 
3.2.2 New Glycomimetics as Antagonists of the PapG-II Adhesin of E. coli 
 113
times with DCM, dried on Na2SO4, filtered, and evaporated. Chromatography on 
silica (PE/EtOAc gradient) yielded 7a (240 mg, 96%). 
ESI-MS: m/z: Calcd for C34H36NaO5S [M+Na]+: 579.2, found 579.2. 
1H NMR (500 MHz, CDCl3): δ = 7.56 (d, J = 2.6 Hz, 2H, Ar), 7.42 – 7.22 (m, 15H, 
Ar), 7.17 (s, 3H, Ar), 4.97 (d, J = 11.5 Hz, 1H, PhCHH), 4.78 (d, J = 10.2 Hz, 1H, 
PhCHH), 4.70 (dd, J = 19.5, 12.7 Hz, 3H, 3 PhCHH), 4.66 – 4.59 (m, 2H, PhCHH, H-
1), 3.98 - 3.90 (m, 2H, H-4, H-2), 3.62 - 3.50 (m, 4H, H-6a, H6b, H-3, H-5), 3.27 (s, 
3H, OCH3). 
 13C NMR (126 MHz, CDCl3): δ = 138.89 (Ar), 138.49 (Ar), 138.36 (Ar), 134.24 
(Ar), 131.67 (Ar), 128.89 (Ar), 128.55 (Ar), 128.43 (Ar), 128.41 (Ar), 128.33 (Ar), 
127.98 (Ar), 127.83 (Ar), 127.81 (Ar), 127.68, (Ar) 127.61 (Ar), 127.17 (Ar), 87.78 
(C-1), 84.25, 77.49, 77.37, 75.71, 74.57, 73.56, 72.75, 71.04, 59.21 (OCH3). 
 
Phenyl 6-O-propyl-2,3,4-tris-O-benzyl-1-thio-β-D-galactopyranoside (7b): 
A dispersion of 60% NaH in mineral oil (9.2 mg, 0.23 mmol) was suspended in dry 
DMF (2 mL) at 0 °C, then compound 6 (62.2 mg, 0.115 mmol) in dry DMF (1.25 mL) 
was added dropwise, followed by 1-iodopropane (22 µL, 0.23 mmol). The mixture 
was then allowed to warm to rt. The reaction was monitored by TLC (PE/EtOAc, 
3:2). After 2 h, 0.5 eq of NaH were added (2.3 mg, 0.06 mmol), followed by 0.5 eq of 
1-iodopropane (5.5 µL, 0.06 mmol). After 2.5 h the reaction was quenched with 
MeOH. The solvents were evaporated and the residue was taken up in DCM. The 
organic solution was washed with water. The water phase was extracted three times 
with DCM. The collected organic phases were dried on Na2SO4, filtered, and 
concentrated. The residue was chromatographed on silica (PE/EtOAc gradient) to 
yield compound 7b (34 mg, 51%). 
[α]D20 -0.5 (c 1.0, CHCl3). 
ESI-MS: m/z: Calcd for C36H40NaO5S [M+Na]+: 607.3, found 607.1. 
1H-NMR (500 MHz, CDCl3): δ = 7.52 – 7.43 (m, 2H, Ar), 7.34 – 7-12 (m, 15H, Ar), 
7.15 – 7.10 (m, 3H, Ar), 4.90 (d, J = 11.5 Hz, 1H, PhCHH), 4.71 (d, J = 10.2 Hz, 1H, 
PhCHH), 4.67 – 4.65 (m, 3H, 3 PhCHH), 4.58 (d, 2H, J = 2.1 Hz, H-1), 3.89 (d, J = 
2.8 Hz, 1H, H-4), 3.86 (t, J = 9.5 Hz, 1H, H-2), 3.54 (dd, J = 9.2, 2.8 Hz, 1H, H-3), 
3.51 – 3.49 (m, 3H, H-5, H-6a, H-6b), 3.33 – 3.27 (m, 1H, OCHHCH2CH3), 3.25 – 
3.12 (m, 1H, OCHHCH2CH3), 1.51 – 1.40 (m, 2H, OCH2CH2CH3), 0.81 (t, J = 7.4 
Hz, 3H, OCH2CH2CH3). 
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13C-NMR (126 MHz, CDCl3): δ = 131.52 (Ar), 128.76 (Ar), 128.43 (Ar), 128.19 (Ar), 
127.83 (Ar), 127.68 (Ar), 127.57 (Ar), 87.75 (C-1), 84.21, 77.27, 75.66, 74.47, 73.61, 
73.21, 72.73, 68.98(CH2CH2CH3), 22.88 (CH2CH3), 10.58 (CH3). 
 
Phenyl 6-O-(2-methylpropyl)-2,3,4-tris-O-benzyl-1-thio-β-D-galactopyranoside 
(7c): 
Powdered KOH (94.7 mg, 1.57 mmol) was suspended in dry DMSO (1 mL) and 
stirred for 10 min at 0 °C. Compound 6 (91.7 mg, 0.169 mmol) was added dropwise, 
followed by 1-bromo-2-methylpropane (0.185 mL, 1.69 mmol). The  mixture was 
allowed to warm to rt. The reaction was monitored by TLC (PE/EtOAc, 3:2). After 6 
h, an additional aliquot of KOH was added (94.7 mmol, 1.69 mmol). After 20 h, the 
reaction was complete. The mixture was diluted with water and the water phase was 
extracted three times with DCM. The collected organic phases were dried on Na2SO4, 
filtered, and concentrated. The residue was chromatographed on silica (PE/EtOAc 
gradient) to yield compound 5c (44 mg, ≈ 44%), slightly contaminated with an 
impurity. The compound was directly used for the next step without further 
purification. 
ESI-MS: m/z: Calcd for C37H42NaO5S [M+Na]+: 621.3, found 621.2. 
 
 
 
 
General procedure for the synthesis of compounds 11a-c: 
 
Glycosylation: 
Compound 10 was synthesized from 3 as described in ref. [12]. It was dissolved in 
dry DCM, together with 1.2 eq of NIS and 1.2 eq of compounds 7a-c. To the solution 
was added dry Et2O to a final composition of 1:2 DCM/Et2O, and final concentration 
of compound 10 of 0.03 M. The mixture was cooled to -55 °C, and then 0.17 eq of 
TMSOTf were added. The mixture was stirred at -55 °C for 1 – 5 h. To quench the 
reaction TEA was added (27 – 200 µL) at -55 °C. The temperature was then increased 
to rt, the mixture was diluted with DCM and washed subsequently with aq. Na2S2O3, 
satd aq. NaHCO3, and water. The organic phase was dried on Na2SO4, filtered and 
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concentrated. The residue was chromatographed on silica (PE/EtOAc gradient) to 
yield the fully protected disaccharides 10a-c. 
 
4-Methoxyphenyl (2,3,4-tri-O-benzyl-6-O-methyl-α-D-galactopyranosyl-(14)-
2,3,6 -tri-O-benzoyl-β-D-galactopyranoside (11a): 
7a (240 mg, 0.431 mmol). Reaction time: 1 h. Yield: 283 mg, 75%. 
ESI-MS: m/z: Calcd for C62H60NaO15 [M+Na]+ 1067.4, found 1067.6. 
1H NMR (500 MHz, CDCl3): δ = 8.04 (d, J = 7.7 Hz, 2H, Ar), 7.96 (t, J = 8.1 Hz, 4H, 
Ar), 7.59 (t, J = 7.3 Hz, 1H, Ar), 7.45 (dd, J = 19.8, 7.4 Hz, 6H, Ar), 7.38 – 7.21 (m, 
15H, Ar), 7.20 – 7.08 (m, 3H, Ar), 6.96 (d, J = 8.5 Hz, 2H, Ar), 6.65 (d, J = 8.5 Hz, 
2H, Ar), 5.98 (t, J = 9.1 Hz, 1H, H-2), 5.31 (d, J = 10.5 Hz, 1H, H-3), 5.14 (d, J = 7.7 
Hz, 1H, H-1), 5.01 – 4.76 (m, 7H, H-6a, H-6b, PhCHH, 2 PhCH2), 4.72 (d, J = 11.7 
Hz, 1H), 4.57 (d, J = 11.2 Hz, 1H, PhCHH), 4.45 (s, 1H, H-4), 4.36 – 4.27 (m, 1H, H-
5’), 4.26 – 4.15 (m, 2H, H-3’, H-5), 4.15 – 3.99 (m, 2H, H-2’, H-4’), 3.69 (s, 3H, Ar-
OCH3), 3.23 (t, J = 8.7 Hz, 1H, H-6a’), 2.96 (s, 3H, OCH3), 2.91 – 2.76 (m, 1H, H-
6b’).  
13C NMR (126 MHz, CDCl3): δ = 166.43 (C=O), 166.10 (C=O), 165.36 (C=O), 
155.56 (Ar), 151.31 (Ar), 138.94 (Ar), 138.75 (Ar), 138.40 (Ar), 133.34 (Ar), 133.25 
(Ar), 133.20 (Ar), 130.08 (Ar), 129.89 (Ar), 129.81 (Ar), 129.69 (Ar), 129.58 (Ar), 
129.11 (Ar), 128.53 (Ar), 128.48 (Ar), 128.41 (Ar), 128.34 (Ar), 128.30 (Ar), 128.20 
(Ar), 128.18 (Ar), 127.59 (Ar), 127.48 (Ar), 118.83 (Ar), 114.44 (Ar), 101.09 (C-1), 
100.00 (C-1’), 78.98, 77.38, 77.12, 76.87, 76.10, 75.47 (C-4), 75.04 (PhCH2), 74.66, 
74.11, 74.05, 73.16, 72.58, 69.79 (C-6’), 69.62 (C-5’), 69.57 (C-2), 62.87 (C-6’), 
60.42, 58.59 (OCH3), 55.59 (Ar-OCH3). 
 
4-Methoxyphenyl (2,3,4-tri-O-benzyl-6-O-propyl-6-α-D-galactopyranosyl-(14)-
2,3,6-tri-O-benzoyl-β-D-galactopyranoside (11b): 
7b (90.0 mg, 0.154 mmol). Reaction time: 1 h. Yield: 73.8 mg, 54%. 
[α]D20 +26.0 (c 1.00, CHCl3).  
ESI-MS: m/z: Calcd for C64H64NaO15 [M+Na]+ 1095.4, found 1095.4. 
1H-NMR (500 MHz, CDCl3): δ = 7.98 – 7.94 (m, 2H, Ar), 7.91 – 7.85 (m, 4H, Ar), 
7.55 – 7.49 (m, 1H, Ar), 7.44 – 7.03 (m, 25H, Ar), 6.91 – 6.82 (m, 2H, Ar), 6.61 – 
6.52 (m, 2H, Ar), 5.89 (dd, J = 10.5, 7.8 Hz, 1H, H-2), 5.20 (dd, J = 10.5, 3.0 Hz, 1H, 
H-3), 5.04 (d, J = 7.8 Hz, 1H, H-1), 4.87 – 4.66 (m, 7H, H-1’, H-6a, H-6b, PhCHH, 2 
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PhCH2), 4.62 (d, J = 11.8 Hz, 1H), 4.48 (d, J = 11.1 Hz, 1H, H-2’), 4.36 (d, J = 2.6 
Hz, 1H, H-4), 4.23 (dd, J = 9.2, 5.5 Hz, 1H, H-5’), 4.16 – 3.96 (m, 4H, H-2’, H-3’, H-
5, H-4’), 3.63 (s, 3H, OCH3), 3.21 (t, J = 8.9 Hz, 1H, H-6’a), 2.92 (dt, J = 8.9, 7.0 Hz, 
1H, OCHHCH2CH3), 2.87 – 2.77 (m, 2H, H-6’b, OCHHCH2CH3), 1.39 – 1.36 (m, 2H, 
OCH2CH2CH3), 0.78 (t, J = 7.4 Hz, 3H, OCH2CH2CH3).  
13C-NMR (126 MHz, CDCl3): δ = 166.41 (C=O), 166.08 (C=O), 165.30 (C=O), 
155.52 (Ar), 151.30 (Ar), 139.03 (Ar), 138.79 (Ar), 138.36 (Ar), 129.78 (Ar), 128.49 
(Ar), 128.43 (Ar), 128.39 (Ar), 128.34 (Ar), 128.29 (Ar), 128.13 (Ar), 128.03 (Ar), 
127.51 (Ar), 118.80 (Ar), 114.40 (Ar), 101.17 (C-1), 101.07 (C-1’), 78.89 (C-3’), 
77.28, 77.03, 76.78, 76.09 (C-2’), 75.51 (C-4), 75.02 (PhCH2), 74.80 (PhCH2), 74.09, 
73.13, 72.72, 72.51, 69.84 (C-5’), 69.58 (C-2), 67.66 (C-6’), 62.84, 55.58 (Ar-CH3), 
22.91 (OCH2CH2CH3), 10.65 (OCH2CH2CH3).  
 
4-Methoxyphenyl [2,3,4-tri-O-benzyl-6-O-(2-methylpropyl)-α-D-galactopyranos-
yl]-(14)-2,3,6-tri-O-benzoyl-β-D-galactopyranoside (11c): 
7c (36.7 mg, 0.061 mmol). Reaction time: 3.5 h, at -55 °C; 1 h at -45 °C, then 
additional TMSOTf (1 μL, 0.050 mmol) at -55 °C and 1 h at -55 °C. Yield: 17.8 mg, 
27%. 
[α]D20 +24.2 (c 1.05, CHCl3).  
ESI-MS: m/z: Calcd for C33H34NaO5S [M+Na]+ 1109.4, found 1109.4. 
1H NMR (500 MHz, CDCl3): δ = 7.99 – 7.95 (m, 2H, Ar), 7.89 (d, J = 7.9 Hz, 4H, 
Ar), 7.53 (t, J = 7.4 Hz, 1H, Ar), 7.45 – 7.04 (m, 25H, Ar), 6.89 – 6.87 (m, 2H, Ar), 
6.59 – 6.55 (m, 2H, Ar), 5.90 (dd, J = 10.5, 7.8 Hz, 1H, H-2), 5.19 (dd, J = 10.5, 2.9 
Hz, 1H, H-3), 5.05 (d, J = 7.8 Hz, 1H, H-1), 4.85 - 4.81 (m, 3H, H-1’, 2 PhCHH), 
4.80 – 4.67 (m, 5H, H-6a, H-6b, 3 PhCHH), 4.63 (d, J = 11.7 Hz, 1H, PhCHH), 4.48 
(d, J = 11.1 Hz, 1H, H-2’), 4.37 (d, J = 2.7 Hz, 1H, H-4), 4.24 (dd, J = 9.3, 5.4 Hz, 1H, 
H-5’), 4.17 – 4.06 (m, 2H, H-3’, H-5), 4.05 – 3.98 (m, 2H, H-2’, H-4’), 3.63 (s, 3H, 
OCH3), 3.23 (t, J = 9.0 Hz, 1H, H-6a’), 2.82 (dd, J = 8.4, 5.0 Hz, 1H, H-6b’), 2.78 – 
2.66 (m, 2H, isobutyl CH2), 1.71 – 1.60 (m, 1H, isobutyl CH), 0.79 (dd, J = 19.1, 6.7 
Hz, 6H, isobutyl (CH3)2).  
13C-NMR (126 MHz, CDCl3): δ = 166.42 (C=O), 166.08 (C=O), 165.20 (C=O), 
155.51 (Ar), 139.09 (Ar), 138.81 (Ar), 138.35 (Ar), 133.26 (Ar), 133.19 (Ar), 129.87 
(Ar), 128.48 (Ar), 128.46 (Ar), 128.33 (Ar), 128.29 (Ar), 128.12 (Ar), 127.93 (Ar), 
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127.49 (Ar), 118.78 (Ar), 114.40 (Ar), 101.24 (C-1), 101.22 (C-1’), 78.99 (C-2’), 
77.96 (OCH2CH(CH3)2), 77.28, 77.02, 76.77, 76.11 (C-3’), 75.61 (C-4), 75.08, 75.01, 
74.08, 73.15, 72.51, 69.80 (C-5’), 69.58, 67.76 (C-6’), 62.88 (C-6), 55.58 (Ar-OCH3), 
28.51 (isobutyl CH), 19.66 (isobutyl CH3), 19.36 (isobutyl CH3).  
 
 
General procedure for the synthesis of compounds 12a-c: 
 
Cleavage of the benzoyl groups: 
The fully protected disaccharides were dissolved in dry MeOH, at a final 
concentration of approximately 0.01 M. Freshly prepared 1 M MeONa in dry 
methanol was added in one portion (approx. 1% of the volume of the solution). After 
stirring at rt under argon for 20 – 40 h, Amberlite IR-120 was added to neutralize the 
solution. After filtration, the solution was concentrated. The residue was 
chromatographed on silica (PE/EtOAc gradient) to yield the tri-O-benzyl protected 
disaccharides 12a-c. 
 
4-Methoxyphenyl (2,3,4-tri-O-benzyl-6-O-methyl-α-D-galactopyranosyl)-(14)-
β-D-galactopyranoside (12a): 
11a (283 mg, 0.386 mmol). Reaction time 20 h. Yield: 167 mg, 84%. 
[α]D20 - 4.0 (c 1.0, CHCl3).  
ESI-MS: m/z: Calcd for C41H48NaO12 [M+Na]+ 755.3, found 755.4. 
1H NMR (500 MHz, CDCl3): δ = 7.45 – 7.27 (m, 15H, Ar), 6.99 (d, J = 8.2 Hz, 2H, 
Ar), 6.79 (d, J = 8.3 Hz, 2H, Ar), 4.92 (m, 2H, 2 PhCHH), 4.85 (s, 1H, H-1’), 4.77 (s, 
2H, PhCH2), 4.74 (d, J = 7.3 Hz, 1H, H-1), 4.70 (d, J = 11.8, 1H, PhCHH), 4.58 (d, J 
= 11.5 Hz, 1H, PhCHH), 4.18 – 4.08 (m, 2H, H-5’, H-2’), 4.07 – 3.96 (m, 2H, H-3’, 
H-4), 3.91 (s, 1H, H-4’), 3.83 – 3.69 (m, 7H, Ar-OCH3, H-2, H-6a, H-6b), 3.62 (s, 
1H), 3.56 – 3.41 (m, 2H, H-3, H-6’a), 3.30 (s, 3H, OCH3), 3.25 (d, J = 9.4 Hz, 1H, H-
6’b).  
13C NMR (126 MHz, CDCl3): δ = 155.39 (Ar), 151.31 (Ar), 138.16 (Ar), 138.10 (Ar), 
137.14 (Ar), 128.77 (Ar), 128.60 (Ar), 128.59 (Ar), 128.49 (Ar), 128.40 (Ar), 128.19 
(Ar), 127.89 (Ar), 127.84 (Ar), 127.43 (Ar), 118.51 (Ar), 114.49 (Ar), 102.57 (C-1), 
101.02 (C-1’), 80.47, 79.12 (C-3’), 77.34, 77.09, 76.83, 75.75, 74.96, 74.68, 74.48 (C-
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4’), 73.97, 73.84, 72.74, 71.99, 71.90 (C-6’), 71.38 (PhCH2), 60.37 (C-6), 59.36 
(OCH3), 55.64 (ArOCH3).  
 
4-Methoxyphenyl (2,3,4-tri-O-benzyl-6-O-propyl-α-D-galactopyranosyl)-(14)-
β-D-galactopyranoside (12b): 
11b (70.7 mg, 0.066 mmol). Reaction time 40 h. Yield: 47.4 mg, 95%. 
[α]D20 -2.5 (c 1.0, CHCl3).  
ESI-MS: m/z: Calcd for C43H52NaO12 [M+Na]+ 783.4, found 783.3. 
1H-NMR (500 MHz, CDCl3): δ = 7.43 – 7.33 (m, 15H, Ar), 7.08 – 7.01 (m, 2H, Ar), 
6.93 – 6.83 (m, 2H, Ar), 4.97 (t, J = 11.6 Hz, 2H), 4.88 (d, J = 3.6 Hz, 1H, H-1’), 4.83 
- 4.70 (m, 4H, H-1, H-1), 4.62 (d, J = 11.5 Hz, 1H), 4.24 – 4.11 (m, 2H, H-2’, H-5’), 
4.10 – 4.03 (m, 2H, H-4, H-3’), 3.96 (d, 1H, J = 1.8 Hz, H-4’), 3.88 – 3.72 (m, 7H, H-
2, Ar-OCH3, H-6a, H-6b, H-5), 3.60 – 3.50 (m, 2H, H-6’a, H-3), 3.45 – 3.27 (m, 3H, 
H-6’b, CH2CH2CH3), 1.68 – 1.56 (m, 2H, CH2CH2CH3), 0.97 - 0.91 (m, 3H, 
CH2CH2CH3).  
13C-NMR (126 MHz, CDCl3): δ = 155.38 (Ar), 151.30 (Ar), 138.22 (Ar), 138.14 (Ar), 
137.15 (Ar), 128.77 (Ar), 128.62 (Ar), 128.58 (Ar), 128.49 (Ar), 128.39 (Ar), 128.19 
(Ar), 127.87 (Ar), 127.84 (Ar), 127.44 (Ar), 118.53 (Ar), 114.49 (Ar), 102.54 (C-1) 
101.12 (C-1’), 80.50 (C-4), 79.11 (C-3’), 77.83, 77.12, 76.87, 75.78 (C-2’), 74.95 
(PhCH2), 74.70 (C-4’), 74.58 (PhCH2), 74.05 (C-3), 73.85, 73.43 (CH2CH2CH3), 
72.74, 71.99, 71.51 (C-5’), 69.95 (C-6’), 60.34, 55.64 (ArOCH3), 22.85 
(CH2CH2CH3), 10.48 (CH2CH2CH3).  
 
4-Methoxyphenyl [2,3,4-tri-O-benzyl-6-O-(2-methylpropyl)-α-D-galactopyranos-
yl]-(14)-β-D-galactopyranoside (12c): 
11c (17.8 mg, 0.016 mmol). Reaction time 24 h. Yield: 11.9 mg, 96%. 
[α]D20 -2.8 (c 1.0, CHCl3).  
ESI-MS: m/z: Calcd for C26H34NaO12 [M+Na]+ 797.4, found 797.4. 
1H NMR (500 MHz, CDCl3): δ = 7.46 – 7.30 (m, 15H, Ar), 7.03 – 7.01 (m, 2H, Ar), 
6.84 – 6.82 (m, 2H, Ar), 4.96 (t, J = 11.4 Hz, 2H), 4.88 (d, J = 3.7 Hz, 1H, H-1’), 4.81 
(s, 2H, PhCH2), 4.78 (d, J = 7.5 Hz, 1H, H-1), 4.78 (d, J = 11.5 Hz, 1H, PhCHH), 
4.61 (d, J = 11.4 Hz, 1H, PhCHH), 4.18 (dd, J = 6.8, 3.9 Hz, 2H, H-5’, H-2’), 4.11 – 
4.04 (m, 2H, H-3’, H-4), 3.96 (d, J = 1.7 Hz, 1H, H-4’), 3.89 – 3.71 (m, 7H, ArOCH3, 
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H-2, H-6a, H-6b, H-5), 3.59 – 3.50 (m, 2H, H-6’a, H-3), 3.31 (dd, J = 9.6, 4.2 Hz, 1H, 
H-6’b), 3.16 (m, 2H, isobutyl CH2), 1.92 – 1.80 (m, 1H, isobutyl CH), 0.96 – 0.88 (m, 
6H, isobutyl (CH3)2).  
13C-NMR (126 MHz, CDCl3): δ = 155.38 (Ar), 151.26 (Ar), 138.19 (Ar), 138.09 (Ar), 
137.07 (Ar), 128.76 (Ar), 128.63 (Ar), 128.57 (Ar), 128.51 (Ar), 128.37 (Ar), 128.15 
(Ar), 127.83 (Ar), 127.41 (Ar), 118.48 (Ar), 114.47 (Ar), 102.48 (C-1), 101.23 (C-1’), 
80.41 (C-4), 79.04, 78.69 (isobutyl CH2), 77.28, 77.03, 76.77, 75.50 (C-2’), 74.99 
(PhCH2), 74.74 (PhCH2), 74.65 (C-4’), 74.01 (C-3’), 73.82, 72.72 (PhCH2), 72.08, 
71.56 (C-5’), 70.15 (C-6’), 60.24, 55.64 (ArOCH3), 29.71, 28.43 (isobutyl CH), 19.41 
(isobutyl CH3), 19.32 (isobutyl CH3).  
 
 
General procedure for the synthesis of compounds 13a-c: 
 
Cleavage of the benzyl groups: 
The benzyl-protected disaccharides were dissolved in AcOH under argon, Pd on 
charcoal (5-10% Pd) was added (2:1 disaccharide/Pd-C) and the mixture was 
hydrogenated (1 atm H2, balloon) with stirring. The reaction was monitored by TLC 
(DCM/MeOH, 9:1). After 2-13 h the mixture was diluted with MeOH and filtered 
through celite. The filtrate was concentrated and the residue chromatographed on 
silica (DCM/MeOH gradient) to yield compounds 13a-c. 
4-Methoxyphenyl (6-O-methyl-α-D-galactopyranosyl)-(14)-β-D-galactopyrano-
side (13a): 
12a (160 mg, 0.218 mmol). Reaction time: 13 h. Yield: 86 mg, 85%. 
[α]D20 +8.0 (c 1.0, CHCl3).  
ESI-MS: m/z: Calcd for C20H30NaO12 [M+Na]+ 485.2, found 485.2. 
1H NMR (500 MHz, CD3OD): δ = 7.08 (d, J = 8.5 Hz, 2H, Ar), 6.86 (d, J = 8.5 Hz, 
2H, Ar), 5.01 (s, 1H, H-1’), 4.83 (d, J = 7.6 Hz, 1H, H-1), 4.44 (t, J = 6.0 Hz, 1H, H-
5’), 4.07 (s, 1H, H-4), 3.92 (s, 1H, H-4’), 3.91 – 3.72 (m, 9H, H-2, H-2’, ArOCH3, H-
6a, H-6b, H-5, H-3’), 3.65 (d, J = 10.1 Hz, 1H, H-3), 3.60 (d, J = 5.9 Hz, 2H, H-6’a, 
H-6’b), 3.42 (s, 3H, OCH3).  
13C NMR (126 MHz, CD3OD): δ = 156.79 (Ar), 153.00 (Ar), 119.31 (Ar), 115.55 
(Ar), 104.08 (C-1), 102.71 (C-1’), 79.60 (C-4), 76.22, 74.60 (C-3), 72.98 (C-6’), 
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72.75 (C-2’), 71.28 (C-5’), 71.13 (C-4’), 71.03, 70.68, 61.13 (C-6), 59.57 (OCH3), 
56.11 (ArOCH3).  
 
4-Methoxyphenyl (6-O-propyl-α-D-galactopyranosyl)-(14)-β-D-galactopyrano-
side (13b): 
12b (47.4 mg, 0.062 mmol). Reaction time: 2 h. Yield: 24.4 mg, 81%. 
[α]D20 +5.8 (c 1.0, MeOH).  
ESI-MS: m/z: Calcd for C22H34NaO12 [M+Na]+ 513.2, found 513.1. 
1H-NMR (500 MHz, CD3OD): δ = 7.08 (m, 2H, Ar), 6.87 (m, 2H, Ar), 5.00 (d, J = 
1.9 Hz, 1H, H-1’), 4.83 (d, J = 7.6 Hz, 1H, H-1), 4.44 (t, J = 6.3 Hz, 1H, H-5’), 4.07 
(d, J = 3.0 Hz, 1H, H-4), 3.95 (s, 1H, H-4’), 3.92 – 3.70 (m, 9H, H-2, ArOCH3, H-2’, 
H-6a, H-6b, H-5, H-3’), 3.68 – 3.59 (m, 3H, H-3, H-6’a, H-6’b), 3.49 (t, J = 6.4 Hz, 
2H, OCH2CH2CH3), 1.70 – 1.59 (m, 2H, OCH2CH2CH3), 0.96 (t, J = 7.4 Hz, 3H, 
OCH2CH2CH3).  
13C-NMR (126 MHz, CD3OD): δ = 156.79 (Ar), 153.00 (Ar), 119.31 (Ar), 115.53 
(Ar), 104.11 (C-1), 102.73 (C-1’), 79.50 (C-4), 76.24, 74.59 (C-3), 74.42, 72.78 (C-2), 
71.36 (C-5’), 71.14 (C-2’), 71.03, 70.83, 70.72 (C-6’), 61.07, 56.09, 49.55, 49.38, 
49.21, 49.04, 48.87, 48.70, 48.53, 23.85 (OCH2CH2CH3), 10.91 (OCH2CH2CH3).  
 
4-Methoxyphenyl [6-O-(2-methylpropyl)-α-D-galactopyranosyl]-(14)-β-D-ga-
lactopyranoside (13c): 
12c (11.9 mg, 0.015 mmol). Reaction time: 2 h. Yield: 6 mg, 79%. 
[α]D20 +2.6 (c 1.0, MeOH).  
ESI-MS: m/z: Calcd for C23H36NaO12 [M+Na]+ 527.2, found 527.1. 
1H NMR (500 MHz, CD3OD): δ = 7.11 – 7.05 (m, 2H, Ar), 6.89 – 6.82 (m, 2H, Ar), 
5.01 (s, 1H, H-1’), 4.83 (d, J = 7.5 Hz, 1H, H-1), 4.46 (t, J = 6.5 Hz, 1H, H-5’), 4.07 
(d, J = 3.0 Hz, 1H, H-4), 3.97 (d, J = 1.0 Hz, 1H, H-4’), 3.91 – 3.71 (m, 9H, H-2, H-2’, 
H-3’, H-6a, H-6b, H-5, ArOCH3), 3.69 – 3.58 (m, 3H, H-6’a, H-6’b), 3.30 (d, J = 6.7 
Hz, 2H, isobutyl CH2), 1.91 (dp, J = 13.4, 6.7 Hz, 1H, isobutyl CH), 0.95 (d, J = 0.6 
Hz, 3H, isobutyl CH3), 0.94 (d, J = 0.6 Hz, 3H, isobutyl CH3). 
13C-NMR (126 MHz, CD3OD): δ = 156.80 (Ar), 153.00 (Ar), 119.30 (Ar), 115.51 
(Ar), 104.10 (C-1), 102.70 (C-1’), 79.68 (isobutyl CH2), 79.24 (C-4), 76.29, 74.57 (C-
3), 72.79 (C-2), 71.37, 71.02, 70.95 (C-6’), 70.74 (C-5’), 61.00 (C-6), 56.07 
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(ArOCH3), 49.53, 49.36, 49.10, 49.02, 48.85, 48.68, 48.51, 29.54 (isobutyl CH), 
19.76 (isobutyl CH3).  
 
Phenyl 2,3,4-tri-O-allyl-6-O-tert-butyldiphenylsilyl-1-thio-β-D-galactopyranoside 
(14): 
To a cooled solution (0 °C) of AllBr (0.206 mL, 2.38 mmol) in dry DMF (3 mL) 
under argon, a 60% NaH dispersion in oil (95.2 mg, 2.38 mmol) was added, followed 
by a solution of 4 (320 mg, 0.627 mmol) in dry DMF (3 mL). The temperature was 
increased to rt. The reaction was monitored by TLC (PE/EtOAc, 1:1). After 1 h, the 
reaction was quenched with MeOH. The mixture was neutralized with a solution of 
10% AcOH in MeOH, diluted with DCM, and washed with water. The water phase 
was extracted three times with DCM. The organic phases were collected and extracted 
twice with a 1:1 mixture of water and brine, dried over Na2SO4, filtered and 
concentrated. The residue was purified by chromatography on silica gel (PE/EtOAc 
gradient) to yield 14 (288.3 mg, 73%).  
[α]D20 +1.8 (c 1.0, CHCl3).  
ESI-MS: m/z: Calcd for C37H46NaO5SSi [M+Na]+ 653.3, found 653.2. 
1H NMR (500 MHz, CDCl3): δ = 7.67 – 7.62 (m, 4H, Ar), 7.51 – 7.47 (m, 2H, Ar), 
7.45 – 7.33 (m, 6H, Ar), 7.23 – 7.15 (m, 3H, Ar), 6.00 – 5.80 (m, 3H, 3 
CH2CHCH2O), 5.33 – 5.06 (m, 6H, 3 CH2CHCH2O), 4.48 (d, J = 9.7 Hz, 1H, H-1), 
4.38 – 4.36 (m, 1H, CH2CHCHHO), 4.27 – 4.16 (m, 4H, 2 CH2CHCHHO), 4.12 – 
4.07 (m, 1H, CH2CHCHHO), 3.89 (d, J = 1.8 Hz, 1H, H-4), 3.86 (d, J = 7.7 Hz, 1H, 
H-6a), 3.81 – 3.78 (m, 1H, H-6b), 3.65 (t, J = 9.4 Hz, 1H, H-2), 3.42 (dd, J = 7.1, 6.2 
Hz, 1H, H-5), 3.36 (dd, J = 9.2, 2.8 Hz, 1H, H-3), 1.07 (d, J = 5.2 Hz, 9H, C(CH3)3).  
13C-NMR (126 MHz, CDCl3): δ = 135.58 (CH2CHCH2O), 135.56 (Ar), 135.07 
(CH2CHCH2O), 134.93 (CH2CHCH2O), 134.51 (Ar), 133.29 (Ar), 131.17 (Ar), 
129.77 (Ar), 128.70 (Ar), 127.75 (Ar), 127.74 (Ar), 126.83 (Ar), 116.89 
(CH2CHCH2O), 116.68 (CH2CHCH2O), 116.17 (CH2CHCH2O), 87.76 (C-1), 83.77 
(C-3), 78.68 (C-5), 74.44 (CH2CHCH2O), 73.55 (CH2CHCH2O), 73.13 (C-4), 72.74 
(C-2), 71.64 (CH2CHCH2O), 62.24 (C-6), 26.90 (C(CH3)3).  
 
Phenyl 2,3,4-tri-O-allyl-1-thio-β-D-galactopyranoside (15): 
A solution of TBAF (1M in THF, 1.363 mL, 4.709 mmol) was neutralized with 
glacial acetic acid, cooled down to 0 °C and added to 14 (288 mg, 0.457 mmol). The 
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reaction was monitored with TLC (PE/EtOAc, 1:1). After 20 h, the reaction was 
complete. The product was diluted with EtOAc and washed twice with a mixture of 
brine and water (1:1). The organic phases were collected, dried over Na2SO4, filtered 
and concentrated. The residue was purified by chromatography on silica gel 
(PE/EtOAc gradient) to yield 15 (139.5 mg, 78%). 
[α]D20 +2.3 (c 0.80, CHCl3).  
ESI-MS: m/z: Calcd for C21H28NaO5S [M+Na]+ 415.2, found 414.8. 
1H NMR (500 MHz, CDCl3): δ = 7.57 – 7.51 (m, 2H, Ar), 7.30 – 7.18 (m, 3H, Ar), 
6.02 – 5.82 (m, 3H, 3 CH2CHCH2O), 5.34 – 5.12 (m, 6H, 3 CH2CHCH2O), 4.57 (d, J 
= 9.7 Hz, 1H, H-1), 4.37 (ddt, J = 12.8, 5.1, 1.4 Hz, 1H, CH2CHCHHO), 4.31 – 4.20 
(m, 2H, 2 CH2CHCHHO), 4.19 – 4.16 (m, 2H, CH2CHCH2O), 4.11 – 4.04 (m, 1H, 
CH2CHCHHO), 3.90 (dd, J = 11.4, 7.3 Hz, 1H, H-6a), 3.76 (d, J = 2.3 Hz, 1H, H-4), 
3.68 (m, 2H, H-2, H-6b), 3.49 – 3.44 (m, 1H, H-5), 3.40 (dd, J = 9.2, 2.9 Hz 1H, H-3).  
13C NMR (126 MHz, CDCl3): δ = 135.13 (CH2CHCH2O), 134.93 (CH2CHCH2O), 
134.70 (CH2CHCH2O), 134.07 (Ar), 131.51 (Ar), 128.84 (Ar), 127.18 (Ar), 117.27 
(CH2CHCH2O), 117.07 (CH2CHCH2O), 116.91 (CH2CHCH2O), 87.67 (C-1), 83.61 
(C-3), 78.85 (C-5), 74.50 (CH2CHCH2O), 73.75(C-4), 73.51 (CH2CHCH2O), 71.77 
(CH2CHCH2O), 62.54 (C-6). 
 
Phenyl 2,3,4-tri-O-allyl-6-O-benzyl-1-thio-β-D-galactopyranoside  (16): 
A dispersion of 60% NaH in oil (25.7 mg, 0.642 mmol) was suspended in dry DMF (2 
mL) at 0 °C was diluted with EtOAc and washed twice with a mixture of brine and 
water (1:1)15 (126 mg, 0.321 mmol) in dry DMF (1.5 mL). The mixture was allowed 
to warm to rt. The reaction was monitored by TLC (PE/EtOAc, 1:1). After 1 h, the 
reaction was quenched with MeOH. The solvents were evaporated and the residue 
taken up in DCM. The organic phase was washed with water. The water phase was 
extracted three times with DCM. The organic phases were collected, dried over 
Na2SO4, filtered and evaporated. The residue was purified by chromatography on 
silica gel (PE/EtOAc gradient) to yield 16 (118.8 mg, 77%).  
[α]D20 -5.9 (c 0.9, CHCl3).  
ESI-MS: m/z: Calcd for C28H34NaO5S [M+Na]+ 505.2, found 505.1. 
1H NMR (500 MHz, CDCl3): δ = 7.56 – 7.52 (m, 2H, Ar), 7.37 – 7.27 (m, 6H, Ar), 
7.27 – 7.18 (m, 3H, Ar), 6.02 – 5.82 (m, 3H, 3 CH2CHCH2O), 5.38 – 5.07 (m, 6H, 3 
CH2CHCH2O), 4.60 – 4.48 (m, 3H, H-1, PhCH2), 4.34 (dd, J = 12.8, 5.3 Hz, 1H, 
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CH2CHCHHO), 4.29 – 4.03 (m, 5H, 5 CH2CHCHHO), 3.83 (d, J = 2.7 Hz, 1H, H-4), 
3.75 – 3.62 (m, 3H, H-6a and 6b, H-2), 3.60 – 3.54 (m, 1H, H-5), 3.38 (dd, J = 9.2, 
2.9 Hz, 1H, H-3).  
13C-NMR (126 MHz, CDCl3): δ = 137.92 (Ar), 135-46 (CH2CHCH2O), 135.02 
(CH2CHCH2O), 134.81 (CH2CHCH2O), 134.41 (Ar), 131.45 (Ar), 128.74 (Ar), 
128.45 (Ar), 127.94 (Ar), 127.82 (Ar), 127.00 (Ar), 116.99 (CH2CHCH2O), 116.74 
(CH2CHCH2O), 116.52 (CH2CHCH2O), 87.89 (C-1), 83.52 (PhCH2), 77.37 (C-5), 
74.51 (CH2CHCH2O), 73.68 (CH2CHCH2O), 73.64 (CH2CHCH2O), 73.31 (C-4), 
71.57, 68.75 (C-6).  
 
4-Methoxyphenyl (2,3,4-tri-O-allyl-6-O-benzyl-α-D-galactopyranosyl)-(14)-
2,3,6-tri-O-benzoyl-β-D-galactopyranoside (17): 
Compound 10 (122 mg, 0.203 mmol), 16 (118 mg, 0.244 mmol) and NIS (54.9 mg, 
0.244 mmol) were dissolved in dry DCM (2.2 mL), then dry Et2O (4.3 mL) was added, 
and the mixture was cooled to -55 °C. TMSOTf (6.0 μL, 0.035 mmol) was then added, 
and the mixture stirred at the same temperature. The reaction was monitored by TLC 
(PE/EtOAc, 4:1). After 1 h the temperature was raised to -45 °C and after 2 h the 
temperature was increased to -30 °C. After 4 h TEA (0.120 mL) was added, and the 
reaction was stirred for 1 h at -30 °C. The temperature was increased to rt. The 
mixture was diluted with DCM, subsequently washed with aq. Na2S2O3, aq. NaHCO3 
and water, dried over Na2SO4, filtered and concentrated. The residue was purified by 
chromatography on silica gel (PE/EtOAc gradient) to yield 17 (77.5 mg, 39%).  
[α]D20 +28.5 (c 1.0, CHCl3).  
ESI-MS: m/z: Calcd for C56H58NaO15 [M+Na]+ 993.4, found 993.5. 
1H NMR (500 MHz, CDCl3): δ = 8.03 – 7.95 (m, 2H, Ar), 7.89 (dt, J = 8.4, 4.2 Hz, 
4H, Ar), 7.53 (dd, J = 10.5, 4.3 Hz, 1H, Ar), 7.47 – 7.38 (m, 3H, Ar), 7.35 (t, J = 7.4 
Hz, 1H, Ar), 7.32 – 7.14 (m, 12H, Ar), 6.96 – 6.85 (m, 2H, Ar), 6.65 – 6.53 (m, 2H, 
Ar), 5.95 – 5.70 (m, 4H, 3 CH2CHCH2O, H-2), 5.31 – 4.92 (m, 8H, 3 CH2CHCH2O, 
H-1, H-3), 4.88 (d, J = 3.6 Hz, 1H, H-1’), 4.78 (d, J = 6.6 Hz, 2H, H-6a, H-6b), 4.42 
(d, J = 2.7 Hz, 1H, H-4), 4.29 – 4.17 (m, 3H, H-5’, 2 CH2CHCHHO), 4.17 – 4.01 (m, 
6H, 3 CH2CHCHHO, H-5, PhCH2), 3.95 (dd, J = 12.4, 6.0 Hz, 1H, CH2CHCHHO), 
3.89 – 3.81 (m, 2H, H-3’, H-4’), 3.76 (dd, J = 10.0, 3.5 Hz, 1H, H-2’), 3.64 (s, 3H, 
ArOCH3), 3.41 – 3.29 (m, 1H, H-6’a), 2.97 (dd, J = 8.3, 4.9 Hz, 1H, H-6’b). 
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13C NMR (126 MHz, CDCl3): δ = 166.67 (C=O), 166.27 (C=O), 165.46 (C=O), 
155.66 (Ar), 151.45 (Ar), 138.54 (Ar), 135.72 (CH2CHCH2O), 135.23 
(CH2CHCH2O), 135.10 (CH2CHCH2O), 133.36 (Ar), 130.16 (Ar), 129.88 (Ar), 
129.80 (Ar), 128.65 (Ar), 128.59 (Ar), 128.53 (Ar), 128.41 (Ar), 127.70 (Ar), 127.56 
(Ar), 118.94 (Ar), 117.39 (CH2CHCH2O), 116.72 (CH2CHCH2O), 116.27 
(CH2CHCH2O), 114.55 (Ar), 101.47 (C-1’), 101.23 (C-1), 78.27, 77.89 (C-3’), 76.48 
(C-2’), 76.04, 75.84 (C-4), 74.46 (CH2CHCH2O), 74.35 (C-4’), 74.27 (C-3), 73.34, 
71.41, 69.83 (CH2CHCH2O), 69.68, 67.51 (C-6’), 63.06 (PhCH2), 55.72 (ArOCH3). 
 
4-Methoxyphenyl 6-O-benzyl-α-D-galactopyranosyl-(14)-2,3,6-tri-O-benzoyl-β-
D-galactopyranoside (18): 
DMBA (38.4 mg, 0.246 mmol), Pd(OAc)2 (1.8 mg, 0.008 mmol) and PPh3 (6.6 mg, 
0.025 mmol) were mixed in a reaction tube. A solution of 17 (39.8 mg, 0.041 mmol) 
in dry MeOH (0.3 mL) and dry DCM (0.1 mL) was added. The reaction was stirred at 
rt, monitoring by TLC (PE/EtOAc, 1:1). After 2 h the temperature was increased to 
40 °C. After 3 h the mixture was diluted with EtOAc and washed once with satd aq. 
NaHCO3. The water phase was extracted twice with EtOAc. The organic phases were 
collected and washed once with brine, dried over Na2SO4, filtered and concentrated. 
The residue was purified by chromatography on silica gel (PE/EtOAc gradient) to 
yield 18 (27.1 mg, 78%). 
[α]D20 +21.8 (c 1.00, CHCl3).  
ESI-MS: m/z: Calcd for C47H46NaO15 [M+Na]+ 873.3, found 873.4. 
1H NMR (500 MHz, CDCl3): δ = 8.10 – 8.05 (m, 2H, Ar), 7.99 – 7.90 (m, 4H, Ar), 
7.71 – 7.65 (m, 1H, Ar), 7.64 – 7.54 (m, 2H, Ar), 7.53 – 7.43 (m, 5H, Ar), 7.41 – 7.24 
(m, 7H), 7.15 – 7.09 (m, 2H, Ar), 6.98 – 6.92 (m, 2H, Ar), 6.72 – 6.65 (m, 2H, Ar), 
5.93 (dd, J = 10.5, 7.8 Hz, 1H, H-2), 5.33 (dd, J = 10.5, 3.0 Hz, 1H, H-3), 5.16 (d, J = 
7.8 Hz, 1H, H-1), 5.10 (d, J = 3.1 Hz, 1H, H-1’), 4.89 (dd, J = 11.4, 7.4 Hz, 1H, H-
6a), 4.75 (dd, J = 11.4, 6.4 Hz, 1H, H-6b), 4.56 (d, J = 2.9 Hz, 1H, H-4), 4.26 – 4.16 
(m, 3H, H-5’, PhCHH, H-5), 4.15 – 4.13 (m, 1H, H-4’), 4.03 (d, J = 12.0 Hz, 1H, 
PhCHH), 4.00 – 3.94 (m, 2H, H-2’, H-3’), 3.72 (s, 3H, ArOCH3), 3.07 (dd, J = 10.2, 
5.0 Hz, 1H, H-6’a), 3.00 (dd, J = 10.2, 3.7 Hz, 1H, H-6’b). 
13C NMR (126 MHz, CDCl3): δ = 166.21 (C=O), 166.11 (C=O), 165.61 (C=O), 
155.87 (Ar), 151.18 (Ar), 137.40 (Ar), 133.71 (Ar), 133.57 (Ar), 132.29 (Ar), 129.99 
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(Ar), 129.83 (Ar), 128.77 (Ar), 128.71 (Ar), 128.61 (Ar), 128.55 (Ar), 127.96 (Ar), 
127.68 (Ar), 127.18 (Ar), 119.06 (Ar), 114.62 (Ar), 101.23 (C-1), 100.87 (C-1’), 
74.09 (C-4), 73.92, 73.65 (PhCH2), 72.99 (C-5), 70.89 (C-4’), 70.60, 69.98 (C-6’), 
69.54, 69.12 (C-5’), 62.05 (C-6), 55.73 (ArOCH3). 
 
4-Methoxyphenyl 6-O-benzyl-α-D-galactopyranosyl-(14)-β-D-galactopyrano-
side (19): 
Compound 18 (53.6 mg, 0.063 mmol) was diluted in MeOH (7.5 mL) and freshly 
prepared 1 M MeONa/MeOH (59 μL) was added. The reaction was stirred at rt, 
monitoring by TLC (DCM/MeOH, 9:1). After 18 h, an additional aliquot of MeONa 
(30 µL) was added. After 24 h 10% AcOH in MeOH was added to neutralize the 
mixture. The mixture was evaporated and the residue chromatographed on silica gel 
(DCM/MeOH gradient) to yield 19 (22.7 mg, 67%).  
[α]D20 +3.4 (c 1.0, MeOH).  
ESI-MS: m/z: Calcd for C26H34NaO12 [M+Na]+ 561.2, found 561.2. 
1H NMR (500 MHz, CD3OD): δ = 7.41 (d, J = 7.3 Hz, 2H, Ar), 7.36 (t, J = 7.5 Hz, 
2H, Ar), 7.29 (t, J = 7.3 Hz, 1H, Ar), 7.10 – 7.06 (m, 2H, Ar), 6.88 – 6.84 (m, 2H, 
Ar), 5.02 (d, J = 1.8 Hz, 1H, H-1’), 4.83 (d, J = 7.6 Hz, 1H, H-1), 4.62 (s, 2H, 
PhCH2), 4.52 (t, J = 6.3 Hz, 1H, H-5’), 4.08 (d, J = 3.0 Hz, 1H, H-4), 3.95 (s, 1H, H-
4’), 3.89 (dd, J = 10.1, 6.3 Hz, 1H, H-6a), 3.85 – 3.75 (m, 8H, H-2’, H-2, H-3’, H-5, 
H-6b, ArOCH3), 3.70 – 3.63 (m, 3H, H-6’a, H-6’b, H-3). 
13C-NMR (126 MHz, CD3OD): δ = 156.80 (Ar), 152.96 (Ar), 139.67 (Ar), 129.39 
(Ar), 128.95 (Ar), 128.66 (Ar), 119.32 (Ar), 115.50 (Ar), 104.07 (C-1), 102.67 (C-1’), 
79.37 (C-4), 76.25 (C-3’), 74.62 (C-3), 74.43 (PhCH2), 72.74 (C-2), 71.29 (C-5’), 
71.20 (C-4’), 71.01 (C-2’), 70.69 (C-5), 70.34 (C-6’), 61.05 (C-6), 56.05 (ArOCH3). 
 
4-Methoxyphenyl (2,3,4-tri-O-allyl-6-O-tert-butyldiphenylsilyl-α-D-galacto-
pyranosyl)-(14)- 2,3,6-tri-O-benzoyl-β-D-galactopyranoside (20): 
Compound 14 (518.0 mg, 0.821 mmol), 10 (590 mg, 0.985 mmol), NIS (222 mg, 
0.985 mmol) and activated MS-4Å (20 mg) were mixed in dry DCM (18.6 mL) and 
stirred at rt for 30 min. The mixture was then cooled to -42 °C and TMSOTf (25 μL, 
0.14 mmol) was added. The reaction was monitored by TLC (PE/EtOAc, 2:8). After 1 
h the temperature was increased to -30 °C. After 3 h the reaction was quenched with 
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TEA at -40 °C, then warmed to rt, diluted with DCM, washed with 10% aq. Na2S2O3, 
aq. NaHCO3 and water. The organic phases were collected, dried over Na2SO4, 
filtered and concentrated. The residue was flash chromatographed on silica gel 
(PE/EtOAc gradient) to yield 20 (36 mg, 74%). 
[α]D20 +22.4 (c 1.00, CHCl3).  
ESI-MS: m/z: Calcd for C65H70NaO15Si [M+Na]+ 1141.5, found 1141.2. 
1H NMR (500 MHz, CDCl3): δ = 8.10 (d, J = 7.4 Hz, 2H, Ar), 7.96 (d, J = 7.4 Hz, 
2H, Ar), 7.83 (d, J = 7.5 Hz, 2H, Ar), 7.72 (d, J = 6.7 Hz, 2H, Ar), 7.67 (d, J = 6.5 Hz, 
2H, Ar), 7.60 (t, J = 7.4 Hz, 1H, Ar), 7.50 (dt, J = 21.2, 7.6 Hz, 4H, Ar), 7.44 – 7.26 
(m, 9H, Ar), 6.97 (d, J = 9.0 Hz, 2H, Ar), 6.92 (t, J = 7.8 Hz, 2H, Ar), 6.63 (d, J = 9.0 
Hz, 2H, Ar), 6.03 – 5.91 (m, 2H, CH2CHCH2O, H-2), 5.91 – 5.71 (m, 2H, 2 
CH2CHCH2O), 5.37 (dd, J = 17.2, 1.6 Hz, 1H, CHHCHCH2O), 5.26 (dd, J = 10.3, 2.8 
Hz, 1H, H-3), 5.20 – 5.18 (m, 1H), 5.18 – 5.15 (m, 2H, 2 CHHCHCH2O), 5.11 – 5.03 
(m, 2H, 2 CHHCHCH2O), 5.00 (d, J = 10.3 Hz, 1H, CHHCHCH2O), 4.90 – 4.82 (m, 
3H, H-1’, H-6a, H-6b), 4.52 (d, J = 2.0 Hz, 1H, H-4), 4.39 – 4.32 (m, 2H, 
CH2CHCHHO, H-5’), 4.30 – 4.18 (m, 4H, 3 CH2CHCHHO, H-5), 4.11 – 3.99 (m, 
3H, 2 CH2CHCHHO, H-4’), 3.94 (dd, J = 10.2, 2.5 Hz, 1H, H-3’), 3.81 – 3.74 (m, 
2H, H-2’, H-6’a), 3.70 (s, 3H, ArOCH3), 3.64 (m, 1H, H-6’b), 1.10 (s, 9H, C(CH3)3). 
13C NMR (126 MHz, CDCl3): δ = 166.60 (C=O), 166.21 (C=O), 164.84 (C=O), 
155.45 (Ar), 151.42 (Ar), 135.80, 135.77 (CH2CHCH2O), 135.64 (CH2CHCH2O), 
135.23 (CH2CHCH2O), 134.96 (Ar), 133.47 (Ar), 133.42 (Ar), 133.11 (Ar), 130.14 
(Ar), 130.02 (Ar), 129.75 (Ar), 129.67 (Ar), 129.59 (Ar), 129.55 (Ar), 128.90 (Ar), 
128.44 (Ar), 128.36 (Ar), 128.17 (Ar), 127.77 (Ar), 127.66 (Ar), 118.53 (Ar), 117.29 
(CH2CHCH2O), 116.35 (CH2CHCH2O), 116.03 (CH2CHCH2O), 114.41 (Ar), 101.87 
(C-1), 100.99 (C-1’), 78.49 (C-3’), 77.10 (C-2’), 76.83 (C-4), 74.57 (CH2CHCH2O), 
74.20 (C-3), 73.56 (C-4’), 73.02 (CH2CHCH2O), 71.79 (C-5), 71.50 (CH2CHCH2O), 
69.72 (C-2), 64.39 (C-6), 60.95 (C-6’), 55.56 (ArOCH3), 27.00 (C(CH3)3), 19.14 
(C(CH3)3).  
 
4-Methoxyphenyl (2,3,4-tri-O-allyl-6-O-tert-butyldiphenylsilyl-α-D-galacto-
pyranosyl)-(14)-β-D-galactopyranoside (21): 
Compound 20 (465 mg, 0.415 mmol) was dissolved in dry MeOH (3 mL) and freshly- 
prepared 1 M MeONa/MeOH (30 μL) was added. The reaction was stirred at rt and 
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monitored by TLC (PE/EtOAc, 1:1). After 4 h additional MeONa (30 μL) was added. 
After 24 h the mixture was diluted with MeOH and neutralized with 10% AcOH in 
MeOH. The mixture was concentrated and the residue was chromatographed on silica 
(PE/EtOAc gradient) to yield 21 (242.7 mg, 73%). 
[α]D20 +3.3 (c 1.0, CHCl3).  
ESI-MS: m/z: Calcd for C44H58NaO12 Si [M+Na]+ 829.4, found 829.5. 
1H NMR (500 MHz, CDCl3): δ = 7.74 – 7.64 (m, 4H, Ar), 7.50 – 7.39 (m, 6H, Ar), 
7.03 (d, J = 9.0 Hz, 2H Ar), 6.83 (d, J = 9.0 Hz, 2H, Ar), 6.04 – 5.70 (m, 3H, 3 
CH2CHCH2O), 5.37 – 5.32 (m, 1H, CHHCHCH2O), 5.31 – 5.26 (m, 1H, 
CHHCHCH2O), 5.23 (d, J = 10.3 Hz, 1H, CHHCHCH2O), 5.21 – 5.13 (m, 2H, 2 
CHHCHCH2O), 5.11 – 5.06 (m, 1H, CHHCHCH2O), 5.04 (d, J = 3.6 Hz, 1H, H-1’), 
4.73 (d, J = 7.3 Hz, 1H, H-1), 4.45 – 4.32 (m, 2H, CH2CHCH2O), 4.23 – 4.11 (m, 4H, 
CH2CHCH2O, CH2CHCHHO,  H-5’), 4.10 – 4.03 (m, 2H, CH2CHCHHO, H-4), 4.00 
– 3.90 (m, 2H, H-2’, H-4), 3.89 – 3.73 (m, 9H, H-3’, ArOCH3, H-6’a, H-6’b, H-6a, H-
6b, H-5), 3.59 (dd, J = 9.9, 7.5 Hz, 1H, H-2), 3.55 – 3.48 (m, 1H, H-3), 1.09 (s, 9H, 
C(CH3)3). 
 13C NMR (126 MHz, CDCl3): δ = 135.67 (Ar), 135.63 (CH2CHCH2O), 135.14 
(CH2CHCH2O), 134.71 (CH2CHCH2O), 133.84 (Ar), 133.68 (Ar), 130.06 (Ar), 
130.06 (Ar), 128.13 (Ar), 128.07 (Ar), 119.23 (CH2CHCH2O), 118.44 (Ar), 117.49 
(Ar), 117.38 (CH2CHCH2O), 116.76 (Ar), 116.60 (CH2CHCH2O), 114.69 (Ar), 
101.76 (C-1), 101.46 (C-1’), 80.21, 78.23 (C-3’), 76.37 (C-2’), 74.28, 73.89, 72.94 
(C-3), 72.54 (C-2), 71.41 (CH2CHCH2O), 74.12 (C-4’), 62.82 (C-6’), 60.13 (C-6), (C-
6’), 55.80 (ArOCH3), 27.08(C(CH3)3), 19.36 (C(CH3)3). 
 
4-Methoxyphenyl (2,3,4-tri-O-allyl-6-O-tert-butyldiphenylsilyl-α-D-galacto-
pyranosyl)-(14)-(2,3,6-tri-O-allyl-β-D-galactopyranoside) (22): 
To a cooled suspension (0 °C) of a 60% NaH dispersion in oil (42.1 mg, 1.05 mmol) 
in dry DMF (2 mL) under argon, a solution of 21 (243 mg, 0.301 mmol) in dry DMF 
was added, followed by AllBr (0.156 mL, 1.81 mmol). The mixture was allowed to 
warm to rt. The reaction was monitored by TLC (PE/EtOAc, 1:1). After 45 min the 
reaction was quenched with MeOH. The mixture was neutralized with a solution of 
10% AcOH in MeOH, diluted with DCM, and washed with water. The water phase 
was extracted three times with DCM, the organic phases were collected and washed 
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four times with a mixture of water and brine (1:1), dried over Na2SO4, filtered and 
concentrated. The residue was purified by chromatography on silica (PE/EtOAc 
gradient) to yield 22 (187 mg, 67%).  
[α]D20 +5.8 (c 0.9, CHCl3).  
ESI-MS: m/z: Calcd for C53H70NaO12 Si [M+Na]+ 949.5, found 949.6. 
1H NMR (500 MHz, CDCl3): δ = 7.75 – 7.61 (m, 4H, Ar), 7.48 – 7.33 (m, 6H, Ar), 
7.10 – 6.96 (m, 2H, Ar), 6.85 – 6.74 (m, 2H, Ar), 6.03 – 5.81 (m, 5H, 5 
CH2CHCH2O), 5.69 (ddd, J = 22.9, 10.8, 5.6 Hz, 1H, CH2CHCH2O), 5.36 (dq, J = 
17.2, 1.7 Hz, 1H, CHHCHCH2O), 5.28 – 5.26 (m, 1H, CHHCHCH2O), 5.26 – 5.21 
(m, 2H, 2 CHHCHCH2O), 5.21 – 5.17 (m, 1H, CHHCHCH2O), 5.17 – 5.15 (m, 2H, 2 
CHHCHCH2O), 5.15 – 5.09 (m, 3H, 3 CHHCHCH2O), 5.08 – 5.04 (m, 1H, 
CHHCHCH2O), 5.04 – 4.98 (m, 1H, CHHCHCH2O) 4.93 (d, J = 1.9 Hz, 1H, H-1’), 
4.74 (d, J = 7.7 Hz, 1H, H-1), 4.50 – 4.41 (m, 1H, CH2CHCHHO), 4.37 – 4.26 (m, 
4H, 3 CH2CHCHHO, H-5’), 4.26 – 4.20 (m, 2H, CH2CHCH2O), 4.19 – 4.03 (m, 3H, 
H-4, 2 CH2CHCHHO), 4.01 – 3.84 (m, 9H, H-2’, CH2CHCHHO, H-4, CH2CHCHHO, 
H-6’a, H-3’, CH2CHCH2O, H-6b), 3.76 (s, 3H, ArOCH3), 3.72 – 3.66 (m, 2H, H-2, 
H-6’b), 3.62 (dd, J = 9.2, 6.0 Hz, 1H, H-6a), 3.57 (t, J = 6.5 Hz, 1H,), 3.32 (dd, J = 
9.9, 3.0 Hz, 1H, H-3), 1.07 (s, 9H,  C(CH3)3). 
13C NMR (126 MHz, CDCl3): δ = 155.27 (Ar), 151.93 (Ar), 135.96 (Ar), 135.82 (Ar), 
135.73 (Ar), 135.49 (CH2CHCH2O), 135.43 (CH2CHCH2O), 135.32 (CH2CHCH2O), 
134.74 (Ar), 133.53 (Ar), 133.46 (Ar), 129.82 (Ar), 127.88 (Ar), 127.84 (Ar), 118.72 
(Ar), 117.32 (CH2CHCH2O), 117.05 (CH2CHCH2O), 116.79 (CH2CHCH2O), 116.58 
(CH2CHCH2O), 116.15 (CH2CHCH2O), 115.94 (CH2CHCH2O), 114.57 (Ar), 103.31 
(C-1), 100.55 (C-1), 79.45 (C-3), 79.05 (C-4), 78.16 (C-2), 76.80 (CH2CHCH2O), 
74.77 (C-3’), 74.62 (C-4’), 74.14 (CH2CHCH2O), 74.11(CH2CHCH2O), 74.05 (C-5), 
73.12 (CH2CHCH2O), 72.23 (CH2CHCH2O), 71.33 (CH2CHCH2O), 71.20 (C-2’), 
70.91 (C-5’), 68.19 (C-6’), 61.55 (C-6), 55.78 (ArOCH3), 27.10 C(CH3)3, 19.37 
C(CH3)3. 
 
4-Methoxyphenyl (2,3,4-tri-O-allyl-α-D-galactopyranosyl)-(14)-(2,3,6-tri-O-
allyl-β-D-galactopyranoside) (23): 
A solution of TBAF (1 M in THF, 0.585 mL, 2.02 mmol) was neutralized with glacial 
acetic acid, cooled down to 0 °C and added to compound 22 (182 mg, 0.196 mmol). 
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The mixture was stirred overnight at rt. The reaction was monitored by TLC 
(PE/EtOAc, 1:1). After complete consumption of the starting, the mixture was diluted 
with EtOAc and extracted twice with a mixture of brine and water (1:1). The organic 
phase was dried over Na2SO4, filtered and concentrated. The residue was 
chromatographed on silica (PE/EtOAc gradient) to yield 23 (12.6 mg, 91%).  
[α]D20 +14.8 (c 1.00, CHCl3).  
ESI-MS: m/z: Calcd for C37H52NaO12 [M+Na]+ 711.8, found 711.4. 
1H NMR (500 MHz, CDCl3): δ = 7.09 – 6.93 (m, 2H), 6.87 – 6.59 (m, 2H), 6.05 – 
5.77 (m, 6H), 5.37 – 5.30 (m, 2H), 5.30 – 5.27 (m, 2H), 5.27 – 5.23 (m, 2H), 5.22 – 
5.10 (m, 6H), 5.01 (d, J = 3.5 Hz, 1H, H-1’), 4.75 (d, J = 7.6 Hz, 1H, H-1), 4.54 – 
4.36 (m, 2H, 2 CH2CHCHHO), 4.32 – 4.21 (m, 3H, 3 CH2CHCHHO), 4.21 – 4.07 (m, 
6H, H-5’, 5 CH2CHCHHO), 4.05 – 3.90 (m, 4H, C-4, H-6a, 2 CH2CHCHHO), 3.88 – 
3.84 (m, 2H, H-2’, H-4’), 3.84 – 3.79 (m, 2H, H-6’a, H-3’), 3.77 (s, 3H, ArOCH3), 
3.73 – 3.62 (m, 4H, H-2, H-6’b, H-6b, H-5), 3.38 (dd, J = 10.0, 3.0 Hz, 1H, H-3), 2.69 
(dd, J = 9.3, 1.8 Hz, 1H, 6’-OH). 
13C NMR (126 MHz, CDCl3): δ = 155.34 (Ar), 151.86 (Ar), 135.42 (CH2CHCH2O), 
135.31 (CH2CHCH2O), 135.18 (CH2CHCH2O), 134.96(CH2CHCH2O), 134.76 
(CH2CHCH2O), 118.64 (Ar), 117.75  (CH2CHCH2O), 117.51 (CH2CHCH2O), 117.15 
(CH2CHCH2O), 116.85 (CH2CHCH2O), 116.77 (CH2CHCH2O), 116.28 
(CH2CHCH2O), 114.61 (Ar), 103.41 (C-1), 100.64 (C-1’), 80.84 (C-3), 78.79 (C-2), 
78.55 (C-3’), 76.77 (C-4’), 76.05 (C-2’), 75.97 (C-4), 74.27 (C-5), 74.18 
(CH2CHCH2O), 73.88 (CH2CHCH2O), 73.07 (CH2CHCH2O), 72.35 (CH2CHCH2O), 
72.18 (CH2CHCH2O), 71.60 (CH2CHCH2O), 71.41 (C-5), 68.46 (C-6), 63.23 (C-6’), 
55.80 (ArOCH3). 
  
 
General procedure for the synthesis of compounds 24a-g: 
 
Alkylation 
A 60% dispersion of NaH in oil (1.5 eq.) was suspended in dry DMF (1 mL) at 0 °C, 
then the halogenide (2.5 eq.) was added, followed by a solution of the carbohydrate (1 
eq.) in dry DMF (0.5 mL). The mixture was allowed to warm to rt. The reaction was 
monitored by TLC (PE/EtOAc, 8:2). When necessary, additional aliquots of NaH 
were added until completion of the reaction. After completion of the reaction the 
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mixture was poured on ice and diluted with DCM. The water phase was extracted 
three times with DCM. The organic phases were collected and dried over Na2SO4, 
filtered and concentrated. The residue was chromatographed on silica (PE/EtOAc 
gradient). 
 
4-Methoxyphenyl [2,3,4-tri-O-allyl-6-O-(3-pyridylmethyl)]-α-D-galactopyrano-
syl-(14)-2,3,4-tri-O-allyl-β-D-galactopyranoside (24a): 
Halogenide: 3-Chloromethyl pyridine•HCl. In this case, a catalytic amount of TBAI 
was also added. After 6.5 h a byproduct started to be evident on the TLC and the 
reaction was quenched by pouring on water at 0 °C. Yield: 34.4 mg, 49%.  
[α]D20 +10.7 (c 1.00, CHCl3).  
ESI-MS: m/z: Calcd for C43H58NO12 [M+H]+ 780.9, found 780.4. 
1H NMR (500 MHz, CDCl3): δ = 8.58 (s, 1H, Py),  8.55 (d, J = 3.7 Hz, 1H, Py), 7.66 
(dt, J = 7.8, 1.8 Hz, 1H, Py), 7.28 (dd, J = 7.8, 5.0 Hz, 1H, Py), 7.09 – 6.94 (m, 2H, 
Ar), 6.83 – 6.75 (m, 2H, Ar), 5.99 – 5.82 (m, 6H, 6 CH2CHCH2O), 5.37 – 5.29 (m, 
2H, 2 CHHCHCH2O), 5.29 – 5.25 (m, 2H, 2 CHHCHCH2O), 5.25 – 5.22 (m, 2H, 2 
CHHCHCH2O), 5.21 – 5.14 (m, 2H, 2 CHHCHCH2O), 5.14 – 5.06 (m, 4H, 4 
CHHCHCH2O), 4.99 (d, J = 3.1 Hz, 1H, H-1’), 4.74 (d, J = 7.7 Hz, 1H, H-1), 4.59 – 
4.48 (m, 2H, PyCH2O), 4.43 (dd, J = 8.6, 5.3 Hz, 1H, H-5’), 4.40 – 4.29 (m, 3H, 3 
CH2CHCHHO), 4.24 (m, 2H, 2 CH2CHCHHO), 4.18 (dt, J = 5.2, 1.5 Hz, 2H, 2 
CH2CHCHHO), 4.13 (ddt, J = 12.8, 6.0, 1.3 Hz, 1H, CH2CHCHHO), 4.11 – 4.04 (m, 
2H, 2 CH2CHCHHO), 4.02 (d, J = 3.1 Hz, 1H, H-4), 4.01 – 3.92 (m, 3H, H-6a, 2 
CH2CHCHHO), 3.91 (s, 1H, H-4’), 3.88 – 3.80 (m, 2H, H-2’, H-3’), 3.76 (s, 3H, 
ArOCH3), 3.73 – 3.65 (m, 2H, H-2, H-6’a), 3.64 – 3.57 (m, 2H, H-6b, H-5), 3.53 (dd, 
J = 8.3, 4.9 Hz, 1H, H-6’b), 3.34 (dd, J = 9.9, 3.1 Hz, 1H, H-3). 
13C NMR (126 MHz, CDCl3): δ = 155.30 (Py), 151.80 (Py), 149.48 (Py), 149.36 (Py), 
135.74 (CH2CHCH2O), 135.60 (CH2CHCH2O), 135.44 (Ar and CH2CHCH2O), 
135.33 (CH2CHCH2O), 135.24 (CH2CHCH2O), 134.65 (CH2CHCH2O), 133.67 (Ar), 
123.51 (Py), 118.78 (Ar), 117.24 (CH2CHCH2O), 116.77 (CH2CHCH2O), 116.71 
(CH2CHCH2O), 116.69 (CH2CHCH2O), 116.15 (CH2CHCH2O), 114.57 (Ar), 103.32 
(C-1), 100.15 (C-1’), 80.52 (C-3), 78.58 (C-2), 78.36 (C-5), 76.47 (C-2’), 74.48 (C-
4’), 74.28 (C-4), 74.17 (CH2CHCH2O), 74.05 (CH2CHCH2O), 73.97 (CH2CHCH2O), 
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73.14 (CH2CHCH2O), 72.28, 72.16 (CH2CHCH2O), 71.24 (CH2CHCH2O), 71.08 
(PyCH2O), 69.02 (C-5’), 68.63 (C-6’), 67.83 (C-6), 55.78 (ArOCH3). 
 
4-Methoxyphenyl [2,3,4-tri-O-allyl-6-O-(4-methoxyphenyl)]-α-D-galactopyrano-
syl)-(14)-2,3,6-tri-O-allyl-β-D-galactopyranoside (24b): 
Halogenide: 4-Methoxybenzyl chloride. After 2 h, additional 0.2 eq. of NaH (1 mg, 
0.027 mmol) and 2 eq. of 4-methoxybenzyl chloride (3 μL, 0.027 mmol) were added. 
After further 3.5 h, the reaction was complete. Yield: 65.4 mg, 60%.  
[α]D20 +9.2 (c 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.32 – 7.23 (m, 2H, Ar), 7.11 – 6.98 (m, 2H, Ar), 
6.95 – 6.84 (m, 2H, Ar), 6.82 – 6.71 (m, 2H, Ar), 6.16 – 5.80 (m, 6H, 6 
CH2CHCH2O), 5.35 – 5.16 (m, 7H, 7 CHHCHCH2O), 5.16 – 5.07 (m, 5H, 5 
CHHCHCH2O), 4.96 (d, J = 3.4 Hz, 1H, H-1’), 4.73 (d, J = 7.7 Hz, 1H, H-1), 4.47 – 
4.39 (m, 3H, H-5’, ArCH2O), 4.39 – 4.30 (m, 3H, 3 CH2CHCHHO), 4.30 – 4.24 (m, 
1H, CH2CHCHHO), 4.23 – 4.10 (m, 4H, 4 CH2CHCHHO), 4.10 – 4.02 (m, 2H, 2 
CH2CHCHHO), 4.01 (d, J = 3.1 Hz, 1H, H-4), 3.99 – 3.93 (m, 3H, 2 CH2CHCHHO, 
H-6a), 3.91 (d, J = 7.0 Hz, 1H, H-4’), 3.85 (dd, J = 10.3, 3.4 Hz, 1H, H-3’), 3.83 – 
3.80 (m, 2H, H-2’), 3.80 (s, 3H, ArOCH3), 3.76 (s, 3H, ArOCH3), 3.68 (dd, J = 9.9, 
7.7 Hz, 1H, H-2), 3.66 – 3.55 (m, 3H, H-6’a, H-6b, H-5), 3.47 (dd, J = 8.2, 4.7 Hz, 
1H, H-6’b), 3.33 (dd, J = 9.9, 3.1 Hz, 1H, H-3). 
13C NMR (126 MHz, CDCl3): δ = 159.45 (Ar), 155.28 (Ar), 151.81 (Ar), 135.92 
(CH2CHCH2O), 135.49 (CH2CHCH2O), 135.48 (CH2CHCH2O),  135.40 
(CH2CHCH2O), 135.29 (CH2CHCH2O), 134.64 (CH2CHCH2O), 130.35 (Ar), 129.77 
(Ar), 128.80 (Ar), 118.81 (Ar), 117.24 (CH2CHCH2O), 116.82 (CH2CHCH2O), 
116.73 (CH2CHCH2O), 116.66 (CH2CHCH2O), 116.62 (CH2CHCH2O), 116.09 
(CH2CHCH2O), 114.56 (Ar), 114.12, 113.96 (Ar), 103.30 (C-1), 100.16 (C-1’), 80.30, 
78.54, 78.36, 76.43, 74.40, 74.19 (CH2CHCH2O), 74.12 (CH2CHCH2O), 74.09 
(CH2CHCH2O), 73.96 (CH2CHCH2O), 73.28 (CH2CHCH2O), 73.14, 72.27, 72.05, 
71.09, 69.06 (C-6’), 67.81 (C-6), 55.78 (ArOCH3), 55.43 (ArOCH3). 
 
4-Methoxyphenyl (2,3,4-tri-O-allyl-6-O-pentafluorophenylmethyl)-α-D-galacto-
pyranosyl)-(14)-2,3,6- tri-O-allyl-β-D-galactopyranoside (24c): 
Halogenide: 2,3,4,5,6-Pentafluorobenzyl bromide. After 1.5 h, additional 0.3 eq. of 
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NaH were added, then stirring was continued for further 2 h. Yield: 54.5 mg, 56%.  
[α]D20 +7.7 (c 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.09 – 6.96 (m, 2H, Ar), 6.85 – 6.75 (m, 2H, Ar), 
6.00 – 5.80 (m, 6H, 6 CH2CHCH2O), 5.35 – 5.24 (m, 4H, 4 CHHCHCH2O), 5.25 – 
5.21 (m, 2H, 2 CHHCHCH2O), 5.20 – 5.14 (m, 3H, 3 CHHCHCH2O), 5.14 – 5.10 (m, 
2H, 2 CHHCHCH2O), 5.10 – 5.07 (m, 1H, CHHCHCH2O), 4.96 (d, J = 3.3 Hz, 1H, 
H-1’), 4.74 (d, J = 7.7 Hz, 1H, H-1), 4.59 (dd, J = 24.9, 11.1 Hz, 2H, ArCH2O), 4.43 
– 4.32 (m, 3H, H-5’, 2 CH2CHCHHO), 4.32 – 4.19 (m, 3H, 3 CH2CHCHHO), 4.20 – 
4.15 (m, 2H, 2 CH2CHCHHO), 4.14 – 3.99 (m, 5H, H-4, 4 CH2CHCHHO), 3.99 – 
3.86 (m, 4H, 2 CH2CHCHHO, H-6a, H-4’), 3.87 – 3.78 (m, 2H, H-2’, H-3’), 3.76 (s, 
3H, ArOCH3), 3.71 – 3.62 (m, 2H, H-2, H-6’a), 3.62 – 3.55 (m, 2H, H-6b, H-5), 3.51 
(dd, J = 7.9, 4.7 Hz, 1H, H-6’b), 3.34 (dd, J = 9.9, 3.1 Hz, 1H, H-3). 
13C NMR (126 MHz, CDCl3): δ = 155.31 (Ar), 151.78 (CH2CHCH2O), 135.60 
(CH2CHCH2O), 135.41 (CH2CHCH2O), 135.40 (CH2CHCH2O), 135.29 
(CH2CHCH2O), 135.20 (CH2CHCH2O), 134.61 (CH2CHCH2O), 118.81 (Ar), 117.26 
(CH2CHCH2O), 116.81 (CH2CHCH2O), 116.67 (CH2CHCH2O), 116.38 
(CH2CHCH2O), 116.16 (CH2CHCH2O) (C-1’), 100.16 (C-1’), 80.55 (C-3), 78.51 (C-
2), 78.38, 76.33 (C-2’), 74.30 (C-4), 74.26, 74.08, 73.88, 73.18, 72.27, 72.21, 71.18, 
68.75 (C-3’), 68.53 (C-6), 67.67 (C-6’), 59.89 (ArCH2O), 55.78 (ArOCH3). 
 
4-Methoxyphenyl [2,3,4-tri-O-allyl-6-O-(4-fluorophenyl)]-α-D-galactopyranosyl)-
(14)-2,3,6-tri-O-allyl-β-D-galactopyranoside (24d): 
Halogenide: 4-Fluorobenzyl bromide. After 1.5 h, additional 0.3 eq. of NaH were 
added, then stirring was continued for further 2 h. Yield: 79 mg, 70%. 
[α]D20 +9.7 (c 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.06 – 6.98 (m, 2H, Ar), 6.84 – 6.75 (m, 4H, Ar), 
6.84 – 6.75 (m, 2H, Ar), 6.05 – 5.77 (m, 6H, 6xCH2CHCH2O), 5.37 – 5.19 (m, 6H, 3 
CH2CHCH2O ), 5.19 – 5.07 (m, 6H, 3 CH2CHCH2O), 4.98 (d, J = 3.2 Hz, 1H, H-1’), 
4.74 (d, J = 7.7 Hz, 1H, H-1), 4.47 (s, 2H, ArCH2O), 4.42 (dd, J = 8.9, 5.2 Hz, 1H, H-
5’), 4.39 – 4.30 (m, 3H, 3 CH2CHCHHO), 4.30 – 4.24 (m, 1H, CH2CHCHHO), 4.24 
– 4.16 (m, 3H, 3 CH2CHCHHO), 4.16 – 4.11 (m, 1H, CH2CHCHHO), 4.11 – 4.03 (m, 
2H, 2 CH2CHCHHO), 4.02 (d, J = 3.0 Hz, 1H, H-4), 4.00 – 3.93 (m, 3H, H-6a, 2 
CH2CHCHHO), 3.91 (s, 1H, H-4’), 3.88 – 3.80 (m, 2H, H-2’, H-3’), 3.76 (s, 3H, 
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OCH3), 3.73 – 3.67 (m, 1H, H-2), 3.67 – 3.62 (m, 1H, H-6’a), 3.62 – 3.56 (m, 2H, H-
6b, H-5), 3.49 (dd, J = 8.3, 4.8 Hz, 1H, H-6’b), 3.34 (dd, J = 9.9, 3.1 Hz, 1H, H-3).  
13C NMR (126 MHz, CDCl3): δ = 163.50 (Ar), 161.55 (Ar), 155.29 (Ar), 151.78 (Ar), 
135.81 (CH2CHCH2O), 135.44 (CH2CHCH2O), 135.42 (CH2CHCH2O), 135.33 
(CH2CHCH2O), 135.25 (CH2CHCH2O), 134.63 (CH2CHCH2O), 134.03 (Ar), 134.01 
(Ar), 129.83 and 129.77 (Ar), 118.78 (Ar), 117.21 (CH2CHCH2O), 116.78 
(CH2CHCH2O), 116.76 (CH2CHCH2O), 116.63 (CH2CHCH2O), 116.62 
(CH2CHCH2O), 116.10 (CH2CHCH2O), 115.47 (Ar), 115.30 (Ar), 114.55 (Ar), 
103.30 (C-1), 100.13 (C-1’), 80.38 (C-3), 78.54 (C-2), 78.35 (C-2’), 76.46 (C-3’), 
74.46 (C-4), 74.20 (CH2CHCH2O), 74.15 (C-4’), 74.05, 73.95 (C-5), 73.14 
(ArCH2O), 72.87 (CH2CHCH2O), 72.26 (CH2CHCH2O), 72.06(CH2CHCH2O), 71.17 
(CH2CHCH2O), 69.04 (C-5’), 68.15 (C-6’), 67.80 (C-6), 55.76 (ArOCH3). 
 
 
4-Methoxyphenyl (2,3,4-tri-O-allyl-6-O-propylphenyl)-α-D-galactopyranosyl)-
(14)-2,3,6-tri-O-allyl-β-D-galactopyranoside (24e): 
Halogenide: 1-Bromo-3-phenylpropane. After 1.5 h, additional 0.3 eq. of NaH and 0.2 
eq. of bromide were added. Reaction time: 2 h. Yield: 74.4 mg, 77%. 
[α]D20 + 11.2 (c 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.34 – 7.26 (m, 2H, Ar), 7.21 – 7.14 (m, 3H, Ar), 
7.07 – 6.94 (m, 2H, Ar), 6.90 – 6.62 (m, 2H), 6.04 – 5.82 (m, 6H, 6 CH2CHCH2O), 
5.37 – 5.20 (m, 6H, 6 CHHCHCH2O), 5.18 – 5.08 (m, 6H, 6 CHHCHCH2O), 4.98 (d, 
J = 2.9 Hz, 1H, H-1’), 4.75 (d, J = 7.7 Hz, 1H, H-1), 4.41 – 4.31 (m, 4H, 3 
CH2CHCHHO, H-5’), 4.31 – 4.25 (m, 2H, 2 CH2CHCHHO), 4.24 – 4.17 (m, 2H, 2 
CH2CHCHHO), 4.17 – 4.09 (m, 3H, 3 CH2CHCHHO), 4.03 (d, J = 3.0 Hz, 1H, H-4), 
4.00 – 3.94 (m, 3H, 2 CH2CHCHHO, H-6a), 3.93 – 3.90 (m, 1H, H-4’), 3.88 – 3.81 
(m, 2H, H-2’, H-3’), 3.76 (s, 3H, ArOCH3), 3.71 (dd, J = 9.9, 7.7 Hz, 1H, H-2), 3.64 – 
3.55 (m, 3H, H-6’a, H-6b, H-5), 3.53 – 3.41 (m, 3H, H-6’b, OCH2CH2CH2Ph), 3.35 
(dd, J = 9.9, 3.0 Hz, 1H, H-3), 2.70 (dt, J = 8.4, 6.4 Hz, 2H, OCH2CH2CH2Ph), 2.05 – 
1.68 (m, 2H, OCH2CH2CH2Ph).  
13C NMR (126 MHz, CDCl3): δ = 155.27 (Ar), 151.79 (Ar), 142.01 (Ar), 135.88 
(CH2CHCH2O), 135.46 (CH2CHCH2O), 135.35 (CH2CHCH2O), 135.30 
(CH2CHCH2O), 134.64 (CH2CHCH2O), 128.50 (Ar), 128.48 (Ar), 125.96 (Ar), 
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118.79 (Ar), 117.21 (CH2CHCH2O), 116.83 (CH2CHCH2O), 116.72 (CH2CHCH2O), 
116.66 (CH2CHCH2O), 116.59 (CH2CHCH2O), 116.06 (CH2CHCH2O), 114.55 (Ar), 
103.29 (C-1), 100.17 (C-1’), 80.45 (C-3), 78.60 (C-2), 78.31 (C-3’), 77.32 
(CH2CHCH2O), 76.49 (CH2CHCH2O), 74.41 (C-4’), 74.16 (C-4), 74.06 (C-5), 73.99 
(CH2CHCH2O), 73.12 (CH2CHCH2O), 72.26 (C-2’), 72.12 (CH2CHCH2O), 71.16, 
70.75 (CH2CHCH2O), 68.98 (C-5’), 68.46 (C-6’), 67.82 (C-6), 55.76 (ArOCH3), 
32.56 (OCH2CH2CH2Ph), 31.47 (OCH2CH2CH2Ph). 
  
4-Methoxyphenyl [2,3,4-tri-O-allyl-6-O-(biphenyl-4yl-methyl)]-α-D-galactopyra-
nosyl)-(14)-2,3, 6-tri-O-allyl-β-D-galactopyranoside (24f): 
Halogenide: 4-(Bromomethyl)biphenyl. Reaction time: 1.5 h. Yield: 57.1 mg, 55%.  
[α]D20 +9.2 (c 1.0, CHCl3). 
1H NMR (500 MHz, CDCl3): δ = 7.62 – 7.54 (m, 4H, Ar), 7.47 – 7.39 (m, 4H, Ar), 
7.35 (t, J = 7.4 Hz, 1H, Ar), 7.06 – 6.99 (m, 2H, Ar), 6.85 – 6.75 (m, 2H, Ar), 6.05 – 
5.77 (m, 6H, 6 CH2CHCH2O), 5.38 – 5.20 (m, 6H, 6 CHHCHCH2O), 5.20 – 5.09 (m, 
6H, 6 CHHCHCH2O), 4.99 (d, J = 3.1 Hz, 1H, H-1’), 4.75 (d, J = 7.6 Hz, 1H, H-1), 
4.60 – 4.52 (m, 2H, ArCH2O), 4.46 (dd, J = 9.0, 4.7 Hz, 1H, H-5’), 4.42 – 4.32 (m, 
3H, 3 CH2CHCHHO), 4.32 – 4.17 (m, 4H, 4 CH2CHCHHO), 4.17 – 4-05 (m, 3H, 3 
CH2CHCHHO), 4.03 (d, J = 2.9 Hz, 1H, H-4), 4.01 – 3.92 (m, 4H, H-4’, H-6a, 2 
CH2CHCHHO), 3.92 – 3.80 (m, 2H, H-3’, H-2’), 3.76 (s, 3H, ArOCH3), 3.73 – 3.67 
(m, 2H, H-6’a, H-2), 3.65 – 3.57 (m, 2H, H-6b, H-5), 3.54 (dd, J = 8.2, 4.7 Hz, 1H, 
H-6’b), 3.35 (dd, J = 9.9, 3.0 Hz, 1H, H-3). 
13C NMR (126 MHz, CDCl3): δ = 155.29 (Ar), 151.79 (Ar), 141.03 (Ar), 140.90 (Ar), 
137.23 (Ar), 135.86 (CH2CHCH2O), 135.46 (CH2CHCH2O), 135.43 (CH2CHCH2O), 
135.36 (CH2CHCH2O), 135.27 (CH2CHCH2O), 134.63 (CH2CHCH2O), 128.90 (Ar), 
128.59 (Ar), 127.44 (Ar), 127.33 (Ar), 127.24 (Ar), 118.81 (Ar), 117.23 
(CH2CHCH2O), 116.84  (CH2CHCH2O), 116.79  (CH2CHCH2O), 116.67  
(CH2CHCH2O), 116.10  (CH2CHCH2O), 114.55 (Ar), 103.31 (C-1), 100.15 (C-1’), 
80.34 (C-3), 78.56 (C-3’), 78.38 (C-2), 76.45 (C-2’), 74.46, 74.21 (C-4), 74.17, 74.09 
(CH2CHCH2O), 73.95 (C-5), 73.35 (ArCH2O), 73.17, 72.27 (CH2CHCH2O), 72.10, 
71.14 (CH2CHCH2O), 69.07 (C-5’), 68.16 (C-6’), 67.77 (C-6), 55.77 (ArOCH3). 
 
4-Methoxyphenyl [2,3,4-tri-O-allyl-6-O-(2-pyridylmethyl)]-α-D-galactopyrano-
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syl)-(14)-2,3,6-tri-O-allyl-β-D-galactopyranoside (24g): 
Halogenide: 2-(Bromomethy)pyridineHBr. Reaction time: 1 h. Yield: 48 mg, 71%.  
[α]D20 -11.2, (c 1.60, CHCl3). 
ESI-MS: m/z: Calcd for C43H57NNaO12 802.4, found 802.4. 
1H NMR (500 MHz, CDCl3): δ = 8.58 – 8.50 (m, 1H, H-1 Py), 7.68 (td, J = 7.7, 1.8 
Hz, 1H, H-3 Py), 7.44 (d, J = 7.8 Hz, 1H, H-4 Py), 7.19 (dd, J = 6.5, 5.0 Hz, 1H, H-2 
Py), 7.08 – 6.97 (m, 2H, Ar-H), 6.87 – 6.75 (m, 2H, Ar-H), 6.02 – 5.80 (m, 6H, 
CH2CHCH2O), 5.34 (dd, J = 17.3, 1.8 Hz, 1H, CHHCHCH2O), 5.30 – 5.19 (m, 5H, 5 
CHHCHCH2O), 5.18 – 5.16 (m, 1H, CHHCHCH2O), 5.16 – 5.14 (m, 1H 
CHHCHCH2O), 5.14 – 5.12 (m, 1H CHHCHCH2O), 5.11 (d, J = 1.2 Hz, 2H, 2 
CHHCHCH2O), 5.08 (dd, J = 2.7, 1.6 Hz, 1H, CHHCHCH2O), 4.99 (d, J = 2.9 Hz, 
1H, H-1’), 4.75 (d, J = 7.7 Hz, 1H, H-1), 4.65 (s, 2H, -OCH2Py), 4.47 (dd, J = 8.8, 5.4 
Hz, 1H, H-5’), 4.41 – 4.32 (m, 3H, 3 CH2CHCHHO), 4.31 – 4.26 (m, 1H, 
CH2CHCHHO), 4.26 – 4.18 (m, 3H, 3 CH2CHCHHO), 4.17 – 4.06 (m, 3H, 3 
CH2CHCHHO), 4.03 (d, J = 3.0 Hz, 1H, H-4), 4.01 – 3.92 (m, 4H, 2 CH2CHCHHO, 
H-4’, H-6a), 3.91 – 3.82 (m, 2H, H-2’, H-3’), 3.76 (s, 3H, -OCH3) 3.75 – 3.69 (m, 2H, 
H-2 and H-6’a), 3.63 – 3.56 (m, 3H, H-6’b, H-5, H-6b), 3.35 (dd, J = 9.9, 3.1 Hz, 1H, 
H-3). 
13C NMR (126 MHz, CDCl3): δ = 158.57 (Ar), 155.29 (Ar), 151.79 (Ar), 149.26, 
136.67 (Ar), 135.79 (CH2CHCH2O), 135.46 (CH2CHCH2O), 135.40 (CH2CHCH2O), 
135.28 (CH2CHCH2O), 134.62 (CH2CHCH2O), 122.47 (Ar), 121.44 (Ar), 118.80 
(Ar), 117.22 (CH2CHCH2O), 116.89 (CH2CHCH2O), 116.82 (CH2CHCH2O), 116.71 
(CH2CHCH2O), 116.64 (CH2CHCH2O), 116.09 (CH2CHCH2O), 114.55 (Ar), 103.32 
(C-1), 100.13 (C-1’), 80.34 (C-3), 78.59 (C-3’), 78.35 (C-2), 76.50 (C-2’), 74.49, 
74.35 (ArCH2O), 74.24, 74.15 (C-4), 74.05 (CH2CHCH2O), 73.97 (C-5), 73.17 
(CH2CHCH2O), 72.26, 72.09, 71.23, 69.07 (C-5’), 68.82 (C-6’), 67.82 (C-6), 55.76 
(ArOCH3). 
 
General procedures for the synthesis of compounds 25a-g: 
Cleavage of the allyl groups [21] 
 
DMBA (12 eq), Pd(OAc)2 (0.3 eq) and PPh3 (0.9 eq) were mixed in a reaction tube 
under argon, then a solution of the carbohydrate (1 eq.) in dry MeOH (0.5 mL) and 
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dry DCM (0.1 mL) was added. The reaction was stirred at 40 °C and monitored by 
TLC (9:1 DCM/MeOH). After completion of the reaction the mixture was diluted 
with DCM and washed once with aq. Na2CO3. The water phase was extracted four 
times with DCM. The organic phases were collected, dried over Na2SO4, filtered and 
concentrated. The residue was purified by chromatography on silica gel (DCM/MeOH 
gradient). 
 
4-Methoxyphenyl [6-O-(3-pyridylmethyl)-α-D-galactopyranosyl]-(14)-β-D-ga-
lactopyranoside (25a): 
Reaction time: 17 h. Purification: Chromatography on silica (DCM/MeOH gradient + 
0.2% NH4OH). Yield: 10.5 mg, 46%.  
[α]D20 -13.0 (c 0.10, MeOH). 
ESI-MS: m/z: Calcd for C25H33NNaO12[M+Na]+ 562.5, found 562.1. 
1H NMR (500 MHz, CD3OD): δ = 8.60 (s, 1H, Py), 8.49 (d, J = 3.8 Hz, 1H, Py), 7.95 
(d, J = 7.9 Hz, 1H, Py), 7.47 (dd, J = 7.8, 4.9 Hz, 1H, Py), 7.13 – 7.02 (m, 2H, Ar), 
6.92 – 6.80 (m, 2H, Ar), 5.03 (d, J = 2.9 Hz, 1H, H-1’), 4.84 (d, J = 7.6 Hz, 1H, H-1), 
4.70 – 4.65 (m, 2H, PyCH2O), 4.55 (t, J = 6.3 Hz, 1H, H-5’), 4.09 (d, J = 3.1 Hz, 1H, 
H-4), 3.97 (s, 1H, H-4’), 3.90 (dd, J = 9.7, 6.0 Hz, 1H, H-6a), 3.88 – 3.79 (m, 4H, H-
2’, H-3’, H-6’a, H-6b, H-5), 3.77 (s, 3H, ArOCH3), 3.76 – 3.70 (m, 2H, H-2, H-6’b), 
3.67 (dd, J = 10.0, 2.9 Hz, 1H, H-3). 
13C NMR (126 MHz, CD3OD): δ = 156.80 (Py), 152.97 (Ar), 149.34 (Py), 149.12 
(Py), 137.91 (Py), 136.31 (Ar), 125.23 (Py), 119.31 (Ar), 115.51 (Ar), 104.10 (C-1), 
102.70 (C-1’), 79.37 (C-4), 76.26 (C-3’), 74.57 (C-3), 72.79 (C-5), 71.52 (PyCH2O), 
71.22 (C-5’), 71.11 (C-2’), 70.91 (C-4’), 70.67 (C-6’), 61.02 (C-6), 56.06 (ArOCH3). 
 
4-Methoxyphenyl [6-O-(4-methoxyphenyl)]-α-D-galactopyranosyl)-(14)-β-D-
galactopyranoside (25b): 
Reaction time: 24 h. Purification: Chromatography on silica (DCM/MeOH gradient), 
followed by reversed phase chromatography (RP, C18, water/ACN gradient). Yield: 
21 mg, 51%. 
[α]D20 +2.3 (c 1.0, MeOH). 
1H NMR (500 MHz, CD3OD): δ = 7.37 – 7.31 (m, 2H, Ar), 7.12 – 7.05 (m, 2H, Ar), 
6.96 – 6.91 (m, 2H, Ar), 6.89 – 6.83 (m, 2H, Ar), 5.02 (s, 1H, H-1’), 4.84 (d, J = 7.6 
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Hz, 1H, H-1), 4.60 – 4.51 (m, 2H, ArCH2O), 4.49 (t, J = 6.2 Hz, 1H, H-5’), 4.08 (d, J 
= 3.0 Hz, 1H, H-4), 3.94 (s, 1H, H-4’), 3.89 (dd, J = 10.5, 6.7 Hz, 1H, H-6a), 3.84 – 
3.83 (m, 2H, H-2’, H-3’), 3.82 – 3.79 (m, 5H, ArOCH3, H-6b, H-5), 3.79 – 3.75 (m, 
4H, H-2, ArOCH3), 3.68 – 3.63 (m, 3H, H-3, H-6’a, H-6’b). 
13C NMR (126 MHz, CD3OD): δ = 160.82 (Ar), 156.77 (Ar), 152.94 (Ar), 131.58 
(Ar), 130.63 (Ar), 119.32 (Ar), 115.49 (Ar), 114.77 (Ar), 104.03 (C-1), 102.65 (C-1’), 
79.43 (C-4), 76.21 (C-2), 74.62 (C-3), 74.09 (ArCH2O), 72.72 (C-5), 71.28 (C-5’), 
71.22 (C-4’), 71.03 (C-2’), 70.66 (C-3’), 70.08 (C-6’), 61.07 (C-6), 56.05 (ArOCH3), 
55.68 (ArOCH3). 
 
4-Methoxyphenyl (6-O-pentafluorophenyl)-α-D-galactopyranosyl)-(14)-β-D-
galactopyranoside (25c): 
Reaction time: 24 h. Purification: Chromatography on silica (DCM/MeOH gradient), 
followed by reversed phase chromatography (RP, C18, water/ACN gradient). Yield: 
8.4 mg, 23%.  
[α]D20 +1.3 (c 1.0, MeOH). 
ESI-MS: m/z: Calcd for C26H29F5NaO12 [M+Na]+ 651.2, found 651.3. 
1H NMR (500 MHz, CD3OD): δ = 7.11 – 7.04 (m, 2H, Ar), 6.89 – 6.83 (m, 2H, Ar), 
4.99 (d, J = 3.0 Hz, 1H, H-1’), 4.82 (d, J = 7.5 Hz, 1H, H-1), 4.78 – 4.70 (m, 2H, 
ArOCH2), 4.51 (t, J = 6.4 Hz, 1H, H-5’), 4.06 (d, J = 3.0 Hz, 1H, H-4), 3.94 – 3.91 
(m, 1H, H-4’), 3.88 (dd, J = 10.4, 6.8 Hz, 1H, H-6a), 3.85 – 3.76 (m, 7H, H-2’, 
ArOCH3, H-6b, H-5, H-3’), 3.76 – 3.65 (m, 3H, H-2, H-6’a, H-6’b), 3.64 (dd, J = 
10.1, 3.0 Hz, 1H, H-3). 
13C NMR (126 MHz, CD3OD): δ = 156.79 (Ar), 152.96 (Ar), 119.28 (Ar), 115.49 
(Ar), 104.06 (C-1), 102.52 (C-1’), 78.88 (C-4), 76.33 (C-5), 74.48 (C-3), 72.68 (C-2), 
71.27 (C-3’), 70.69 (C-2’, C-4’, and C-6’), 70.50 (C-5’), 60.91 (ArCH2O and C-6), 
56.05 (ArOCH3).  
 
4-Methoxyphenyl [6-O-(4-fluorophenyl)]-α-D-galactopyranosyl)-(14)-β-D-ga-
lactopyranoside (25d): 
Reaction time: 7 h. Purification: Chromatography on silica (DCM/MeOH gradient), 
followed by reversed phase chromatography (RP, C18, water/ACN gradient). Yield: 
22.5 mg, 44%.  
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[α]D20 +4.6 (c 1.1, MeOH).  
ESI-MS: m/z: Calcd for C26H33FNaO12 [M+Na]+ 579.2, found 579.3. 
1H NMR (500 MHz, CD3OD): δ = 7.41 (dd, J = 8.2, 5.7 Hz, 2H, Ar), 7.20 – 7.01 (m, 
4H, Ar), 6.87 – 6.80 (m, 2H, Ar), 4.99 (d, J = 1.62 Hz, 1H, H-1’), 4.81 (d, J = 7.6 Hz, 
1H, H-1), 4.61 – 4.53 (m, 2H, ArCH2O), 4.48 (t, J = 6.2 Hz, 1H, H-5’), 4.06 (d, J = 
3.0 Hz, 1H, H-4), 3.92 (s, 1H, H-4’), 3.87 (dd, J = 10.2, 6.4 Hz, 1H, H-6a), 3.81 (s, 
2H, H-3’, H-2’), 3.80 – 3.72 (m, 6H, ArOCH3, H-6b, H-2, H-5), 3.69 – 3.59 (m, 3H, 
H-3, H-6’a, H-6’b). 
13C NMR (126 MHz, CD3OD): δ = 164.74 (Ar), 162.80 (Ar), 156.79 (Ar), 152.96 
(Ar), 135.73 and 135.71 (Ar(F)), 130.92 and 130.86 (Ar(F)), 119.31 (Ar), 116.09 and 
115.92 (Ar(F)), 115.51 (Ar), 104.07 (C-1), 102.69 (C-1’), 79.46 (C-4), 76.23, 74.60 
(C-3), 73.58 (ArOCH2), 72.76 (C-2), 71.26 (C-4’), 71.20 (C-5’), 70.98 (C-3’), 70.67 
(C-2’), 70.30 (C-6’), 61.06 (C-6), 56.06 (ArOCH3). 
 
4-Methoxyphenyl [6-O-(3-phenylpropyl)]-α-D-galactopyranosyl)-(14)-β-D-ga-
lactopyranoside (25e): 
Reaction time: 14h. Purification: Chromatography on silica (DCM/MeOH gradient), 
followed by reversed phase chromatography (RP, C18, water/ACN gradient). Yield: 
27.2 mg, 55%.  
[α]D20 +3.9 (c 1.0, MeOH).  
ESI-MS: m/z: Calcd for C26H38NaO12 [M+Na]+ 589.2, found 589.4. 
1H NMR (500 MHz, CD3OD): δ = 7.35 – 7.23 (m, 4H, Ar), 7.20 – 7.11 (m, 1H, Ar), 
7.12 – 6.95 (m, 2H, Ar), 6.92 – 6.78 (m, 2H, Ar), 5.02 (d, J = 1.5 Hz, 1H, H-1’), 4.84 
(d, J = 7.6 Hz, 1H, H-1), 4.46 (s, 1H, H-5’), 4.08 (d, J = 3.0 Hz, 1H, H-4), 3.97 (s, 1H, 
H-4’), 3.90 (dd, J = 10.5, 6.6 Hz, 1H, H-6a), 3.86 – 3.74 (m, 8H, H-2’, ArOCH3, H-2, 
H-6b, H-3’, H-5), 3.71 – 3.61 (m, 3H, H-6’a, H-6’b, H-3), 3.57 – 3.51 (m, 2H, 
OCH2CH2CH2Ph), 2.73 (t, J = 7.7 Hz, 1H, OCH2CH2CH2Ph), 1.99 – 1.89 (m, 2H, 
OCH2CH2CH2Ph). 
13C NMR (126 MHz, CD3OD): δ = 156.78 (Ar), 152.98 (Ar), 143.41 (Ar), 129.58 
(Ar), 129.32 (Ar), 126.74 (Ar), 119.30 (Ar), 115.50 (Ar), 104.10 (C-1), 102.74 (C-1’), 
79.56 (C-4), 76.22 (C-3’), 74.60 (C-3), 72.78 (C-2), 71.82 (OCH2CH2CH2Ph), 71.33 
(C-5’), 71.16 (C-5), 71.03 (C-4’), 70.90 (C-6’), 70.70 (C-2’), 61.06 (C-6), 56.06 
(ArOCH3), 33.28 (OCH2CH2CH2Ph), 32.55 (OCH2CH2CH2Ph). 
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4-Methoxyphenyl (6-O-biphenyl-1-yl-methyl)-α-D-galactopyranosyl)-(14)-β-D-
galactopyranoside (25f): 
Reaction time: 7 h. Purification: Chromatography on silica (DCM/MeOH gradient), 
followed by reversed phase chromatography (RP, C18, water/ACN gradient). Yield: 
19.2 mg, 48%. 
[α]D20 +1.2 (c 1.0, MeOH).  
1H NMR (500 MHz, CD3OD): δ =7.64 (d, J = 8.0 Hz, 4H, Ar), 7.51 (d, J = 8.2 Hz, 
2H, Ar), 7.47 – 7.42 (m, 2H, Ar), 7.38 – 7.32 (m, 1H, Ar), 7.11 – 7.07 (m, 2H, Ar), 
6.89 – 6.84 (m, 2H, Ar, H-1’), 4.84 (d, J = 7.6 Hz, 1H, H-1), 4.71 – 4.62 (m, 2H, 
ArCH2O), 4.53 (t, J = 6.3 Hz, 1H, H-5’), 4.09 (d, J = 3.1 Hz, 1H, H-4), 3.98 (s, 1H, 
H-4’), 3.90 (dd, J = 9.7, 5.9 Hz, 1H, H-6a), 3.86 – 3.83 (m, 2H, H-3’, H-2’), 3.83 – 
3.78 (m, 3H, H-2, H-6b, H-5), 3.77 (s, 3H, ArOCH3), 3.75 – 3.71 (m, 2H, H-6’a, H-
6’b), 3.67 (dd, J = 10.1, 3.1 Hz, 1H, H-3). 
13C NMR (126 MHz, CD3OD): δ = 156.80 (Ar), 152.97 (Ar), 129.85 (Ar), 129.50 
(Ar), 128.33 (Ar), 128.00 (Ar), 127.94 (Ar), 119.34 (Ar), 115.50 (Ar), 104.09 (C-1), 
102.71 (C-1’), 79.45 (C-4), 76.24 (C-5), 74.65 (C-3), 74.11 (ArCH2O), 72.77 (C-2), 
71.30 (C-5’), 71.04 (C-4’), 70.70 (3’), 70.38 (C-6’), 61.06 (C-6), 56.05 (ArOCH3). 
 
4-Methoxyphenyl [6-O-(2-pyridylmethyl)-α-D-galactopyranosyl]-(14)-β-D-ga-
lactopyranoside (25g): 
Reaction time: 7 h. No aqueous work-up. Purification: Chromatography on silica 
(DCM/MeOH gradient, + 0.2% NH4OH), followed by reversed phase 
chromatography (RP, C18, water/ACN gradient). Yield: 22 mg, 65%. 
[α]D20 -1.9 (c 1.1, MeOH). 
ESI-MS: m/z: Calcd for C25H34NO12 [M]+ 540.2, found 540.2. 
1H NMR (500 MHz, CD3OD): δ = 8.80 (d, J = 5.6 Hz, 1H, Py-H), 8.53 (td, J = 8.0, 
1.4 Hz, 1H, Py-H), 8.00 (d, J = 8.09 Hz, 1H, Py-H), 7.95 (t, J = 6.72, 1H, Py-H), 7.11 
- 6.99 (m, 2H, Ar-H), 6.89 - 6.79 (m, 2H, Ar-H), 5.09 – 4.99 (m, 3H, PyCH2O, H-1’), 
4.83 (d, J = 7.0 Hz, 1H, H-1), 4.52 (t, J = 5.7 Hz, 1H, H-5’), 4.12 (d, J = 2.3 Hz, 1H, 
H-4), 3.97 (m, 1H, H-4’), 3.96 – 3.92 (m, 2H, H-6’a, H-6’b), 3.91 – 3.87 (m, 3H, H-
2’, H-3’, H-6a), 3.86 – 3.83 (m, 1H, H-6b), 3.82 – 3.78 (m, 3H, H-2, H-3, H-5), 3.77 – 
3.75 (m, 1H, H-3), 3.74 (s, 3H, -OCH3). 
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13C NMR (126 MHz, CD3OD): δ = 156.82 (Py), 154.87 (Ar), 152.94 (Ar), 146.99 
(Py), 142.93 (Py), 126.76 (Py), 125.90 (Py), 119.27 (Ar), 115.51 (Ar), 104.12 (C-1), 
103.37 (C-1’), 81.64 (C-4), 75.91 (C-5), 74.72 (C-3), 72.91 (C-6’), 72.87 (C-2), 72.25 
(C-5’), 71.15 (C-4’), 70.91 (C-2’), 70.22 (C-3’), 69.73 (PyCH2O), 61.46 (C-6), 56.05 
(ArOCH3). 
 
 
Isothermal Titration Calorimetry. ITC experiments were performed using a VP-
ITC instrument (GE Healthcare, Uppsala, Sweden) at a temperature of 25° C, an 
injection volume between 6 and 15 l, a reference power of 10 cal/s, a stirring speed 
of 307 rpm, high feedback, a spacing time of 300 - 600 s and a filter period of 2 s. 
Preceding the measurements, PapGIILD-6His was dialyzed against assay buffer [2-(N-
morpholino)ethanesulfonic acid, 20 mM, pH 5.8] using Slide-A-Lyzer G2 dialysis 
cassettes (10K MWCO) (Thermo Fisher Scientific, Rockford, IL, USA). Protein 
concentration was determined by HPLC-UV against a BSA standard [22,23]. All 
experiments were performed with c-values below 1. Therefore, stoichiometry was 
fixed to 1 to allow reliable determination of KD and ∆H° [24,25]. Two independent 
experiments evaluated the consistency of the measurements. Experiments with c-
values below 0.01 were performed only once, due to high material consumption. 
Baseline adjustment and peak integration were carried out using Origin 7.0 as 
described by the manufacturer (OriginLab, Northampton, MA, USA). The first 
injection was always excluded from data analysis. The three-parameter nonlinear 
least-square fitting and calculation of 95% confidence intervals were calculated by 
performing a global analysis of multiple ITC experiments by public domain 
multimethod analysis software SEDPHAT to determine N (stoichiometry), KD 
(dissociation constant) and ΔH° (change in enthalpy) [26]. 
 
DG° = DH°-TDS° = RT ln KD = -RT ln KA          eq. 2 
 
Thermodynamic parameters ΔG° (change in Gibb’s free energy) and ΔS° (change in 
Entropy) are calculated using equation 2, where T is the absolute temperature, and R 
is the universal gas constant (8.314 J/mol K).  
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Cloning of PapGII: genomic DNA was prepared from the uropathogenic E. coli 
clinical isolate BI47 (University Hospital, Basel, Switzerland) using the extraction kit 
from Wizard (Promega, Wallisellen, Switzerland). The PapG-II lectin domain (PapG-
IILD, amino acids: 1-196) was amplified by PCR using the iproof high fidelity pfu 
polymerase (BioRad, Basel, Switzerland). The forward and reverse primers were 
designed on the basis of the published PapG-II sequences and were synthesized at 
Microsynth (Balgach, Switzerland). The PCR-generated fragment was treated with 
restriction enzymes XhoI and NcoI and ligated into the appropriate cloning site of the 
expression vector pET-22b(+) (Novagen, Switzerland). The ligation products, with or 
without 6His-Tag, were amplified in chemocompetent E. coli DH5. After single 
clone selection and plasmid DNA-minipreparation, the correctness of the constructs 
was confirmed by restriction control and DNA sequencing (Microsynth, Balgach, 
Switzerland). For protein expression the constructs containing PapGIILD without tag 
or PapGIILD-6His were transformed into the E. coli strain AD494(DE3). 
 
Protein expression: E. coli AD494(DE3) clones containing the constructs PapGIILD-
6His or PapG-IILD were cultivated in LB-medium at 30 °C and 180 rpm. The PapG-II 
expression was induced with 1 mM final concentration of isopropyl β-D-1-
thiogalactopyranoside (IPTG) at OD600 of 0.8. The culture was allowed to grow for 
further 14 h at 30 °C and 180 rpm. The cells were then cooled on ice for 5 min and 
harvested by centrifugation at 5,000 rpm for 20 min at 4 °C. The pellet was suspended 
in a cold solution of 50 mM Tris–HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA and 1 
mg/mL polymyxin B sulfate and stirred for 2 h at 4 °C. The periplasmic extract was 
collected by centrifugation at 11,000 rpm for 20 min at 4 °C. His-tagged protein was 
dialyzed overnight against 50 mM NaH2PO4, 300 mM NaCl, and 10 mM imidazole, 
pH 8 (Binding buffer), and applied to a Ni-NTA column attached to a fast protein 
liquid chromatography system and pre-equilibrated with binding buffer. The column 
wash step was performed with binding buffer and His-tagged protein was eluted with 
50 mM NaH2PO4, 300 mM NaCl, and 250 mM imidazole, pH 8.0 (elution buffer). 
The eluted fraction was dialyzed overnight against a buffer containing 20 mM Hepes, 
pH 7.4, 150 mM NaCl and 1 mM CaCl2 (assay buffer).  
PapG-IILD without tag was extracted from the periplasm similar to the 6His-tagged 
protein, dialyzed overnight against assay buffer and applied to a GbO3 functionalized 
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fractogel. The protein was eluted using a 1 M lactose solution. Protein purity was 
confirmed by SDS-PAGE analysis followed by Coomassie Brillant Bleu G-250 
staining. The protein concentration was determined by HPLC as reported [23]. At 4 
°C, the protein was stable up to 4 weeks. For long-term storage, the protein was 
frozen at -80 °C. 
 
Competitive binding assay: To determine the affinity of the various PapG-II 
antagonists, the competitive binding assay described previously was applied [13]. 
Microtiter plates (F96 MaxiSorp, Nunc) were coated with 100 µL/well of a 10 µg/mL 
solution of PapG-IILD-6His in 20 mM Hepes, 150 mM NaCl and 1 mM CaCl2, pH 7.4 
(assay buffer) overnight at 4 °C. The coating solution was discarded and the wells 
were blocked with 150 µL/well of 3% BSA in assay buffer for 2 h at 4 °C. After three 
washing steps with assay buffer (150 µL/well), a four-fold serial dilution of the test 
compound (50 µL/well) in assay buffer containing 5% DMSO and streptavidin-
peroxidase coupled GbO3-PAA polymer (50 µL/well of a 0.5 µg/mL solution) were 
added. On each individual microtiter plate the reference compound 2 was tested in 
parallel. The plates were incubated for 3 h at 25 °C and 350 rpm and then carefully 
washed four times with 150 µL/well assay buffer. After the addition of 100 µL/well 
of the horseradish peroxidase substrate 2,2'-azino-di-(3-ethylbenzothiazoline-6-
sulfonic acid) (ABTS), the colorimetric reaction was allowed to develop for 4 min, 
then stopped by the addition of 2% aqueous oxalic acid before the optical density 
(OD) was measured at 415 nm on a microplate-reader (Spectramax 190, Molecular 
Devices, California, USA). The IC50 values of the compounds tested in duplicates 
were calculated with prism software (GraphPad Software, Inc., La Jolla, USA). The 
IC50 defines the molar concentration of the test compound that reduces the maximal 
specific binding of GbO3-PAA polymer to PapG-IILD by 50%. 
 
Crystallization of PapG-IILD 
All crystallization experiments were carried out with 10 mg/mL in sitting-drop vapor 
diffusion experiments in a 1:1 ratio of protein and precipitant. Initial crystals were 
optimized by streak seeding. PapG-IILD in spacegroup P1 was crystallized at 4 °C 
with 30% PEG2000 MME, 0.15 M KBr and 40 mM SiaGal disaccharide. PapG-IILD 
crystals in P21212 were grown at 20 °C with 10% PEG10000 and 30 mM SiaαGal. 
The complex of PapG-IILD/2 crystallized with 0.15 M Zn acetate, 0.05 M ZnCl2, 0.1 
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M Tris pH 7.5, 13% PEG6000 at 20 °C. The complexes with compounds 13a, 19, 
or 25e were crystallized at 20 °C with 10-14% PEG10000 (fivefold excess of ligand).  
 
Data collection and structure determination 
PapG-IILD crystals were cryo-preserved by addition of glycerol to a final 
concentration of 20% (v/v) and flash cooled in liquid nitrogen. All measurements 
were done at the SLS beamlines X06DA and X06SA (Swiss Light Source, Paul 
Scherrer Institute, Switzerland) at 100 K. All data were integrated, indexed and scaled 
using the XDS software [27,28], 5% of the reflections were set aside as test set, 
respectively. Data collection statistics are summarized in Table S1. All structures 
were solved by molecular replacement using the crystal structure of PapG-IILD (PDB 
ID: 1J8S) [10] as search models with the program Phaser [29]. Model building and 
structure refinement were performed with Coot [30], PHENIX [31], Buster-TNT [32], 
and Refmac [33]. Geometric restraints for the ligands were generated with grade [32] 
and PRODRG [34]. Refinement statistics are summarized in Table S1. 
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Table S1. Statistics on diffraction data and refinement of PapG-IILD and its complexes 
 
 
 
  
 
PapG-IILD   
(Apo-P21212) 
PapG-IILD   
 (Apo-P1) 
PapG-IILD : cpd 2 
(P212121) 
PapG-IILD : cpd 
2 
(P21) 
PDB Identifier 4Z3I 4Z3J 4Z3G 4Z3H 
Wavelength (Å) 1.00000 0.99986 0.97618 1.00000 
Resolution range 
(Å) 
46.01 - 1.74  
(1.80 - 1.74)* 
52.07 - 2.5  
(2.59 - 2.5) 
57.66 - 1.45  
(1.502 - 1.45) 
20.07 - 1.50  
(1.554 - 1.5) 
Space group P 21 21 2 P 1 P 21 21 21 P 1 21 1 
Unit cell  54.99 83.98 45.36 50.76 56.56 70.94 56.27 72.61 94.86 47.35 53.77 48.32 
, β, γ (°) 90 90 90 112.8 102.8 88.1 90 90 90 90 117.58 90 
Total reflections 201325 (9104) 42079 (4352) 790755 (35901) 224884 (19076) 
Unique reflections 21920 (710) 23346 (2342) 69025 (6338) 33319 (3003) 
Multiplicity 12.6 (12.8) 1.8 (1.9) 11.5 (5.7) 6.7 (6.4) 
Completeness (%) 98.4 (84.2) 95.2 (95.5) 99.2 (92.6) 96.5 (87.4) 
Mean I/sigma(I) 20.5 (2.6) 8.5 (2.5) 21.2 (1.3) 15.2 (2.9) 
Wilson B-factor 22.0 22.9 20.0 14.9 
R-merge 0.090 (0.221) 0.080 (0.308) 0.0577 (0.909) 0.075 (0.614) 
R-meas 0.09426 0.1137 0.06035 0.08173 
CC1/2 0.999 (0.994) 0.991 (0.849) 0.999 (0.554) 0.998 (0.876) 
CC* 1 (0.999) 0.998 (0.958) 1 (0.844) 1 (0.966) 
R-work 0.159 (0.302) 0.219 (0.302) 0.166 (0.295) 0.147 (0.222) 
R-free 0.200 (0.282) 0.245 (0.347) 0.201 (0.296) 0.173 (0.267) 
Number of atoms 3523 6613 7291 2018 
  macromolecules 1671 6395 3333 1678 
  ligands --- --- 86 31 
  water 230 218 561 304 
Protein residues 197 783 399 197 
RMS(bonds) 0.008 0.003 0.008 0.013 
RMS(angles) 1.17 0.85 1.26 1.64 
Ramachandran 
 favored (%) 99 98 99 99 
Ramachandran 
 outliers (%) 0 0 0 0 
Clashscore 2.43 2.08 3.29 0.90 
Average B-factor 25.9 28.7 25.7 20.8 
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Table S1 (Contd.). Statistics on diffraction data and refinement of PapG-IILD and its complexes 
 
 
PapG-IILD : cpd 
13a 
(P212121) 
PapG-IILD : cpd 19 
(P212121) 
PapG-IILD : cpd 
25e 
(P212121) 
PDB Identifier - - - 
Wavelength (Å) 0.97618 0.97618 0.97618 
Resolution range 
(Å) 
57.17  - 1.8  
(1.864  - 1.8)*  
58.08  - 1.66 
(1.719  - 1.66)  
58.12  - 1.74 
(1.802  - 1.74)  
Space group P 21 21 21 P 21 21 21 P 21 21 21 
Unit cell  55.77 71.82 94.44  56.62 73.43 94.91 56.59 73.59 94.74 
a, β, γ (°) 90 90 90 90 90 90 90 90 90 
Total reflections 454206 (42384) 618436 (62710) 492976 (25896) 
Unique reflections 35852 (3501) 47485 (4693) 37834 (2260) 
Multiplicity 12.7 (12.1) 13.0 (13.4) 13.0 (11.5) 
Completeness (%) 99.91 (99.40) 99.97 (99.96) 91.52 (55.53) 
Mean I/sigma(I) 10.93 (1.26) 14.50 (1.21) 14.83 (1.32) 
Wilson B-factor 24.1 21.45 23.21 
R-merge 0.1741 (1.988) 0.1237 (1.943) 0.1196 (1.744) 
R-meas 0.1816 0.1289 0.1246 
CC1/2 0.998 (0.531) 0.999 (0.561) 0.999 (0.413) 
CC* 0.999 (0.833) 1 (0.848) 1 (0.764) 
R-work 0.1876 (0.2890) 0.1662 (0.2915) 0.1576 (0.2924) 
R-free 0.2333 (0.3646) 0.1985 (0.3094) 0.1926 (0.3198) 
Number of atoms 7087 7237 7148 
  macromolecules 3339 3339 3333 
  ligands 88 100 104 
  water 340 460 382 
Protein residues 400 400 400 
RMS(bonds) 0.008 0.008 0.006 
RMS(angles) 1.18 1.25 1.13 
Ramachandran 
favored (%) 99 99 99 
Ramachandran 
outliers (%) 0 0 0 
    
Clashscore 2.97 2.97 1.78 
    
Average B-factor 27.8 27.9 29 
 
    
Generation of figures 
The figures were generated with Maestro (Schrödinger Release 2012: Maestro, 
version 9.3.5, Schrödinger, LLC, New York, NY, 2012), VMD [35], Prism 5 
(GraphPad Software Inc., San Diego, U.S.A.), Microsoft Excel 2013, or 
ChemBioDraw Ultra (12.0.3.1216). 
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Abstract  
 
The PapG-II adhesion, a surface proteins of E. coli, is involved in the bacterial 
adhesion to epithelial cells in the human urinary tract. Their expression correlates 
with an increased risk of developing pyelonephritis, a potentially life-threatening 
disease. Therefore, antagonizing PapG-II offers a meaningful alternative to an 
antibiotic therapy. Despite intensive medicinal chemistry efforts, the most promising 
reported antagonist – carbohydrate mimic 4 – exhibits only mid-micromolar affinity. 
Based on previous studies, we predicted that a substantial affinity increase would be 
possible by linking antagonist 4 with fragments binding outside the carbohydrate 
recognition domain of PapG-II. Thus, a library of fragment-sized compounds was 
screened for binding to PapG-II by NMR. The best binder 6, recognizing a second-
site proximal to the main binding pocket, was connected to antagonist 4 via linkers of 
variable length. With the best representative, compound 43, a clear increase in affinity 
was reached, albeit at the cost of higher complexity. Further thermodynamic and 
structural studies are ongoing to reveal the structural background for the improved 
affinity.  
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Introduction 
Carbohydrate-lectin interactions play major biological roles in as different areas as 
inflammation, cell-cell recognition and bacterial adhesion [1]. Among bacteria, 
uropathogenic E. coli (UPEC) is a classic example of a pathogen that utilizes a 
carbohydrate epitope as a target to adhere to the host cell and start colonization. 
UPEC strains causing infections in the upper urinary tract use PapG adhesins, which 
exist in three molecular variants (classes I-III) [2-6]. The PapG-II adhesin is of 
particular medical interest, as it is strongly associated with pyelonephritis in humans 
[7-10], a potentially life-threatening disease and a frequent complication during 
pregnancy [11]. PapG-II recognizes preferentially the globoside GbO4, present in the 
upper urinary tract of humans. Its binding epitope is oligosaccharide 1 (Figure 1) 
consisting of the D-Gal(1-4)-D-Gal core, flanked by β(1-3)-linked D-GlcNAc on the 
non-reducing end, and (1-4)-linked D-Glc on the reducing end [12].  
 
Since for the current treatment of pyelonephritis antibiotic are frequently used [13], 
bacterial resistance is rapidly increasing [13-15]. Therefore, the development of new 
therapeutic options is an urgent need. Preventing bacterial adhesion by blocking 
PapG-II interaction with its human target GbO4 is a promising new strategy not only 
to combat the infection but also to reduce the risk of resistance [16].  
 
Despite intensive synthetic efforts and detailed structural information on PapG-II (apo 
structure, PDB code: 18JS; co-crystal with 1, PDB code: 18JR [17]), the design of 
potent small-molecule inhibitors has been only partially successful. Major 
achievements are summarized in Figure 1. Starting from the natural epitope 1, the 
minimal binding epitope 2 was identified [18]. The corresponding β-methyl 
galabioside (3) exhibited a 4-fold higher affinity [12]. With an aromatic aglycone ( 
4), an even 9-fold increase of affinity was observed [19]. However, further small 
improvements of affinity could only be realized at the cost of much higher complexity 
( 5) [19]. Finally, for the therapy of pyelonephritis, the affinity of the to-date 
available PapG-II antagonists is still insufficient and has to be improved by almost a 
factor 100. 
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Figure 1. Relevant PapG-II ligands [18]: tetrasaccharide epitope of GbO4 (1, natural ligand); D-
galabiose (2) (minimal binding epitope); methyl β-D-galabioside (3); p-methylphenyl β-D-galabioside 
(4); the yet most potent published antagonist 5. 
 
Recently, we published the results of two fragment-based campaigns that provided 
high affinity antagonists for MAG [20] and E-selectin [21]. As in those cases, the 
development of highly potent PapG-II antagonists is hampered by a shallow, water-
accessible and highly polar binding site [17]. Therefore, a similar strategy was applied 
to discover fragments binding in close proximity of the carbohydrate recognition 
domain (CRD), which later on should be linked to the carbohydrate core structure. 
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Figure 2. Fragment-based second-site ligand search: A) Fragments binding to PapG-II are identified by 
spin-locked filtered transverse magnetization (T2) decay experiments; B) Fragments binding in close 
proximity of the first-site ligand are identified by proton relaxation enhancement (PRE), which permits 
to deduce also their orientation relative to the first-site ligand; C) Different linkers are used to connect 
identified fragments and the first-site ligand, resulting in “linked compounds” which are evaluated for 
binding to PapG-II. 
 
Results and Discussion 
For the first step, namely the identification of fragments binding to PapG-II, a library 
of sixty Rule-of-Three [22] compliant fragments was screened by NMR. Detailed 
experimental procedures are reported in the supporting information. By this approach, 
nine hits (6 – 14) were identified (Figure 3-A).  
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Figure 3. A) Fragments binding to PapG-II identified by NMR screening; B) TEMPO-labeled first site 
ligand 15 used to identify those fragments binding to PapG-II in close proximity to the first-site ligand.  
 
 
To identify the fragments binding in close proximity of 4, paramagnetic relaxation 
enhancement (PRE) experiments were performed (Figure 2-B) [23]. For this 
approach, the first-site ligand 4 (Figure 1) was labeled with a paramagnetic moiety (in 
this case TEMPO) to yield 15 (Figure 3-B, for the synthesis see supporting 
information). The TEMPO label was introduced at the 3’-position, because this is a 
tolerated exit vector [24].  
 
With the spin-labeled antagonist 15 those fragments binding simultaneously to and in 
close proximity of the first-site ligand were identified. The unpaired electron on the 
TEMPO label accelerates substantially the transverse relaxation of protons (PRE 
effect) in its vicinity (~10 Å distance) [25], thus reducing the intensity of the proton 
signals. This effect is distance dependent and allows not only to identify proximal 
binders, but also to uncover their orientation relative to the paramagnetic center 
(Figure 2-B and supporting information). Although compounds 6 and 12 were 
identified, the later had to be excluded due to chemical stability issues. The signal 
reduction of all protons of fragment 6 revealed the hydroxamic acid moiety is 
pointing towards the first-site ligand and can therefore be used as a handle for linking.  
 
For linking fragment 6 with the first-site ligand, several linking strategies are 
available. An ideal linker should allow the linked compound to adopt the proper 
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conformation and orientation for binding with minimal strain [26]. On the other hand, 
excessive flexibility should be avoided, causing an entropic penalty and thus reducing 
the affinity. And finally, ideally, the linker would also provide additional interactions 
with the protein. The first library was synthesized by copper-catalyzed azide-alkyne 
coupling (Schemes 1 & 2) [27]. In order to screen for different linker lengths, the 
homologous azides 23a-c and a series of terminal alkynes were generated (Scheme 1). 
The former was built from compound 21, which was obtained by a slightly modified 
known procedure from inexpensive 19 and 20 [28]. When 21 was heated up in the 
corresponding neat diamine, amines 22a-c were obtained in good yields. Diazo-
transfer with triflyl azide [29] finally afforded the azides 23a-c. For the alkynes series, 
galabioside 16 was regioselectively alkylated in the 3’-position with the appropriate 
bromoalkyne. Whereas the alkylation with 3-bromopropyne and 5-bromo-1-pentyne 
worked well, 4-bromobutyne did not react with compound 16. 
 
 
Scheme 1. a) i. Bu2SnO, toluene, reflux, 2-4h; ii. bromoalkyne, TBABr, toluene, 70-80 °C, overnight, 
50-60%; b) i. NaOMe, MeONa, rt, 66-90%; c) EtOH, reflux, 70%; d) diamine, solvent-less, 70 °C, 45 
min, 60%-quant; e) CuSO4, water, MeOH, TfN3, rt, 10-30 min, 89%-quant.; f) 23a-c, CuSO4, sodium 
ascorbate, t-BuOH:H2O = 2:1, rt, 1-2h, 66-80%.  
 
Therefore, a different route was devised for introducing the butynyl moiety (Scheme 
2). Starting from the partially deprotected galactoside 25, the tert-butyldimethylsilyl 
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ether of 3-bromo-1-propanol was introduced by nucleophilic substitution, to afford 
26. Desilylation, followed by oxidation with Dess-Martin periodinane [30] gave 
access to aldehyde 27, which was converted into the terminal alkyne 28 under Corey-
Fuchs conditions [31]. Glycosylation of galactoside 29 [32] with 28 provided 
galabioside 30. The p-methoxybenzyl (PMB) protecting groups were removed with 
10% trifluoroacetic acid (TFA), and the benzoyl esters were cleaved under Zemplén 
conditions [33], affording 31. Click chemistry with the azides 23a-c finally afforded 
the test compounds 24g-i. 
 
 
Scheme 2. a) NaH, 3-bromo-1-propanol TBDMS ether, DMF, 0 °C to rt, 71%; b) i. TBAF 1M, THF, 
rt, 1h, 88%; ii. Dess-Martin periodinane, DCM, rt, 40 min, 86%; c) i. CBr4, PPh3, DCM, 0 °C; ii. BuLi, 
THF, 90 min, 48%; d) TMSOTf, NIS, DCM/Et2O, -55 °C, 57%; e) i. TFA 10% in DCM, rt, 5 min, 
quant.; ii. MeONa, MeOH, rt, 2h, 70%; f) 23a-c, CuSO4, sodium ascorbate, t-BuOH:H2O = 2:1, rt, 1-
2h, 48-72%. 
 
The affinity of the test compounds 24a-i for PapG-II was determined in a competitive 
binding assay [34]. Although the majority of the triazole-linked compounds exhibited 
slightly better affinity then the reference compound 4, only a minor improvement 
could be reached.  
 
The limited affinity increase – the best compound 24i exhibits only a two-fold 
stronger binding as compared to 4 – could be due to the rigidity of the linker 
preventing the fragment to reach the proximal second binding site in an optimal 
spatial orientation. In order to verify this assumption, we designed a second series 
compounds, with a more flexible linker. 
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The linker for the second library was established by reductive amination (Scheme 3), 
leading to a flexible, sterically less demanding linker. Galabioside 32 was obtained 
from 16 by regioselective allylation of the 3’-position, followed by peracetylation 
[35]. By treatment with OsO4 and NaIO4 the terminal alkene function was converted 
into aldehyde 33. 
 
 
 
Table 1. Affinity values from the competitive binding assay for the triazole library 
 
 
 
Entry Cpd R IC50 (μM) rIC50 
1 4 H 382 1.00 
2 24a 
 
352 0.92 
3 24b 
 
348 0.91 
4 24c 
 
454 1.19 
5 24d 
 
389 1.02 
6 24e 
 
336 0.88 
7 24f 
 
267 0.70 
8 24g 
 
225 0.59 
9 24h 
 
323 0.84 
10 24i 
 
204 0.53 
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Reductive amination with amines 22a-c (scheme 1) and 36 (obtained from the ester 
33 by direct amidation with 2,2’-(ethylenedioxy)bis(ethylamine) and subsequent 
deprotection provided test compounds 34a-c and 38. 
 
 
 
Scheme 3. a) OsO4, NaIO4, 2,6-lutidine, dioxane/water 3:1, rt, overnight, 70%; b) i. amine 22a and 
22c, NaBH3CN, MeOH, rt; ii. MeONa, MeOH, rt, 23-26% or i. amine 22b, NaBH(AcO)3, DCE, rt, 
63%; ii. MeONa, MeOH, rt, 4h, 93%; c) 2,2’-(ethylenedioxy)bis(ethylamine), DMF, 70 °C, 45 min, 
53%; d) 36, NaBH(AcO)3, DCE, rt, 2h, 67%; ii. MeONa, MeOH, rt, 2h, 97%. 
 
In the amine series, the elongation of the carbon linkers by two carbons led to a 10-
fold improvement in affinity. Obviously, with antagonist 34b (Table 2, entry 3) 
exhibiting the elongated linker a better positioning of fragment 6 becomes possible, 
whereas the linker in 34a (Table 2, entry 2) is just too short. On the other side, a 
further elongation of the linker ( 34c & 38) resulted in a loss of affinity. One 
plausible reason is that the secondary amine of the linker, which is charged at 
physiological pH, generates repulsion with Lys172, which is part of the rim of the 
binding site and faces the 3’-position of the galabiose (Figure S1).  
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Scheme 4. a) i. TfN3, CuSO4, NaHCO3, MeOH, water, 15 min, 88%; ii. CBr4, PPh3, DCM, 73%; b) i. 
Bu2SnO, toluene, reflux, 2h; ii. 4, TBABr, toluene, 75 °C, 2 d; iii. MeONa, MeOH, rt, 5h, 40% over 3 
steps; c) i. Pd/C 10%, H2, MeOH, rt, 97%; ii. HOBt, HBTU, DIPEA, DMF, rt, 1.5h, 59%.   
 
To further improve affinity of antagonist 34b, the bioisostere 43 was synthesized 
(Scheme 4), where the charged amino group is replaced by a neutral methylene group. 
This should reduce the costs of desolvation but could beneficially or non-beneficially 
influence the linker length. First, the bromoazide 40 was synthesized starting from 6-
amino-1-hexanol (39) by diazo-transfer [29] followed by Appel bromination [36]. 
Regioselective alkylation of the 3’-position of 16 with bromide 40 afforded 41. 
Finally, reduction of the azide to the amine followed by HOBt/HBTU-promoted 
amide bond formation with 42 [37] yielded 43. Affinity measurements, however, 
revealed only a moderate increase in affinity (Table 2, entry 6) could be reached. 
 
  
3.2 Results 
160 
 
Table 2. Affinity values from the competitive binding assay for the secondary amines 
library 
 
 
Entry Cpd R IC50 (μM) rIC50 
1 4 H 382 1 
2 34a 
 
2’100 5.5 
3 34b 
 
197 0.51 
4 34c 
 
332 0.87 
5 38 
 
733 1.92 
6 43 
 
144 0.38 
 
 
To verify our interpretations, compound 43 was co-crystallized with PapG-II and 
studied by X-ray. Disappointingly, the pyridylthiazolyl moiety is outcompeted by 
crystal contacts and cannot be visualized in the electron density map (not shown). At 
the same time, the binding epitopes of compounds 43 and 4 were determined by STD-
NMR (Figure 4). Evidently, the interaction is mainly driven by the galabiose core, 
with the aromatic moieties at the reducing and non-reducing end interacting only 
loosely. Interestingly, while the 4-methoxyphenyl in the anomeric position is able to 
increase the affinity of 4 as compared to galabiose, the same does not hold true for the 
pyridylthiazolyl moiety in the 3’-position of 43, despite a comparable contribution to 
the binding epitope is suggested by the STD-NMR data. Most likely this is due to the 
high flexibility of the linear linker, related to high entropy costs. Attempts to confirm 
this interpretation by isothermal titration calorimetry (ITC) experiments have been 
initiated. 
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Figure 4. Binding epitopes of compounds 4 (above) and 43 (below). Due to the large overlap of the 
signals in the NMR spectra, not all protons can be assigned. Overlapping signals are indicated by 
dashed lines and the overall saturation is indicated. 
 
Conclusion 
In conclusion, we successfully screened a library of fragments by NMR and identified 
compound 6 as second-site ligand suitable for linking to the first-site ligand 4. In total, 
fourteen antagonists linked to the 3’-position to fragment 6 were synthesized and their 
binding affinities for PapG-II determined. By a bioisosteric substitution of the linker 
of the most potent compound 34b, antagonist 43 with a approximately 3-fold 
increased affinity as compared to the lead structure 4 was discovered. Likely, the 
rather low improvement in affinity is due to the high flexibility of the linker, causing a 
high entropy penalty, a hypothesis we are currently studying by ITC. In addition, 
structural information would help to identify appropriately rigidified linkers. So far, 
X-ray studies were compromized by crystal contacts and therefore new crystallization 
conditions are currently under investigation. We are convinced that by following up 
on our results, highly potent ligands can be discovered, as we already showed when 
targeting MAG and E-selectin [20,21].   
O
O
O
HO
O
HO
HO
HO
O
OH
OH
N
H
O
N
S
N
H
H
H
H
H
H
H
H
H
H
H
H
H
H
100-120%
80-100%
60-80%
40-60%
20-40%
0-20%
O
O
O
HO
HO
HO
HO
HO
O
OH
OH
H
H
H
H
H
H
H
H
H
85%
H
H
73%
33%
OMe
O
43%
32%
3.2 Results 
162 
 
References 
 
[1] N. Sharon, Trends Biochem. Sci 1993, 18, 221-226. 
 
[2]  H. Hoschützky, F. Lottspeich, K. Jann. Infect. Immun. 1989, 57, 76-81. 
 
[3] J. R. Johnson, A. L. Stell, N. Kaster, C. Fasching, T. T. O'Bryan. Infect Immun 
2001, 69, 2318–2327. 
 
[4] N. Strömberg, B.-I. Marklund, B. Lund, D. Ilver, A. Hamers, W. Gaastra, A. 
Karlsson, S. Normark. EMBO J. 1990, 9, 2001–2010. 
 
[5] N. Strömberg, P.-G. Nyholm, I. Pascher, S. Normark. Proc. Natl. Acad. Sci. 
USA 1991, 88, 9340–9344. 
 
[6] S. D. Manning, L. Zhang, B. Foxman, A. Spindler, P. Tallman, C. F. Marrs. 
Clin. Diagn. Lab. Immunol. 2001, 8, 637–640. 
 
[7] I. M. Johanson, K. Plos, B. I. Marklund, C. Svanborg. Microb. Pathogenesis 
1993, 15, 121-129. 
 
[8] J. A. Roberts, B. I. Marklund, D. Ilver, D. Haslam, M. B. Kaack, G. Baskin, M. 
Louis, R. Möllby, J. Winberg, S. Normark. Proc. Natl. Acad. Sci. USA 1994, 91, 
11889-11893. 
 
[9] C.C. Tseng, J.J. Huang, M.C. Wang, A.B. Wu, W. C. Ko, W.C. Chen, J.J. Wu. 
Kidney int. 2007, 71, 764-770. 
 
[10] J. R. Johnson. papG Alleles among Escherichia coli Infect. Immun. 1998, 66, 
4568-4571. 
 
[11] J. B. Hill, J. S. Sheffield, D. D. McIntire, G. D. Wendel. Obstet. Gynecol. 2005, 
105, 18-23. 
 
[12] A. Larsson, J. Ohlsson, K. W. Dodson, S. J. Hultgren, U. Nilsson, J. Kihlberg. 
Bioorg. Med. Chem. 2003, 11, 2255-2261. 
 
[13] [Urinary Tract Infection, Chapter 11] Litwin M. S., Saigal C. S., editors. 
Urologic Diseases in America. US Department of Health and Human Services, 
Public Health Service, National Institutes of Health, National Institute of 
Diabetes and Digestive and Kidney Diseases. Washington, DC: US Government 
Printing Office, 2012; NIH Publication No. 12-7865. 
 
[14] K. Gupta, D. Scholes, W. E. Stamm. J. Amer. Med. Assoc. 1999, 281, 736-738. 
 
[15] L. G. Greer, S. W. Roberts, J. S. Sheffield, V. L. Rogers, J. B. Hill, D. D. 
Mcintire, G. D. Wendel. Infect. Dis. Obstet. Gynecol. 2008 ID 891426. 
 
[16] N. Sharon. Biochim. Biophys. Acta 2006, 1760, 527-537. 
3.2.3 New PapG-II Antagonists by a Fragment-Based Approach 
 163
[17] K. W. Dodson, J. S. Pinkner, T. Rose, G. Magnusson, S. J. Hultgren, G. 
Waksman. Cell 2001, 105, 733 – 743. 
 
[18]  R. Striker, U. Nilsson, A. Stonecipher, G. Magnusson, S. J. Hultgren. Molec. 
Biol. 1995, 16, 1021-1029.  
 
[19]  J. Ohlsson, J. Jass, B. E. Uhlin, J. Kihlberg, U. J. Nilsson. ChemBioChem 2002, 
3, 772-779. 
 
[20] Shelke, S.; Cutting, B.; Jiang, X.; Koliwer-Brandl, H.; Strasser, D.; Schwardt, 
O.; Kelm, S.; Ernst, B. Angew. Chem., Int. Ed. 2010, 49, 5721−5725. 
 
[21] Jonas Egger, Céline Weckerle, Brian Cutting, Oliver Schwardt, Said Rabbani, 
Katrin Lemme, and Beat Ernst J. Am. Chem. Soc. 2013, 135, 9820–9828. 
 
[22] M. Congreve, R. Carr, C. Murray, H. Jhoti. Drug Discov Today 2003, 8, 876-7.  
 
[23] W. Jahnke, L. B. Perez, C. G. Paris, A. Strauss, G. Fendrich, C. M. Nalin. 
Second-Site NMR Screening with a Spin-Labeled First Ligand J. Am. Chem. 
Soc. 2000, 122, 7394-7395. 
 
[24]  J. Ohlsson, J. Jass, B. E. Uhlin, J. Kihlberg, U. J. Nilsson. ChemBioChem 2002, 
3, 772-779. 
 
[25] Bertini, I.; Luchinat, C.; Parigi, G.; Pierattelli, R. ChemBioChem 2005, 6, 1536-
1549. 
 
[26] T. G. Davies, M. Hyvönen (Eds.). Fragment-Based drug Discovery and X-ray 
Crystallography. Springer 2012, XII. 
 
[27] F. Himo, T. Lovell, R. Hilgraf, V. V. Rostovtsev, L. Noodleman, K. B. 
Sharpless, V. V. Fokin. J. Am. Chem. Soc., 2005, 127, 210-216. 
 
[28] P. Gillespie et al., US. Patent 2007/0167622 A1, 2007. 
 
[29] A.Titz, Z. Radic, O. Schwardt, B. Ernst. Tetr. Lett. 2006, 47, 2383-2385. 
 
[30] D. B. Dess, J. C. Martin. Readily accessible 12-I-5 oxidant for the conversion of 
primary and secondary alcohols to aldehydes and ketones. J. Org. Chem. 1983, 
48, 4155-4156. 
 
[31] E. J. Corey, P. L. Fuchs. Tetrahedron Lett. 1972, 13, 3769-3772. 
 
[32]  J. Ohlsson, G. Magnusson. Carbohyd. Res. 2000, 329, 49-55. 
 
[33] W. Zerong. Zemplén Deacetylation. Comprehensive Organic Name Reactions 
and Reagents. John Wiley & Sons 2010, 691, 3123-3128. 
 
[34]  S. Rabbani, X. Jiang, O. Schwardt, B. Ernst. Anal. Biochem. 2010, 407, 188-
195. 
3.2 Results 
164 
 
[35] J. Ohlsson, J. Jass, B. E. Uhlin, J. Kihlberg, U. J. Nilsson. ChemBioChem 2002, 
3, 772-779. 
 
[36] R. Appel. Angew. Chem. 1975, 14, 801-811. 
 
[37]  S. Schlimme, A.-T. Hauser, V. Carafa, R. Heinke, S. Kannan, D. A. Stolfa, S. 
Cellamare, A. Carotti, L. Altucci, M. Jung, W. Sippl. ChemMedChem 2011, 6, 
1193-1198. 
 
Supporting Information 
3.2.3 New PapG-II Antagonists by a Fragment-Based Approach  
 
Giulio Navarra, Pascal Zihlmann, Brigitte Fiege, Said Rabbani, Rachel Hevey, Beat 
Ernst 
 
[a]  Institute of Molecular Pharmacy, Pharmacenter, University of Basel, 
Klingelbergstrasse 50, CH-4056 Basel, Switzerland 
[b] Biozentrum, University of Basel, Klingelbergstrasse 70, CH-4056 Basel, 
Switzerland 
 
Table of Contents 
 
1. General Methods S1 
2. NMR Experiments S2 
2.1. Protein Preparation S2 
2.2. NMR Fragment Screening S2 
2.3. T1 experiments with reference ligand 4 S4 
2.4. STD NMR experiments S4 
3. Synthesis S5 
3. References       S30 
 
 
1. General methods: 
 
All NMR experiments were performed on a Bruker AVANCE III 500 MHz NMR 
spectrometer equipped with a BBO room temperature probe head with Z-gradients at 
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a temperature of 298 K. Spectra were acquired and processed with Topspin 2.1 
(Bruker BioSpin, Switzerland) and analyzed with MestReNova 6.1.1 (Mestrelab 
Research, Spain). Assignment of 1H and 13C NMR spectra was achieved using 2D 
methods (COSY, HSQC, TOCSY and HMBC). Chemical shifts are expressed in ppm 
using residual CHCl3, CHD2OD, H2O, and TMS as references. Optical rotations were 
measured on a Perkin-Elmer Polarimeter 341. IR spectra were recorded on a Perkin 
Elmer Spectrum One FT-IR spectrometer as KBr pellets, or thin films. Electron spray 
ionization mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. 
Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 
(Merck) and visualized by using UV light and/or by heating to 150 °C for 5 min with 
aq. KMnO4 solution or a molybdate solution (a 0.02 M solution of ammonium cerium 
sulfate dihydrate and ammonium molybdate tetrahydrate in aq. 10% H2SO4). Column 
chromatography was performed on a CombiFlash Companion (Teledyne-ISCO, Inc.) 
using RediSep® normal phase disposable flash columns (silica gel) or handmade 
reversed phase columns packed with LiChroprep® RP-18 (Merck, 40-63 μm). LC-MS 
separations were carried out using Sunfire C18 columns (analytical: 2.1 × 50 mm, 3.5 
μm; preparative: 19 × 150 mm, 5.0 μm) on a Waters 2525 LC, equipped with a 
Waters 2996 photodiode array and a Waters micromass ZQ for detection. 
Hydrogenation reactions were performed in a shaking apparatus (Parr Instruments 
Company, Moline, Illinois, USA) in 250 mL or 500 mL bottles with H2 pressure as 
stated, or in conventional flasks equipped with a balloon. Solvents and phosphate 
buffer solutions were purchased from Fluka or Acros. Solvents were dried prior to use 
where indicated. Methanol (MeOH) was dried by refluxing with sodium methoxide 
and distilling. Dry MeOH was stored on activated (400 °C under high vacuum) MS 
3Å. Dichloromethane (DCM) was dried by filtration through activated Al2O3 (Fluka, 
type 5016 A basic, heated at 400 °C under vacuum for 1 h and then cooled under 
argon) and stored over activated MS 3Å. Tetrahydrofurane (THF) was dried by 
distillation from sodium/benzophenone. Dry N,N-dimethylformamide (DMF) was 
purchased from Acros. 
 
 
2. NMR Experiments 
2.1 Protein preparation 
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A deuterated phosphate buffer pH 7.4 (corrected for deuterium effect) containing 
150 mM NaCl was prepared (= NMR buffer). Lyophilized PapG-II protein was 
dissolved in NMR buffer. After centrifugation at 13000 RPM in an Eppendorf 5427 R 
centrifuge, the supernatant was collected and the concentration of the protein was 
determined by UV absorption (NanoDrop ND-100 spectrophotometer, NanoDrop 
Technologies, USA) as µM or mg/ml. Alternatively, a 4 mg/mL stock in phosphate 
buffer 20 mM, containing 150 mM NaCl was diluted with NMR buffer. A 1D NMR 
spectrum of 15 µM PapG-II in NMR buffer was recorded to control the correct 
folding of the protein. 
 
2.2 NMR fragment screening 
Stocks of the cocktail mixtures of fragments (2 to 6 compounds per mixture) were 
prepared in deuterated DMSO (DMSO-d6) at 10 mM final concentration per 
fragment. NMR samples for the screening were prepared in 3 mm tubes (Hilgenberg, 
Germany) by adding the cocktail mixture at a final concentration of 250 µM per 
fragment to either NMR buffer, or to PapG-II at a final concentration of 15 µM in 
NMR buffer. TSP-d4 (3-(trimethylsilyl)-2,2’,3,3’-tetradeuteropropionic acid, Armar 
Chemicals, Switzerland) was added as an internal reference. Identical samples, except 
for the absence of PapG-II protein, were prepared in 5 mm tubes (Bruker BioSpin, 
Switzerland) and were used for recording the reference spectra of the fragments. 
T1 spinlock-filtered experiments [S1] were measured with a standard Bruker pulse 
sequence with excitation sculpting (es) for suppression of residual water [S2] and 
modified by insertion of a continuous wave spinlock pulse between the 90° observe 
pulse and the es sequence. For the fragment screening, T1  experiments of the NMR 
samples in absence and presence of PapG-II protein were measured with spinlock 
pulses of 20 ms and 200 ms at RF field strength of 2.6 kHz. Each experiment was 
recorded with 512 scans, a spectral width of 12 ppm, 32k data points, an acquisition 
time of 2.72 s and an interscan delay of 10 s to ensure efficient longitudinal relaxation 
between the experiments. The difference in signal intensity at 20 ms and 200 ms 
spinlock pulse length was recorded in absence (IredRef=I200 msRef/I20 msRef) and in 
presence of PapG-II (IredPapG=I200 msPapG/I20 msPapG). The percent of signal reduction R 
due to the protein was calculated according to equation 1: 
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R=
I200 ms
PapG
I20 ms
PapG൘
I200 ms
Ref
I20 ms
Ref൘
*100=
Ired
PapG
Ired
Ref *100 eq. 1 
When R  10% the fragment was considered as a binder.  
For the validation of initial hits from cocktail mixtures and for the additional spin-
spin-relaxation experiments with spin-labeled first-site ligand 15, samples with single 
fragments were prepared. PapG-II was present at 20 µM concentration in NMR buffer. 
A 20 mM stock solution of the fragment to test in DMSO-d6 was prepared and added 
to a final sample concentration of 500 µM, resulting in a final DMSO-d6 
concentration of 2.5%. The same experimental scheme as described for the screening 
was used and the signal was recorded at 20 ms and 200 ms spinlock time, in absence 
and presence of spin-labeled compound 15 at 3 mM concentration. For each 
experiment, 256 scans were recorded. The R-value was calculated as shown in 
equation 2: 
R=
I200 msSL
I20 msSL
൘
I200 ms
PapG
I20 ms
PapG൘
*100=
IredSL
Ired
PapG *100 eq. 2 
where IredSL=I200 msSL/I20 msSL is the ratio between signal intensity of the fragment at 
20 ms and 200 ms spinlock pulse length in presence of spin-labeled compound and of 
PapG. If the R-value was significantly increased, the fragment was considered as a 
second-site ligand. 
 
2.3 T1 experiments with reference ligand 4 
In case of the reference ligand 4, whole T1 relaxation curves were measured with 
spinlock pulses from 20 ms to 250 ms. The relative intensity reduction of each ligand 
peak was monitored as a function of the spinlock time and fitted to equation 3 with 
Prism 5 (GraphPad Software Inc., San Diego, U.S.A.): 
I(t)=I0*exp(-T1ρ*t)        eq. 3 
where I(t) is the peak intensity after spinlock time t and T1 is the fitted T1ρ relaxation 
rate constant. 
For determination of the KD value of compound 4, whole T1 relaxation curves were 
measured for a sample of 7.6 µM PapG-II in 20 mM HEPES-d18 with increasing 
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concentrations of compound 4. This buffer was chosen because our previous affinity 
assays were always run in HEPES buffer. For the screening, phosphate buffer was 
used for economic reasons and ease of preparation. The binding in both buffers was 
compared by polymer assay [S3] and showed similar values (not shown). The protein 
concentration was not held constant during the titration and was reduced to 7.5 µM 
(250 µM compound 4), 7.4 µM (500 µM compound 4), 7.3 µM (750 µM compound 
4) and 7.2 µM (1 mM compound 4). A sample of 1 mM compound 4 in absence of 
protein in D2O was measured to obtain the T1 relaxation rate of the free ligand. T1 
relaxation rate constants as a function of the ligand excess were obtained as described 
above and fitted to a one-site binding model with Prism 5 (GraphPad Software Inc., 
San Diego, U.S.A.): 
T1ρ(c)=
T1ρ,free*c
KD'+c
        eq. 4 
where c is the ligand excess and T1,free is the T1 relaxation rate constant of the free 
ligand measured in absence of protein. The KD was calculated from the unit-less KD 
by multiplication with the protein concentration. 
 
2.4 STD NMR experiments 
STD NMR experiments [S4,S5] were measured for determination of binding epitopes 
of fragment hits, reference ligand 4, and compound 42. Samples contained 40 µM 
PapG-II with 2 mM compound 4 or 0.7 mM compound 42 in NMR buffer. 0.1 mM 
TSP-d4 was added as internal reference. A standard Bruker pulse sequence 
(stddiffesgp.3) with interleaved acquisition of on- and off-resonance spectra and with 
an excitation sculpting sequence for water suppression was used. A 30 ms spinlock 
filter at 2.6 kHz RF field strength for suppression of protein signals was applied. A 
train of 50 ms Gaussian shaped pulses at a power level of 45 dB corresponding to an 
RF field strength of 114.2 Hz was used for selective irradiation of the protein. The on-
resonance was set to 0.5 ppm and the off-resonance to 300 ppm. A saturation time of 
20 s and an acquisition time of 1.4 s were applied resulting in a total relaxation time 
of 21.4 s for the off-resonance experiment. For the determination of the binding 
epitopes, the T1 relaxation rate constants of the free ligands were determined by 
measuring T1 inversion recovery experiments with 10 delay times (0.1, 0.2, 0.3, 0.5, 
0.8, 1, 1.5, 2, 3 and 5 s) and a relaxation delay of 20 s for ligand samples in absence of 
protein (2 mM compound 4 in D2O, or 1 mM compound 42 in NMR buffer). T1 
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relaxation rate constants were obtained by fitting the normalized signal intensity 
(intensity on the first experiment with 0.1 s delay set to -1) as a function of the 
inversion recovery delay to equation 5: 
I(t)=A(1-B*exp(-t T1ൗ ))        eq. 5 
 
where I(t) is the signal intensity after delay time t, and A and B are correction factors. 
Absolute STD effects, defined as % of signal intensity in the difference (off – on) 
spectrum relative to the off-resonance spectrum, were determined by manual scaling 
for each non-overlapping peak. Absolute STD effects were then divided by the T1 
relaxation rate constants and further normalized (setting the largest quotient to 100%) 
to yield the STD binding epitope free of any longitudinal relaxation bias [S6]. 
 
3. Synthetic procedures 
 
Scheme S1. a) Pd/C, H2, AcOH, rt, 3 h, 77%; b. i) Bu2SnO, C6H6, reflux, 4 h, ii) BrCH2COOMe, 
TBABr, C6H6, 75 °C overnight, 34%; c. i) MeONa, MeOH, rt, 2d, ii) NaOH 0.5 M, MeOH, rt, 
overnight, 79%; d. 4-NH2-TEMPO, HBTU, HOBt, DIPEA, rt, 1h, 48%. 
 
 
4-Methoxyphenyl -D-galactopyranosyl-(14)-2,3,6-O-benzoyl--D-galactopy-
ranoside (16): 
Compound 44[S8] (424 mg, 0.38 mmol) was dissolved in AcOH (8 mL) under argon. 
Pd(OH)2/C (10-20% w/w, 100 mg) was added. Hydrogen gas was provided by a 
balloon. The mixture was vigorously stirred for 2 h, then the hydrogen atmosphere 
was replaced with argon. The suspension was diluted with MeOH and filtered through 
celite. The filtrate was concentrated and the residue applied to a silica gel column, 
eluting with DCM/MeOH gradient, to yield 220 mg (77%) of 16. 
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ESI-MS: m/z: Calcd for C40H40NaO15+ [M+Na]+: 783.2, found 783.4. 
1H NMR (500 MHz, CD3OD):  = 8.15 – 8.02 (m, 2H, Ar), 8.01 – 7.91 (m, 4H, Ar), 
7.71 – 7.61 (m, 1H, Ar), 7.59 – 7.47 (m, 4H), 7.44 – 7.31 (m, 4H), 6.98 – 6.88 (m, 
2H, Ar), 6.69 – 6.53 (m, 2H, Ar), 5.99 – 5.84 (m, 1H, H-2), 5.57 (d, J = 10.5 Hz, 1H, 
H-3), 5.41 (d, J = 7.8 Hz, 1H, H-1), 5.02 – 4.94 (m, 2H, H-1’, H-6a), 4.76 (dd, J = 
11.6, 3.8 Hz, 1H, H-6b), 4.60 (s, 1H, H-4), 4.46 (dd, J = 7.6, 4.4 Hz, 1H, H-5), 4.19 
(s, 1H, H-5’), 4.04 (s, 1H, H-4’), 4.00 (d, J = 10.5 Hz, 1H, H-3’), 3.87 (d, J = 10.1 Hz, 
1H, H-2’), 3.67 (s, 3H, OCH3), 3.27 (dd, J = 10.7, 4.9 Hz, 2H, H-6’a, H-6’b). 
13C NMR (126 MHz, CD3OD):  167.53 (C=O), 167.41 (C=O), 167.13 (C=O), 
156.94 (Ar), 152.39 (Ar), 134.67 (Ar), 134.56 (Ar), 134.43 (Ar), 131.21 (Ar), 130.91 
(Ar), 130.73 (Ar), 130.56 (Ar), 130.47 (Ar), 129.65 (Ar), 129.63 (Ar), 129.58 (Ar), 
119.35 (Ar), 115.46 (Ar), 102.92 (C-1’), 101.59 (C-1), 76.45 (C-4), 75.08 (C-3), 
74.86 (C-5), 71.93 (C-5’), 71.31 (C-4’, C-2), 70.98 (C-3’), 70.48 (C-2’), 64.56 (C-6), 
62.18 (C-6’), 55.96 (OCH3). 
 
4-Methoxyphenyl [3-O-(methoxycarbonylmethyl)-α-D-galactopyranosyl]-(14)-
2,3,6-O-benzoyl-β-D-galactopyranoside (45): 
Compound 16 (190 mg, 0.25 mmol) was dissolved in benzene (25 mL). Bu2SnO (68.4 
mg, 0.275 mmol) was added and the mixture was refluxed in a Dean-Stark apparatus, 
removing 20 mL of solvent. Methyl bromoacetate (0.118 mL, 1.249 mmol) and 
TBABr (40.3 mg, 0.125 mmol) were added and the flask was sealed. The mixture was 
stirred at 75 °C overnight, then the solvent was removed. The residue was 
chromatographed on silica (PE/EtOAc gradient), to yield 71 mg of 45 (34%). 
ESI-MS: m/z: Calcd for C43H44NaO17+ [M+Na]+: 855.3, found 855.4. 
1H NMR (500 MHz, CDCl3): δ = 8.10 – 8.05 (m, 2H, Ar), 7.96 (m, 4H, Ar), 7.61 (t, J 
= 7.4 Hz, 1H), 7.55 – 7.45 (m, 4H, Ar), 7.38 (m, 4H, Ar), 6.97 – 6.92 (m, 2H, Ar), 
6.70 – 6.64 (m, 2H, Ar), 5.93 (dd, J = 10.6, 7.9 Hz, 1H, H-2), 5.35 (dd, J = 10.6, 2.8 
Hz, 1H, H-3), 5.17 (d, J = 7.9 Hz, 1H, H-1), 5.12 (d, J = 3.8 Hz, 1H, H-1’), 4.91 (dd, 
J = 11.5, 7.4 Hz, 1H, H-6a), 4.78 (dd, J = 11.5, 6.1 Hz, 1H, H-6b), 4.54 (d, J = 2.8 Hz, 
1H, H-4), 4.47 (d, J = 17.4 Hz, 1H, -OCH2COOMe), 4.29 – 4.20 (m, 2H, -
OCH2COOMe, H-5), 4.17 – 4.08 (m, 3H, H-2’, H-5’, H-4’ ), 3.82 (s, 3H, -OCH3), 
3.78 (dd, J = 3.0, 10.0 Hz, 1H, H-3’), 3.71 (s, 3H, -OCH3), 3.44 (dt, J = 12.0, 3.9 Hz, 
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1H, H-6a), 3.35 (ddd, J = 12.0, 9.0, 5.1 Hz, 1H, H-6b), 3.09 (d, J = 5.4 Hz, 1H, 4’-
OH), 2.53 (dd, J = 8.9, 3.9 Hz, 1H, 6’-OH). 
13C NMR (126 MHz, CDCl3): δ = 133.36 (Ar), 129.90 (Ar), 129.81 (Ar), 129.73 (Ar), 
128.65 (Ar), 128.56 (Ar), 128.48 (Ar), 118.80 (Ar), 114.46 (Ar), 101.11 (C-1), 100.97 
(C-1’), 81.44, 75.06, 73.72, 73.04, 70.20, 69.95, 69.59, 68.45, 68.02, 67.44, 62.96, 
62.28, 57.19, 55.59, 52.59, 42.97, 40.88, 38.00, 25.52. 
 
4-Methoxyphenyl [3-O-(hydroxycarbonylmethyl)-α-D-galactopyranosyl]-(14)-
β-D-galactopyranoside (46): 
Compound 45 (71 mg, 0.085 mmol) was dissolved in dry methanol (1 mL), then 1 M 
MeONa was added (16 µL) with stirring. After 20 h stirring at rt, additional 10 µL of 
1 M MeONa were added. After 30 h, a further 20 µL aliquot of 1 M MeONa was 
added. After 48 h the mixture was evaporated to reduce the solvent volume, then 0.5 
M NaOH was added at rt, and the mixture was stirred overnight. The mixture was 
acidified to pH 3 with amberlite IR-120, filtered and evaporated. Two 
chromatographies (RP, C18, water/ACN + 0.1 % TFA) yielded 34 mg of 46 (79%). 
ESI-MS: m/z: Calcd for C21H30NaO14+ [M+Na]+: 529.2, found 529.2. 
1H NMR (500 MHz, CD3OD): δ =7.10 – 7.04 (m, 2H, Ar), 6.89 – 6.84 (m, 2H, Ar), 
5.04 (d, J = 3.9 Hz, 1H, H-1’), 4.83 (d, J = 7.6 Hz, 1H, H-1), 4.40 (d, J = 16.9 Hz, 1H, 
-OCHHCOOMe), 4.35 - 4.28 (m, 2H, OCHHCOOMe, H-), 4.16 (d, J = 2.1 Hz, 1H, 
H-4’), 4.08 (d, J = 3.0 Hz, 1H, H-4), 4.01 (dd, J = 10.2, 3.9 Hz, 1H, H-2’), 3.95 – 3.85 
(m, 1H), 3.83 – 3.78 (m, 1H), 3.77 (s, 3H, -OCH3), 3.76 – 3.69 (m, 3H, H-3’, H-2), 
3.65 (dd, J = 10.1, 3.1 Hz, 1H, H-3). 
13C NMR (126 MHz, CD3OD): δ = 175.37 (C=O), 156.78 (Ar), 153.01 (Ar), 119.26 
(Ar), 115.51 (Ar), 103.99, 102.64, 81.08, 79.68, 76.25, 74.67, 72.66, 70.11, 68.45, 
62.61, 61.12, 56.07. 
 
4-Methoxyphenyl 3-[(1-oxyl-2,2,6,6-tetramethylpiperidine-4-amino)carbonyl]me-
thyl-α-D-galactopyranosyl-(14)-β-D-galactopyranoside (15): 
HBTU (7.2 mg, 0.019 mmol), HOBt (5 mg, 0.038 mmol) and compound 46 (6.4 mg, 
0.013 mmol) were dissolved in dry DMF (0.3 mL). After shaking for 10 min, 4-
amino-TEMPO was added (3.2 mg, 0.019 mmol), followed by DIPEA (7 µL, 0.038 
mmol). After 1h, water was added and the solvent was removed under reduced 
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pressure. The residue was purified by silica gel chromatography (DCM/MeOH 
gradient), yielding 15 as reddish oil. 
ESI-MS: m/z: Calcd for C30H49N2O14+ [M+Na]+: 661.3, found 661.4 (reduced form). 
NMR data were measured after treatment with sodium ascorbate, in order to convert 
the N-oxyl group to an N-hydroxyl group. 
1H NMR (500 MHz, D2O): δ = 7.18 – 7.13 (m, 2H, Ar), 7.04 – 6.93 (m, 2H, Ar), 5.06 
(d, J = 4.0 Hz, 1H, H-1’), 5.05 (d, J = 7.1 Hz, 1H, H-1), 4.36 (t, J = 6.4 Hz, 1H), 4.30 
– 4.19 (m, 3H, H-4’), 4.16 (d, J = 16.0 Hz, 1H), 4.14 (d, J = 2.7 Hz, 1H), 4.02 (dd, J = 
10.4, 3.9 Hz, 1H, H-2’), 3.96 – 3.79 (m, 9H, H-2, H-3’, OCH2CO, OCH3), 3.76 (d, J = 
6.3 Hz, 2H), 2.02 – 1.89 (m, 2H, 2 TEMPO CHH), 1.59 (dd, J = 22.8, 12.3 Hz, 2H, 2 
TEMPO CHH), 1.31 – 1.13 (m, 12H, 4 CH3). 
13C NMR (126 MHz, D2O): δ = 193.33 (C=O), 154.76 (Ar), 118.41 (Ar), 115.04 (Ar), 
101.68 (C-1’), 100.28 (C-1), 78.78, 77.47, 75.26, 72.28, 70.72, 67.60, 60.51, 55.84, 
43.60 (TEMPO CH2), 40.53, 30.15 (2 CH3), 19.76 (2 CH3). 
 
General procedure for the synthesis of compounds 17a and 17b: 
A solution of compound 16 in toluene (2 mL) was degassed with ultrasound under 
gentle vacuum for 10 min. To this solution, dibutyltin oxide (1.2 eq) was added under 
argon. The mixture was then refluxed for 2 to 4 h, with azeotropic removal of water. 
The residual toluene (approx 0.5 mL) was evaporated and the residue was dried under 
high vacuum for 2 h. Afterwards, it was dissolved in 0.5 mL of dry toluene. To this 
solution, the bromoalkyne was added, followed by TBABr (0.65 eq). The mixture was 
stirred in a sealed flask at 75 °C (15 to 72 h). The mixture was evaporated, re-
dissolved in DCM and applied to a silica gel column. The product was eluted with a 
DCM/MeOH gradient. 
 
4-Methoxyphenyl 3’-O-(propargyl)-α-D-galactopyranosyl-(14)-2,3,6-tri-O-ben-
zoyl-β-D-galactopyranoside (17a): 
Yield: 51.0 mg (60%) 
[α]D20 +32.2 (c 0.46, CHCl3). 
ESI-MS: m/z: Calcd for C43H42NaO15+ [M+Na]+: 821.2, found 821.3. 
1H NMR (500 MHz, CDCl3): δ = 8.07 (d, J = 7.3 Hz, 2H, Ar), 7.98 (dd, J = 14.1, 7.4 
Hz, 4H, Ar), 7.61 (t, J = 7.4 Hz, 1H, Ar), 7.51 (m, 4H, Ar), 7.38 (m, 4H, Ar), 6.96 (m, 
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2H, Ar), 6.68 (m, 2H, Ar), 5.96 (dd, J = 10.5, 7.9 Hz, 1H, H-2), 5.38 (dd, J = 10.6, 2.7 
Hz, 1H, H-3), 5.19 (d, J = 7.8 Hz, 1H, H-1), 5.10 (d, J = 3.5 Hz, 1H, H-1’), 4.88 (dd, 
J = 11.4, 7.4 Hz, 1H, H-6a), 4.76 (dd, J = 11.4, 6.1 Hz, 1H, H-6b), 4.55 (d, J = 2.6 Hz, 
1H, H-4), 4.43 (m, 2H, HCCCH2-), 4.29 (s, 1H, H-4’), 4.25 (t, J = 6.7 Hz, 1H, H-5), 
4.15 (t, J = 4.2 Hz, 1H, H-5’), 4.07 - 3.96 (m, 2H, H-2’, H-3’), 3.72 (s, 3H), 3.49 – 
3.33 (m, 2H, H-6’a, H-6’b), 2.72 (s, 1H), 2.66 (t, J = 2.2 Hz, 1H, HCCH2-), 2.46 (d, J 
= 6.6 Hz, 1H, 2’-OH), 2.29 – 2.23 (m, 1H, 6’-OH). 
13C NMR (126 MHz, CDCl3): δ = 166.12 (C=O), 166.02 (C=O), 165.71 (C=O), 
155.72 (Ar), 151.12 (Ar), 133.78 (Ar), 133.44 (Ar), 133.41 (Ar), 129.91 (Ar), 129.81 
(Ar), 129.73 (Ar), 129.55 (Ar), 129.20 (Ar), 128.91 (Ar), 128.68 (Ar), 128.57 (Ar), 
128.48 (Ar), 118.84 (Ar), 114.49 (Ar), 101.12 (C-1’), 100.79 (C-1), 79.67 (alkyne 
quart.), 77.71 (C-3’), 75.98 (HCCCH2), 74.64 (C-4), 73.70 (C-3), 73.01 (C-5), 70.32 
(C-5’), 69.54 (C-2), 68.66 (C-4’), 68.34 (C-2’), 62.86 (C-6’), 62.38 (C-6), 57.74 
(HCCCH2), 55.60 (OCH3). 
 
4-Methoxyphenyl 3’-O-(4-pentynyl)-α-D-galactopyranosyl-(14)-2,3,6-tri-O-
benzoyl-β-D-galactopyranoside (17b): 
Yield: 30.0 mg (51%) 
[α]D20 34.5 (c 0.6, CHCl3). 
ESI-MS: m/z: Calcd for C45H46NaO15+ [M+Na]+: 849.3, found 849.3. 
1H NMR (500 MHz, CDCl3): δ = 8.09 – 8.04 (m, 2H, Ar), 7.97 (dd, J = 11.3, 4.2 Hz, 
2H, Ar), 7.61 (t, J = 7.4 Hz, 1H, Ar), 7.56 - 7.46 (m, 4H, Ar), 7.39 (dd, J = 16.9, 8.0 
Hz, 4H, Ar), 6.99 – 6.92 (m, 2H, Ar), 6.72 – 6.61 (m, 2H, Ar), 5.95 (dd, J = 10.6, 7.9 
Hz, 1H, H-2), 5.36 (dd, J = 10.6, 2.9 Hz, 1H, H-3), 5.18 (d, J = 7.8 Hz, 1H, H-1), 5.08 
(d, J = 3.8 Hz, 1H, H-1’), 4.89 (dd, J = 11.4, 7.4 Hz, 1H, H-6a), 4.78 (dd, J = 11.4, 6.3 
Hz, 1H, H-6b), 4.54 (d, J = 2.8 Hz, 1H, H-4), 4.26 – 4.22 (m, 2H, H-5, H-4’), 4.15 – 
4.07 (m, 1H, H-5’), 4.02 - 3.96 (m, 1H, H-2’), 3.92 – 3.86 (m, 1H, OCHHCH2), 3.80 
– 3.73 (m, 2H, OCHHCH2), 3.72 (s, 3H, OCH3), 3.36 (dt, J = 11.6, 3.7 Hz, 1H, H6’a), 
3.33 – 3.25 (m, 1H, H6’b), 2.44 (d, J = 6.35, 1H, 2’-OH), 2.41 – 2.36 (m, 2H, 
HCCCH2CH2), 2.24 (dd, J = 8.2, 4.3 Hz, 1H, 6’-OH), 2.07 (t, J = 2.6 Hz, 1H, 
HCCCH2CH2), 1.94 – 1.80 (m, 2H, HCCH2CH2). 
13C NMR (126 MHz, CDCl3): δ = 166.12 (C=O), 166.05 (C=O), 165.76 (C=O), 
155.72 (Ar), 151.14 (Ar), 133.78 (Ar), 133.46 (Ar), 133.40 (Ar), 129.88 (Ar), 129.81 
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(Ar), 129.73 (Ar), 129.57 (Ar), 129.19 (Ar), 128.97 (Ar), 128.68 (Ar), 128.57 (Ar), 
128.50 (Ar), 118.84 (Ar), 114.49 (Ar), 101.16 (C-1), 100.87 (C-1’), 83.63 (alkyne 
quart.), 78.15 (OCH2CH2), 74.72 (C-4), 73.73 (C-3), 73.01 (C4’), 70.09 , 69.55 (C-2), 
69.41, 68.39 (C-2’), 68.12 , 67.98 (C-5), 62.82 (C-6’), 62.19 (C-6), 55.60 (OCH3), 
28.11 (HCCCH2CH2), 15.24 (HCCCH2CH2). 
 
General procedure for the synthesis of amines 22a-c: 
Compound 21 [20] was suspended in the amine of choice and heated at 70 °C with 
stirring under argon. After 45 min the mixture was evaporated (under high vacuum, 
when needed), and then the residue was chromatographed on silica, eluting with 
DCM/MeOH/water/NH4OHc (8:2:1:0.2).  
 
N-(2-Aminoethyl)-2-(pyridin-3-yl)thiazole-4-carboxamide (22a): 
Compound 21 (88 mg, 0.376 mmol) and ethylendiamine (1mL). Yield 75 mg (80%). 
ESI-MS: m/z: Calcd for C11H13N4OS+ [M]+: 249.1, found 248.8. 
1H NMR (500 MHz, CD3OD): δ = 9.24 (d, J = 2.0 Hz, 1H, Ar), 8.65 (dd, J = 4.9, 1.4 
Hz, 1H, Ar), 8.47 – 8.40 (m, 1H, Ar), 8.29 (s, 1H, thiazole), 7.57 (dd, J = 8.0, 4.9 Hz, 
1H, Ar), 3.53 (t, J = 6.3 Hz, 2H, NHCH2CH2NH2), 2.91 (t, J = 6.3 Hz, 2H, 
NHCH2CH2NH2). 
13C NMR (126 MHz, CD3OD): δ = 166.09 (C=O), 163.65 (Ar), 152.17 (Ar), 151.83 
(Ar), 148.13 (Ar), 136.00 (Ar), 130.82 (Ar), 125.75 (Ar), 125.71 (Ar), 42.67, 42.05. 
 
N-(3-Aminopropyl)-2-(pyridin-3-yl)thiazole-4-carboxamide (22b): 
Compound 21 (100 mg, 0.427 mmol) and 1,3-diaminopropane (0.8 mL). Yield 112 
mg (quant). 
ESI-MS: m/z: Calcd for C12H15N4OS+ [M]+: 263.1, found 262.8. 
1H NMR (500 MHz, CD3OD): δ = 9.26 (d, J = 1.7 Hz, 1H, Ar), 8.67 (dd, J = 4.9, 1.5 
Hz, 1H, Ar), 8.52 – 8.39 (m, 1H, Ar), 8.30 (s, 1H, thiazole), 7.65 – 7.55 (m, 1H, Ar), 
3.53 (t, J = 6.8 Hz, 2H, NHCH2CH2CH2NH2), 2.75 (t, J = 6.9 Hz, 2H, 
NHCH2CH2CH2NH2), 1.83 (p, J = 6.8 Hz, 2H, NHCH2CH2CH2NH2). 
13C NMR (126 MHz, CD3OD): δ = 166.10 (C=O), 163.38 (Ar), 152.29 (Ar), 151.83 
(Ar), 148.11 (Ar), 135.99 (Ar), 130.82 (Ar), 125.71 (Ar), 125.59 (Ar), 39.73, 37.79, 
33.49. 
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N-(4-Aminobutyl)-2-(pyridin-3-yl)thiazole-4-carboxamide (22c): 
Compound 21 (88 mg, 0.376 mmol) and 1,4-diaminobutane (1 mL). Yield 92.5 mg 
(89%). 
ESI-MS: m/z: Calcd for C13H17N4OS 277.11, found 276.88. 
1H NMR (500 MHz, CD3OD): δ = 9.26 (d, J = 1.8 Hz, 1H, Ar), 8.67 (dd, J = 4.9, 1.5 
Hz, 1H, Ar), 8.51 – 8.43 (m, 1H, Ar), 8.29 (s, 1H, thiazole), 7.60 (dd, J = 8.0, 4.9 Hz, 
1H, Ar), 3.47 (t, J = 7.1 Hz, 2H, NHCH2CH2CH2CH2NH2), 2.72 (t, J = 7.2 Hz, 2H, 
NHCH2CH2CH2CH2NH2), 1.78 – 1.66 (m, 2H, NHCH2CH2CH2CH2NH2), 1.65 – 1.52 
(m, 2H, NHCH2CH2CH2CH2NH2). 
13C NMR (126 MHz, CD3OD): δ = 166.08 (C=O), 163.20 (Ar), 152.35 (Ar), 151.82 
(Ar), 148.12 (Ar), 136.00 (Ar), 130.83 (Ar), 125.71 (Ar), 125.53 (Ar), 42.19, 40.28, 
31.00, 28.05. 
 
General procedure for the synthesis of azides 23a-b: 
The amine (1 eq), NaHCO3 (4 eq), and CuSO4 pentahydrate (0.04 eq) were 
dissolved/suspended in water ([amine] = 1.29 mM). To this solution/suspension, a 
freshly prepared 2 M solution of triflyl azide in toluene was added dropwise, with 
vigorous stirring ar rt (2-4 eq). Methanol was added to yield a homogeneous system 
(2 to 4 mL). After completion, solvents were evaporated and the residue was 
chromatographed on silica gel, eluting with DCM/MeOH gradient. 
 
N-(2-Azidoethyl)-2-(pyridin-3-yl)thiazole-4-carboxamide (23a): 
Compound 22a (75 mg, 0.3 mmol). Yield 80 mg (97%). 
ESI-MS: m/z: Calcd for C11H11N6OS+ [M]+: 275.1, found 274.7. 
1H NMR (500 MHz, CD3OD): δ = 9.25 (d, J = 2.0 Hz, 1H, Ar), 8.67 (dd, J = 4.9, 1.4 
Hz, 1H, Ar), 8.50 – 8.43 (m, 1H, Ar), 8.32 (s, 1H, thiazole), 7.59 (dd, J = 8.0, 4.9 Hz, 
1H, Ar), 3.65 (t, J = 5.9 Hz, 2H, NHCH2CH2N3), 3.56 (t, J = 6.0 Hz, 2H, 
NHCH2CH2N3). 
13C NMR (126 MHz, CD3OD): δ = 166.13 (C=O), 163.49 (Ar), 151.95 (Ar), 151.80 
(Ar), 148.09 (Ar), 135.98 (Ar), 130.77 (Ar), 125.90 (Ar), 125.68 (Ar), 51.46 
(NHCH2CH2N3), 39.96 (NHCH2CH2N3). 
 
N-(3-Azidopropyl)-2-(pyridin-3-yl)thiazole-4-carboxamide (23b): 
Compound 22b (42 mg, 0.16 mmol). Yield 41 mg (89%). 
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ESI-MS: m/z: Calcd for C12H13N6OS+ [M]+: 289.1, found 289.0. 
1H NMR (500 MHz, CD3OD): δ = 9.23 (s, 1H, Ar), 8.65 (d, J = 4.3 Hz, 1H, Ar), 8.46 
– 8.39 (m, 1H, Ar), 8.28 (s, 1H, thiazole), 7.57 (dd, J = 8.0, 4.9 Hz, 1H, Ar), 3.53 (t, J 
= 6.9 Hz, 2H, NHCH2CH2CH2N3), 3.45 (t, J = 6.7 Hz, 2H, NHCH2CH2CH2N3), 1.93 
(p, J = 6.8 Hz, 2H, NHCH2CH2CH2N3). 
13C NMR (126 MHz, CD3OD): δ = 166.07 (C=O), 163.31 (Ar), 152.19 (Ar), 151.81 
(Ar), 148.10 (Ar), 135.95 (Ar), 130.78 (Ar), 125.69 (Ar), 125.66 (Ar), 50.33 
(NHCH2CH2CH2N3), 38.07 (NHCH2CH2CH2N3), 29.97 (NHCH2CH2CH2N3). 
 
N-(4-Azidobutyl)-2-(pyridin-3-yl)thiazole-4-carboxamide (23c): 
Compound 22c (51 mg, 0.19 mmol). Yield 56 mg (quant). 
ESI-MS: m/z: Calcd for C13H15N6OS+ [M]+: 303.1, found 303.0. 
1H NMR (500 MHz, CD3OD): δ = 9.23 (s, 1H, Ar), 8.66 (s, 1H, Ar), 8.46 – 8.35 (m, 
1H, Ar), 8.28 (s, 1H, thiazole), 7.57 (dd, J = 7.9, 4.9 Hz, 1H, Ar), 3.47 (t, J = 6.8 Hz, 
2H, NHCH2CH2CH2CH2N3), 3.37 (t, J = 6.6 Hz, 2H, NHCH2CH2CH2CH2N3), 1.79 – 
1.72 (m, 2H, NHCH2CH2CH2CH2N3), 1.72 – 1.65 (m, 2H, NHCH2CH2CH2CH2N3). 
13C NMR (126 MHz, CD3OD): δ = 166.06 (C=O), 163.22 (Ar), 152.26 (Ar), 151.79 
(Ar), 148.10 (Ar), 135.97 (Ar), 125.71 (Ar), 125.59 (Ar), 52.19 
(NHCH2CH2CH2CH2N3), 39.96 (NHCH2CH2CH2CH2N3), 27.95 and 27.40 
(NHCH2CH2CH2CH2N3). 
 
General procedure for the synthesis of compounds 18a-b: 
Compound 17a or 17b (1 eq) was dissolved in dry MeOH (1 mL). To this solution, 10 
µL of a freshly prepared 1M NaOMe solution were added under argon, with stirring at 
rt. The mixture was stirred until TLC showed completion (≈ 6 h) and then neutralized 
with amberlyst 15. The mixture was filtered, concentrated and chromatographed on 
silica (DCM/MeOH gradient) to yield the corresponding deprotected disaccharide. 
 
4-Methoxyphenyl 3’-O-(propargyl)-α-D-galactopyranosyl-(14)-β-D-galactopy-
ranoside (18a): 
Compound 17a (51 mg, 0.064 mmol). Yield: 27.5 mg (88.5%). 
[α]D20 +12.0 (c 0.55, MeOH). 
ESI-MS: m/z: Calcd for C22H30NaO12+ [M+Na]+: 509.2, found 509.2. 
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1H NMR (500 MHz, CD3OD): δ = 7.12 – 7.02 (m, 2H), 6.92 – 6.82 (m, 2H), 5.04 (d, 
J = 3.9 Hz, 1H, H-1’), 4.84 (d, J = 7.6 Hz, 1H, H-1), 4.40 (d, J = 2.3 Hz, 2H, 
HCCCH2), 4.35 (t, J = 6.1 Hz, 1H, H-5’), 4.20 (d, J = 2.6 Hz, 1H, H-4’), 4.10 (d, J = 
2.9 Hz, 1H, H-4), 3.95 (dd, J = 10.2, 3.8 Hz, 1H, H-2’), 3.93 – 3.88 (m, 1H, H-5), 
3.86 (dd, J = 10.2, 3.0 Hz, 1H, H-3’), 3.83 – 3.75 (m, 7H, H-2, OCH3, H-6’b, H-6a, 
H-6b), 3.73 (dd, J = 11.1, 5.5 Hz, 1H, H-6’a), 3.67 (dd, J = 10.1, 3.0 Hz, 1H, H-3), 
2.88 (t, J = 2.3 Hz, 1H, HCCCH2). 
13C NMR (126 MHz, CD3OD): δ = 156.81 (Ar), 152.99 (Ar), 119.31 (Ar), 115.54 
(Ar), 104.03 (C-1), 102.59 (C-1’), 81.13 (alkyne quart.), 79.06 (C-4), 78.58 (C-3’), 
76.25, 75.92 (HCCCH2), 74.64 (C-3), 72.66, 72.61 (C-5’), 69.96, 68.21 (C-4’), 62.62, 
60.93, 57.91 (HCCCH2), 56.08 (OCH3). 
 
4-Methoxyphenyl 3’-O-(penten-4-yl)-α-D-galactopyranosyl-(14)-β-D-galacto-
pyranoside (18b): 
Compound 17b (30 mg, 0.036 mmol). Yield: 16.3 mg (87.3%). 
[α]D20 +16.2 (c 0.37, MeOH). 
ESI-MS: m/z: Calcd for C24H34NaO12+ [M+Na]+: 537.2, found 537.2. 
1H NMR (500 MHz, CD3OD): δ = 7.11 – 7.04 (m, 2H), 6.91 – 6.83 (m, 2H), 5.02 (d, 
J = 3.9 Hz, 1H, H-1’), 4.84 (d, J = 7.6 Hz, 1H, H-1), 4.33 (t, J = 6.1 Hz, 1H, H-5’), 
4.15 (d, J = 2.6 Hz, 1H, H-4’), 4.09 (d, J = 3.0 Hz, 1H, H-4), 3.94 – 3.86 (m, 2H, H-
2’, H-6a), 3.85 – 3.71 (m, 9H, H-2, H-5, H-6’a-b, H-6b, OCH3, HCCCH2CH2CHH), 
3.70 – 3.64 (m, 2H, H-3, HCCCH2CH2CHH), 3.61 (dd, J = 10.2, 3.0 Hz, 1H, H-3’), 
2.36 (tt, J = 7.0, 2.4 Hz, 1H, HCCCH2CH2CH2), 2.23 (t, J = 2.6 Hz, 1H, 
HCCCH2CH2CH2), 1.91 – 1.78 (m, 1H, HCCCH2CH2CH2). 
13C NMR (126 MHz, CD3OD): δ = 156.81 (Ar), 152.99 (Ar), 119.28 (Ar), 115.54 
(Ar), 104.02 (C-1), 102.64 (C-1’), 84.89 (alkyne quart), 79.64 (C-3’), 79.09 (C-4), 
76.31, 74.61, 72.65, 69.92, 69.67, 69.30, 67.96 (C-4’), 62.68, 60.95, 56.09, 30.10 
(HCCCH2CH2CH2), 15.89 (HCCCH2CH2CH2). 
 
General procedure for the synthesis of compounds 24a-f: 
The appropriate terminal alkyne (1 eq) and the azide (1.1 eq) were dissolved in a 2:1 
mixture of t-BuOH and water. Aqueous solutions of sodium ascorbate and CuSO4 
were sequentially added (0.2 and 0.1 eq, respectively). The bright yellow suspension 
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was stirred vigorously ar rt until TLC (DCM/MeOH, 9:1) showed completion (3-5 h). 
Whenever needed, additional aliquots of sodium ascorbate were added. Purification: 
Chromatography on silica (DCM/MeOH/water/NH4OH, 8:2:0.5:0.1). 
 
3-O-[(1-(2-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)ethyl)-1,2,3-triazol-4-yl) 
methyl]-α-D-galactopyranosyl-(14)-β-D-galactopyranoside (24a): 
Compound 18a (14 mg, 0.029 mmol) and azide 23a (8.67 mg, 0.032 mmol). Yield: 
13.7 mg (63%). 
[α]D20 +12.1 (c 0.69, MeOH). 
ESI-MS: m/z: Calcd for C33H40N6NaO13+ [M+Na]+: 783.2, found 783.3. 
1H NMR (500 MHz, CD3OD): δ = 9.20 (d, J = 1.8 Hz, 1H, Ar), 8.68 – 8.62 (m, 1H, 
Ar), 8.43 – 8.37 (m, 1H, Ar), 8.28 (s, 1H, thiazole), 8.07 (s, 1H, triazole), 7.57 (dd, J 
= 8.0, 4.9 Hz, 1H, Ar), 7.08 – 7.00 (m, 2H, Ar), 6.87 – 6.79 (m, 2H, Ar), 5.04 (d, J = 
3.9 Hz, 1H, H-1’), 4.85 (d, J = 12.8 Hz, 1H, OCHH-triazole), 4.82 (d, J = 7.6 Hz, 1H, 
H-1), 4.77 (d, J = 12.5 Hz, 1H, OCHH-triazole), 4.69 (t, J = 5.9 Hz, 2H, NHCH2CH2), 
4.31 (t, J = 6.1 Hz, 1H, H-5’), 4.18 (d, J = 2.4 Hz, 1H, H-4’), 4.08 (d, J = 2.9 Hz, 1H, 
H-4), 3.97 (dd, J = 10.2, 3.8 Hz, 1H, H-2’), 3.92 (t, J = 5.9 Hz, 2H, NHCH2CH2), 3.86 
(dt, J = 10.5, 5.4 Hz, 1H, H-5), 3.83 – 3.70 (m, 10H, H-2, H-3, H6a-b, H-3’. H-6’a-b, 
OCH3), 3.66 (dd, J = 10.1, 3.0 Hz, 1H, H-3). 
13C NMR (126 MHz, CD3OD): δ = 166.09 (C=O), 163.50 (Ar), 156.71 (Ar), 153.00 
(Ar), 151.83 (Ar), 151.73 (Ar), 148.09 (Ar), 146.51 (Ar), 136.01 (Ar), 130.73 (Ar), 
126.14 (Ar), 125.73 (Ar), 125.52 (Ar), 119.22 (Ar), 115.50 (Ar), 103.97 (C-1), 102.63 
(C-1’), 79.39 (C-4), 79.23, 76.18, 74.69 (C-3), 72.82, 72.64, 69.84 (C-2’), 67.80 (C-
4’), 63.46 (OCH2-triazole), 62.74, 61.12, 56.06 (OCH3), 50.65 (NHCH2CH2), 40.73 
(NHCH2CH2). 
 
3-O-[(1-(3-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)propyl)-1,2,3-triazol-4-yl) 
methyl]-α-D-galactopyranosyl-(14)-β-D-galactopyranoside (24b): 
Compound 18a (8.1 mg, 0.017 mmol) and azide 23b (6.72 mg, 0.023 mmol). Yield: 
12.4 mg (96%). 
[α]D20 +11.3 (c 0.62, MeOH). 
ESI-MS: m/z: Calcd for C34H43N6NaO13+ [M+Na]+: 775.3, found 775.5. 
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1H NMR (500 MHz, CD3OD): δ = 9.25 (d, J = 1.8 Hz, 1H, Ar), 8.68 (dd, J = 4.9, 1.3 
Hz, 1H, Ar), 8.48 – 8.43 (m, 1H, Ar), 8.30 (s, 1H, thiazole), 8.10 (s, 1H, triazole), 
7.60 (dd, J = 8.0, 4.9 Hz, 1H, Ar), 7.07 – 7.01 (m, 2H, Ar), 6.85 – 6.79 (m, 2H, Ar), 
5.04 (d, J = 3.9 Hz, 1H, H-1’), 4.83 (d, J = 12.8 Hz, 1H, OCHH-triazole), 4.82 (d, J = 
7.4 Hz, 1H, H-1), 4.76 (d, J = 12.5 Hz, 1H, OCHH-triazole), 4.54 (t, J = 6.8 Hz, 2H, 
NCH2CH2CH2NH), 4.31 (t, J = 6.1 Hz, 1H, H-5’), 4.17 (d, J = 2.3 Hz, 1H, H-4’), 4.08 
(d, J = 2.9 Hz, 1H, H-4), 3.98 (dd, J = 10.2, 3.9 Hz, 1H, H-2’), 3.90 – 3.83 (m, 1H, H-
5), 3.82 – 3.71 (m, 10H, 10H, H-2, H-3, H6a-b, H-3’. H-6’a-b, OCH3), 3.66 (dd, J = 
10.1, 3.0 Hz, 1H, H-3), 3.50 (t, J = 6.7 Hz, 2H, NCH2CH2CH2NH), 2.29 (p, J = 6.8 
Hz, 2H, NCH2CH2CH2NH). 
13C NMR (126 MHz, CD3OD): δ = 166.07 (C=O), 163.42 (Ar), 156.71 (Ar), 152.99 
(Ar), 152.04 (Ar), 151.85 (Ar), 148.13 (Ar), 146.40 (Ar), 136.04 (Ar), 130.80 (Ar), 
125.83 (Ar), 125.74 (Ar), 125.37 (Ar), 119.22 (Ar), 115.49 (Ar), 103.97 (C-1), 102.63 
(C-1’), 79.34 (, 79.17, 76.19, 74.68 (C-3), 72.78 (C-5’), 72.63, 69.85 (C-2), 67.76 (C-
4’), 63.43 (OCH2-triazole), 62.70, 61.07 (C-5), 56.05 (OCH3), 49.37 
(NCH2CH2CH2NH), 37.74 (NCH2CH2CH2NH), 31.17 (NCH2CH2CH2NH). 
 
3-O-[3(1-(2-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)ethyl)-1,2,3-triazol-4-yl) 
propyl]-α-D-galactopyranosyl-(14)-β-D-galactopyranoside (24c): 
Compound 18b (8.5 mg, 0.017 mmol) and azide 23a (5.07 mg, 0.019 mmol). Yield: 
9.4 mg (72%). 
[α]D20 +11.9 (c 0.45, MeOH). 
ESI-MS: m/z: Calcd for C35H45N6O13S+ [M+Na]+: 789.3, found 789.3. 
1H NMR (500 MHz, CD3OD): δ = 9.27 (s, 1H, Ar), 8.73 (s, 1H, Ar), 8.43 (d, J = 7.9 
Hz, 1H, Ar), 8.30 (s, 1H, thiazole), 7.85 (s, 1H, Ar), 7.62 (s, 1H, Ar), 7.10 – 7.01 (m, 
2H, Ar), 6.88 – 6.80 (m, 2H, Ar), 5.02 (d, J = 3.9 Hz, 1H, H-1’), 4.85 (d, J = 7.7 Hz, 
1H, H-1), 4.71 – 4.62 (m, 2H, NCH2CH2NH), 4.25 (t, J = 6.1 Hz, 2H, H-5’), 4.08 (d, 
J = 2.9 Hz, 2H, H-4), 4.05 (d, J = 2.3 Hz, 2H, H-4’), 3.96 – 3.88 (m, 4H, 
NCH2CH2NH, H-2’, H-5), 3.86 – 3.73 (m, 7H, OCH3, H-6’a, H-2, H6a-b), 3.72 – 
3.58 (m, 3H, H-3, H-6’b, CH2CH2CHHO), 3.49 (dd, J = 10.2, 2.9 Hz, 1H, H-3’), 3.45 
– 3.39 (m, 1H, CH2CH2CHHO), 2.90 – 2.80 (m, 2H, CH2CH2CH2O), 2.02 – 1.81 (m, 
2H, CH2CH2CH2O). 
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13C NMR (126 MHz, CD3OD): δ = 163.36 (C=O), 156.70 (Ar), 152.97 (Ar), 151.82 
(Ar), 151.70 (Ar), 148.04 (Ar), 135.95 (Ar), 126.18 (Ar), 119.17 (Ar), 115.50 (Ar), 
103.94 (C-1’), 102.75 (C-1), 79.62 (C-3’), 79.50 (C-4), 76.20, 74.67, 72.80, 72.67, 
69.72, 68.27 (CH2CH2CH2O), 67.45 (C-4’), 62.78, 61.17, 56.04, 50.38, 40.57, 30.56 
(CH2CH2CH2O), 22.36 (CH2CH2CH2O). 
 
3-O-[3(1-(3-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)propyl)-1,2,3-triazol-4-
yl)propyl]-α-D-galactopyranosyl-(14)-β-D-galactopyranoside (23d): 
Compound 18b (9.3 mg, 0.018 mmol) and azide 23b (7.30 mg, 0.025 mmol). Yield: 
11.5 mg (79%). 
[α]D20 +9.0 (c 0.3, MeOH). 
ESI-MS: m/z: Calcd for C36H47N6O13S+ [M+Na]+: 803.3, found 803.5. 
1H NMR (500 MHz, CD3OD): δ = 9.28 (s, 1H, Ar), 8.70 (s, 1H, Ar), 8.47 (d, J = 8.0 
Hz, 1H, Ar), 8.30 (s, 1H, thiazole), 7.88 (s, 1H, Ar), 7.67 – 7.53 (m, 1H, Ar), 7.11 – 
6.98 (m, 2H, Ar), 6.87 – 6.79 (m, 2H, Ar), 5.04 (d, J = 3.9 Hz, 1H, H-1’), 4.84 (d, J = 
7.6 Hz, 1H, H-1), 4.50 (t, J = 6.8 Hz, 2H, NHCH2CH2CH2N), 4.30 (t, J = 6.2 Hz, 1H, 
H-5’), 4.13 (d, J = 2.4 Hz, 1H, H-4’), 4.09 (d, J = 2.9 Hz, 1H, H-4), 3.95 (dd, J = 
10.2, 3.9 Hz, 1H, H-2’), 3.94 – 3.88 (m, 1H, H-5), 3.86 – 3.64 (m, 10H, OCH3, H-2, 
H-3, OCHHCH2CH2, H-6’a-b, H-6a-b), 3.56 (dd, J = 10.2, 3.0 Hz, 1H, H-3’), 3.53 – 
3.43 (m, 3H, OCHHCH2CH2, NHCH2CH2CH2), 2.84 (t, J = 7.2 Hz, 2H, 
OCH2CH2CH2), 2.26 (p, J = 6.7 Hz, 2H, NHCH2CH2CH2), 2.02 – 1.85 (m, 2H, 
OCH2CH2CH2). 
13C NMR (126 MHz, CD3OD): δ = 166.12 (C=O), 163.37 (Ar), 156.74 (Ar), 152.98 
(Ar), 152.05 (Ar), 151.85 (Ar), 148.68 (Ar), 148.14 (Ar), 136.03 (Ar), 125.83 (Ar), 
123.96 (Ar), 119.22 (Ar), 115.52 (Ar), 103.98 (C-1), 102.76 (C-1’), 79.57 (C-3’), 
79.50 (C-4), 76.25, 74.68, 72.79, 72.67, 69.82 (C-2’), 68.68, 67.59 (C-4’), 62.76, 
61.14, 56.06 (OCH3), 49.41 (NHCH2CH2CH2N), 37.89 (NHCH2CH2CH2), 31.16 
(NHCH2CH2CH2), 30.56 (OCH2CH2CH2), 22.54 (OCH2CH2CH2). 
 
3-O-[(1-(4-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)butyl)-1,2,3-triazol-4-yl) 
methyl]-α-D-galactopyranosyl-(14)-β-D-galactopyranoside (24e) 
Compound 18a (9.8 mg, 0.020 mmol) and azide 23c (8.83 mg, 0.029 mmol). Yield: 
12.5 mg (79%). 
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[α]D20 +11.1 (c 0.63, MeOH). 
ESI-MS: m/z: Calcd for C35H45N6O13S+ [M+Na]+: 789.3, found 789.4. 
1H NMR (500 MHz, CD3OD): δ = 9.25 (s, 1H, Ar), 8.67 (d, J = 4.5 Hz, 1H, Ar), 8.46 
(d, J = 8.0 Hz, 1H, Ar), 8.29 (s, 1H, thiazole), 8.05 (s, 1H, triazole), 7.60 (dd, J = 8.0, 
4.9 Hz, 1H, Ar), 7.10 – 7.02 (m, 1H, Ar), 6.87 – 6.82 (m, 1H, Ar), 5.04 (d, J = 3.9 Hz, 
1H, H-1’), 4.85 (d, overlaps with water peak, H-1) 4.83 (d, J = 12.4 Hz, 1H, OCHH), 
4.78 (d, J = 12.4 Hz, 1H, OCHH), 4.49 (t, J = 7.0 Hz, 2H, NHCH2CH2CH2CH2N), 
4.31 (t, J = 6.1 Hz, 1H, H-5’), 4.18 (d, J = 2.5 Hz, 1H, H-4’), 4.08 (d, J = 2.9 Hz, 1H, 
H-4), 3.98 (dd, J = 10.2, 3.8 Hz, 1H, H-2), 3.90 – 3.83 (m, 1H, H-5), 3.82 – 3.71 (m, 
9H, H-2, H-6a-b, H-3’, H-6’a-b, OCH3), 3.66 (dd, J = 10.1, 3.0 Hz, 1H, H-3), 3.48 (t, 
J = 6.9 Hz, 2H, NHCH2CH2CH2CH2N), 2.06 – 1.97 (m, 2H, NHCH2CH2CH2CH2N), 
1.71 – 1.63 (m, 2H, NHCH2CH2CH2CH2N). 
13C NMR (126 MHz, CD3OD): δ = 166.10 (C=O), 163.31 (Ar), 156.74 (Ar), 153.00 
(Ar), 152.21 (Ar), 151.82 (Ar), 148.12 (Ar), 146.43 (Ar), 136.04 (Ar), 130.82 (Ar), 
125.70 (Ar), 125.07 (Ar), 119.22 (Ar), 115.52 (Ar), 103.95 (C-1), 102.67 (C-1’), 
79.43 (C-4), 79.29, 76.18, 74.69 (C-3), 72.82, 72.65, 69.85 (C-2’), 67.79 (C-4’), 63.50 
(OCH2), 62.70, 61.07, 56.07, 50.99 (NHCH2CH2CH2CH2N), 39.66 
(NHCH2CH2CH2CH2N), 28.67, 27.56. 
 
3-O-[3-(1-(4-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)butyl)-1,2,3-triazol-4-
yl)propyl]-α-D-galactopyranosyl-(14)-β-D-galactopyranoside (24f): 
Compound 18b (6.9 mg, 0.013 mmol) and azide 23c (5.25 mg, 0.017 mmol). Yield: 
7.2 (66%). 
[α]D20 +14.9 (c 0.36, MeOH). 
ESI-MS: m/z: Calcd for C37H48N6NaO13S+ [M+Na]+: 839.3, found 839.4. 
1H NMR (500 MHz, CD3OD): δ = 9.26 (d, J = 1.6 Hz, 1H, Ar), 8.74 (t, J = 6.0 Hz, 
1H, CONH), 8.67 (d, J = 3.8 Hz, 1H, Ar), 8.49 – 8.43 (m, 1H, Ar), 8.30 (s, 1H, 
thiazole), 7.83 (s, 1H, triazole), 7.60 (dd, J = 7.9, 4.9 Hz, 1H, Ar), 7.13 – 7.01 (m, 2H, 
Ar), 6.91 – 6.76 (m, 2H, Ar), 5.03 (d, J = 3.9 Hz, 1H, H-1’), 4.84 (d, J = 7.6 Hz, 1H, 
H-1), 4.44 (t, J = 7.0 Hz, 2H, NHCH2CH2CH2CH2N), 4.30 (t, J = 6.2 Hz, 1H, H-5’), 
4.14 (d, J = 2.5 Hz, 1H, H-4’), 4.09 (d, J = 2.9 Hz, 1H, H-4), 3.95 (dd, J = 10.3, 3.9 
Hz, 1H, H-2’), 3.92 – 3.89 (m, 1H, H-6a), 3.85 – 3.69 (m, 10H, OCHHCH2CH2, 
OCH3, H-2, H-5, H-6a, H-6’a-b, OH), 3.66 (dd, J = 10.1, 3.0 Hz, 1H, H-3), 3.57 (dd, 
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J = 10.2, 3.0 Hz, 1H, H-3’), 3.53 - 3.44 (m, 3H, NHCH2CH2CH2CH2N, 
OCHHCH2CH2), 2.87 (t, J = 7.2 Hz, 2H, OCH2CH2CH2), 2.11 – 1.86 (m, 4H, 
NHCH2CH2CH2CH2N, OCH2CH2CH2), 1.75 – 1.52 (m, 2H, NHCH2CH2CH2CH2N). 
13C NMR (126 MHz, CD3OD): δ = 166.09 (C=O), 163.37 (Ar), 156.75 (Ar), 153.00 
(Ar), 152.25 (Ar), 151.81 (Ar), 148.65 (Ar), 148.12 (Ar), 136.04 (Ar), 130.84 (Ar), 
125.71 (Ar), 123.72 (Ar), 119.21 (Ar), 115.52 (Ar), 103.99 (C-1), 102.76 (C-1’), 
101.41, 79.59 (C-3’), 79.50 (C-4), 76.25, 74.67 (C-3), 72.78 (C-5’), 72.67, 69.81 (C-
2’), 68.69 (OCH2CH2CH2), 67.59 (C-4’), 62.75, 61.13, 56.06 (OCH3), 50.87 
(NHCH2CH2CH2CH2N), 39.82, 39.69, 30.62, 28.73, 27.64 (NHCH2CH2CH2CH2N), 
22.53 (NHCH2CH2CH2CH2N). 
 
Phenyl 3-O-3-[(tert-butyldimethylsilyl)oxy]propyl-2,4,6-tri-O-(4-methoxybenzyl)-
1-thio-β-D-galactopyranoside (26): 
Compound 25 (389 mg, 0.615 mmol) was dissolved in DMF and cooled to 0 °C. NaH 
(60% dispersion in mineral oil, 52 mg, 1.29 mmol) was added in 2 portions with 
stirring under argon. The reaction was allowed to warm to rt, then a solution of (3-
bromopropoxy)-(tert-butyl)dimethylsilane (342.5 mg, 1.532 mmol) in 1 mL of dry 
DMF was added with stirring under argon. After 1h, additional 10 mg of NaH were 
added, and this addition was repeated twice (every 30 min). After 2 h, the mixture was 
poured on ice and extracted 3 times with DCM. The organic phases were collected, 
dried, filtered and evaporated. DMF was coevaporated with xylenes. The residue was 
chromatographed on silica (EtOAc/PE gradient), to yield 350 mg (71%) of 26. 
[α]D20 -2.8 (c 2.53, CHCl3). 
ESI-MS: m/z: Calcd for C45H60NaO9SSi+ [M+Na]+: 827.4, found 827.4. 
1H NMR (500 MHz, CDCl3): δ = 7.56 – 7.50 (m, 2H, Ar), 7.36 – 7.30 (m, 2H, Ar), 
7.25 – 7.22 (m, 2H, Ar), 7.21 – 7.15 (m, 5H, Ar), 6.89 – 6.81 (m, 6H, Ar), 4.84 (d, J = 
11.1 Hz, 1H, benzyl-CH), 4.68 (d, J = 9.9 Hz, 1H, benzyl-CH), 4.65 (d, J = 9.9 Hz, 
1H, benzyl-CH), 4.59 (d, J = 9.7 Hz, 1H, H-1), 4.49 (d, J = 11.2 Hz, 1H, benzyl-CH), 
4.40 (d, J = 11.3 Hz, 1H, benzyl-CH), 4.33 (d, J = 11.3 Hz, 1H, benzyl-CH), 3.92 (d, 
J = 2.6 Hz, 1H, H-4), 3.82 (s, 3H, OCH3), 3.80 – 3.64 (m, 11H, H-2, 
OCH2CH2CH2OTBMDS, 2 OCH3), 3.61 – 3.52 (m, 3H, H-5, H-6a-b), 3.39 (dd, J = 
9.2, 2.7 Hz, 1H, H-3), 1.84 (p, J = 6.4 Hz, 2H, OCH2CH2CH2OTBMDS), 1.55 (s, 
3H), 0.88 (s, 9H, t-butyl), 0.03 (d, J = 2.7 Hz, 6H, Si(CH3)2). 
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13C NMR (126 MHz, CDCl3): δ = 159.30 (Ar), 159.08 (Ar), 134.47 (Ar), 131.35 (Ar), 
131.07 (Ar), 130.67 (Ar), 130.04 (Ar), 129.92 (Ar), 129.59 (Ar), 129.42 (Ar), 128.74 
(Ar), 126.88 (Ar), 113.82 (Ar), 113.76 (Ar), 113.57 (Ar), 87.80 (C-1), 84.89 (C-3), 
75.20 (benzyl-CH2), 73.97 (benzyl-CH2), 73.22 (benzyl-CH2), 72.89 (C-4), 68.53, 
67.77, 60.17, 55.29, 33.69 (OCH2CH2CH2OTBMDS), 25.96 (C(CH3)3), 18.31 
(C(CH3)3), -5.27 (Si(CH3)2). 
 
Phenyl 3-O-(3-carbonylpropyl)-2,4,6-tri-O-(4-methoxybenzyl)-1-thio-β-D-galac-
topyranoside (27): 
Compound 26 (314 mg, 0.39 mmol) was dissolved in 1 M TBAF in THF (2 mL) at rt 
and stirred for 1h under argon (TLC: 50% EtOAc/PE), to remove the TBDMS 
protective group. The mixture was then diluted with EtOAc, washed with water and 
brine, dried on Na2SO4, filtered and concentrated. The residue was chromatographed 
on silica (PE/EtOAc gradient) to yield 238 mg (88%) of the corresponding free 
alcohol. 
[α]D20 -2.2 (c 0.6, CHCl3). 
ESI-MS: m/z: Calcd for C39H46NaO9S+ [M+Na]+: 713.3, found 713.4. 
1H NMR (500 MHz, CDCl3): δ = 7.55 – 7.50 (m, 2H, Ar), 7.37 – 7.32 (m, 2H, Ar), 
7.27 – 7.14 (m, 7H, Ar), 6.91 – 6.81 (m, 6H, Ar), 4.79 (d, J = 11.0 Hz, 1H, benzyl-
CH), 4.73 (d, J = 9.8 Hz, 1H, benzyl-CH), 4.60 (t, J = 9.6 Hz, 2H, H-1 and benzyl-
CH), 4.50 (d, J = 11.0 Hz, 1H, benzyl-CH), 4.42 (d, J = 11.3 Hz, 1H, benzyl-CH), 
4.35 (d, J = 11.3 Hz, 1H, benzyl-CH), 3.95 (d, J = 2.5 Hz, 1H, H-4), 3.88 – 3.69 (m, 
14H, OCH2CH2CH2OH, H-2, 3xOCH3), 3.62 – 3.59 (m, 1H), 3.63 – 3.53 (m, 3H, H-
5, H-6a-b), 3.39 (dd, J = 9.2, 2.6 Hz, 1H, H-3), 1.90 – 1.82 (p, J = 5 Hz, 2H, 
OCH2CH2CH2OH). 
13C NMR (126 MHz, CDCl3): δ = 159.50 (Ar), 134.45 (Ar), 131.45 (Ar), 130.95 (Ar), 
130.61 (Ar), 130.06 (Ar), 129.81 (Ar), 129.59 (Ar), 128.94 (Ar), 127.13 (Ar), 114.05 
(Ar), 113.99 (Ar), 113.94 (Ar), 113.77 (Ar), 88.01 (C-1), 84.85 (C-3), 77.41, 77.16, 
77.09, 76.97, 76.91, 75.32 (benzyl-CH2), 74.31 (benzyl-CH2), 73.40 (benzyl-CH2), 
72.94 (C-4), 69.53, 68.41, 61.51, 55.43, 32.78 (OCH2CH2CH2OH). 
The alcohol (233 mg, 0.337 mmol) was dissolved in dry DCM (5 mL). To the 
resulting solution, Dess-Martin periodinane (174.5 mg, 0.411 mmol) was added in 
one portion at rt with stirring under argon. After 40 min (TLC: 50% EtOAc/PE), the 
mixture was diluted with DCM (10 mL), and 4 mL of NaHCO3 satd and 250 mg of 
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Na2S2O3 pentahydrate were added. The mixture was stirred for 5 min, then it was 
transferred to a separating funnel and washed with NaHCO3 satd and brine. The 
organic phase was dried on Na2SO4, filtered and concentrated. The residue was 
chromatographed on silica (EtOAc/PE gradient) to yield 201 mg (87%) of 27. 
[α]D20 +1.00 (c 0.35, CHCl3). 
ESI-MS: m/z: Calcd for C39H44NaO9S+ [M+Na]+: 711.3, found 711.4. 
1H NMR (500 MHz, CDCl3): δ = 9.76 (t, J = 1.7 Hz, 1H, CHO), 7.54 (dd, J = 6.4, 3.1 
Hz, 2H, Ar), 7.32 (d, J = 8.6 Hz, 2H, Ar), 7.26 – 7.14 (m, 7H, Ar), 6.89 – 6.80 (m, 
6H, Ar), 4.74 (d, J = 11.2 Hz, 1H, benzyl-CH), 4.71 (d, J = 10.0 Hz, 1H, benzyl-CH), 
4.58 (d, J = 9.7 Hz, 1H, H-1), 4.55 (d, J = 10.0 Hz, 1H, benzyl-CH), 4.48 (d, J = 11.2 
Hz, 1H, benzyl-CH), 4.41 (d, J = 11.3 Hz, 1H, benzyl-CH), 4.35 (d, J = 11.3 Hz, 1H, 
benzyl-CH), 3.98 – 3.87 (m, 3H, HCOCH2CH2O, H-4), 3.81 (s, 3H, OCH3), 3.79 – 
3.85 (m, 10H, H-2, 2 OCH3), 3.61 – 3.52 (m, 3H, H-5, H-6a-b), 3.39 (dd, J = 9.2, 2.8 
Hz, 1H, H-3), 2.69 – 2.56 (m, 2H, HCOCH2CH2O). 
13C NMR (126 MHz, CDCl3): δ = 201.00 (CHO), 159.56 (Ar), 159.34 (Ar), 134.53 
(Ar), 131.56 (Ar), 131.11 (Ar), 130.73 (Ar), 130.15 (Ar), 130.08 (Ar), 129.85 (Ar), 
129.67 (Ar), 129.01 (Ar), 127.21 (Ar), 114.04 (Ar), 113.80 (Ar), 88.07 (C-1), 85.17 
(C-3), 77.51, 77.26, 77.16, 77.01, 75.38 (benzyl-CH2), 74.29 (benzyl-CH2), 73.46, 
73.24, 68.52, 64.89 (HCOCH2CH2O), 55.51, 44.43 (HCOCH2CH2O). 
 
Phenyl 3-O-(3-propynyl)-2,4,6-tri-O-(4-methoxybenzyl)-1-thio-β-D-galactopyra-
noside (28): 
PPh3 (289.4 mg, 1.10 mmol) and CBr4 were dissolved in dry DCM (4 mL) and cooled 
to 0 °C. To this mixture, a solution of compound 27 in dry DCM (5 mL) was added 
dropwise at 0 °C with stirring under argon. The mixture was stirred for 30 min at 0 
°C, then diluted with DCM and transferred to a separating funnel. The organic phase 
was washed with water. The water phase was extracted twice with DCM. The 
combined organic fractions were dried on Na2SO4, filtered and concentrated. The 
residue was chromatographed on silica (EtOAc/PE gradient) to yield 186 mg (80%) of 
the corresponding ,-dibromoalkene, according to ESI-MS analysis (ESI-MS: m/z: 
Calcd for C40H44Br2NaO8S: 867.1, found 867.2). This compound was immediately 
used for the next step. To a solution of the dibromoalkene (186 mg, 0.22 mmol) in dry 
THF (5 mL) kept under argon and cooled to -70 °C, n-BuLi (1.5 M in hexanes, 0.36 
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mL) was added dropwise. During the addition, the temperature raised to -61 °C, then 
it was kept at -70 °C for 20 min, after which it was raised to -40 - -30 °C during 25 
min. Afterwards, it was cooled again to -70 °C for ice addition (excess). The 
temperature was allowed to reach rt and the mixture was stirred for 1 h, then diluted 
with water and extracted 3 times with Et2O. The combined organic phases were dried 
on Na2SO4, filtered and evaporated. The residue was chromatographed on silica 
(EtOAc/PE gradient) to yield 134 mg (89%) of 28. 
[α]D20 +1.0 (c 0.2, CHCl3). 
ESI-MS: m/z: Calcd for C40H44NaO8S+ [M+Na]+: 707.3, found 707.4. 
1H NMR (500 MHz, CDCl3): δ = 7.56 – 7.51 (m, 2H), 7.36 – 7.31 (m, 2H), 7.26 (t, J 
= 4.3 Hz, 3H), 7.22 – 7.15 (m, 5H), 6.89 – 6.79 (m, 6H), 4.86 (d, J = 11.2 Hz, 1H, 
benzyl-CH), 4.70 (d, J = 10.0 Hz, 1H, benzyl-CH), 4.67 (d, J = 9.9 Hz, 1H, benzyl-
CH), 4.58 (d, J = 9.7 Hz, 1H, H-1), 4.53 (d, J = 11.2 Hz, 1H, benzyl-CH), 4.40 (d, J = 
11.3 Hz, 1H, benzyl-CH), 4.33 (d, J = 11.3 Hz, 1H, benzyl-CH), 3.93 (d, J = 2.7 Hz, 
1H, H-4), 3.84 – 3.81 (m, 4H, OCH3, H-2), 3.80 – 3.77 (m, 6H, 2 OCH3), 3.74 (t, J = 
6.6 Hz, 2H, HCCCH2CH2O), 3.60 – 3.51 (m, 3H, H-5, H-6a-b), 3.41 (dd, J = 9.2, 2.8 
Hz, 1H, H-3), 2.47 (td, J = 6.6, 2.6 Hz, 2H, HCCCH2CH2O), 1.97 (t, J = 2.6 Hz, 1H, 
HCCCH2CH2O). 
13C NMR (126 MHz, CDCl3): δ = 159.33 (Ar), 134.38 (Ar), 131.38 (Ar), 131.01 (Ar), 
130.62 (Ar), 129.98 (Ar), 129.60 (Ar), 128.77 (Ar), 126.96 (Ar), 113.81 (Ar), 113.58 
(Ar), 87.84 (C-1), 84.98 (C-3), 81.55 , 77.29, 77.22, 77.03, 76.96, 76.78, 75.23 
(benzyl-CH2), 73.99 (benzyl-CH2), 73.23 (benzyl-CH2), 73.01, 69.56 
(HCCCH2CH2O), 69.07 (HCCCH2CH2O), 68.46, 55.31, 20.47 (HCCCH2CH2O). 
 
4-Methoxyphenyl 3-O-(3-butynyl)-2,4,6-(4-methoxyphenyl)-α-D-galactopyrano-
syl-(14)-2,3,6-tri-O-benzoyl-β-D-galactopyranoside (30): 
Compound 28 (134 mg, 0.196 mmol), 4-methoxyphenyl 2,3,6-tri-O-benzoyl--D-
galactopyranoside (141 mg, 0.235 mmol) and NIS (48.5 mg, 0.215 mmol) were 
dissolved in dry DCM (2 mL). To this solution, dry Et2O (4 mL) was added, and the 
mixture was cooled to -55 °C under argon. TMSOTf (5 µL) was added with stirring. 
After 1h, triethylamine (0.1 mL) was added. The mixture was stirred for 1 h at -55 °C, 
then the temperature was increased to rt. The mixture was diluted with DCM, washed 
with Na2S2O3 satd and NaHCO3 satd, dried on Na2SO4, filtered and concentrated. The 
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residue was chromatographed on silica (EtOAc/PE gradient) to yield 130 mg (57%) of 
30. 
ESI-MS: m/z: Calcd for C68H68NaO18+ [M+Na]+: 1195.4, found 1195.8. 
1H NMR (500 MHz, CDCl3): δ = 8.04 – 7.99 (m, 2H, Ar), 7.95 (d, J = 7.4 Hz, 4H, 
Ar), 7.60 (t, J = 7.4 Hz, 1H, Ar), 7.52 – 7.40 (m, 4H, Ar), 7.35 (t, J = 7.8 Hz, 2H, Ar), 
7.26 (dd, J = 15.4, 7.6 Hz, 5H, Ar), 7.17 (dd, J = 8.6, 3.0 Hz, 4H, Ar), 6.98 – 6.92 (m, 
2H, Ar), 6.87 – 6.82 (m, 2H, Ar), 6.81 – 6.75 (m, 2H, Ar), 6.72 – 6.68 (m, 2H, Ar), 
6.68 – 6.63 (m, 2H, Ar), 5.96 (dd, J = 10.5, 7.8 Hz, 1H, H-2), 5.25 (dd, J = 10.6, 2.9 
Hz, 1H, H-3), 5.12 (d, J = 7.8 Hz, 1H, H-1), 4.87 – 4.71 (m, 5H, H-1’, H-6a-b, 2 
benzyl-CH), 4.62 (d, J = 11.5 Hz, 1H, benzyl-CH), 4.41 (d, J = 2.8 Hz, 1H, H-4), 4.39 
(d, J = 10.7 Hz, 1H, benzyl-CH), 4.31 (dd, J = 9.4, 5.0 Hz, 1H, H-5’), 4.14 (t, J = 6.6 
Hz, 1H, H-5), 4.08 – 4.03 (m, 2H, benzyl-CH, H-4’), 4.02 – 3.91 (m, 3H, benzyl-CH, 
H-2’, H-3’), 3.87 – 3.81 (m, 2H, HCCCH2CH2O), 3.78 (s, 3H, OCH3), 3.76 (s, 3H, 
OCH3), 3.71 (s, 3H, OCH3), 3.63 (s, 3H, OCH3), 3.36 (t, J = 8.9 Hz, 1H, H-6’b), 2.90 
(dd, J = 8.3, 4.9 Hz, 1H, H-6’a), 2.54 – 2.48 (m, 2H, HCCCH2CH2O), 1.98 (t, J = 2.6 
Hz, 1H, HCCCH2CH2O). 
13C NMR (126 MHz, CDCl3): δ = 166.47 (C=O), 166.08 (C=O), 165.33 (C=O), 
159.07 (Ar), 155.51 (Ar), 151.29 (Ar), 133.32 (Ar), 133.19 (Ar), 131.25 (Ar), 130.56 
(Ar), 130.48 (Ar), 130.01 (Ar), 129.94 (Ar), 129.84 (Ar), 129.73 (Ar), 129.66 (Ar), 
129.55 (Ar), 129.32 (Ar), 129.25 (Ar), 129.08 (Ar), 128.48 (Ar), 128.40 (Ar), 118.76 
(Ar), 114.41 (Ar), 113.70 (Ar), 113.63 (Ar), 113.57 (Ar), 113.50 (Ar), 101.43 (C-1’), 
101.01 (C-1), 81.84, 79.55, 75.73, 75.18, 74.52, 74.16, 73.60, 73.16, 72.63 (benzyl-
CH2), 69.76 (C-5’), 69.57, 69.48, 68.54 (HCCCH2CH2O), 67.13 (C-6’), 62.82 (C-6), 
55.58 (OCH3), 55.25 (OCH3), 55.06 (OCH3), 20.58 (HCCCH2CH2O). 
 
4-Methoxyphenyl 3-O-(3-butynyl)-α-D-galactopyranosyl-(14)-β-D-galactopyra-
noside (31): 
Compound 30 (116 mg, 0.099mmol) was dissolved in 9 mL of a 10 % TFA solution 
in dry DCM. After 5 min, the reaction was complete (TLC: DCM/MeOH 95:5). The 
mixture was carefully poured on excess NaHCO3 satd. The water phase was extracted 
4 times with DCM, the organic fractions were collected, dried on Na2SO4, filtered and 
concentrated. The residue was chromatographed on silica gel (DCM/MeOH gradient) 
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to yield 80 mg (quant) of the intermediate 4-methoxyphenyl 3-O-(3-butynyl)-α-D-
galactopyranosyl-2,3,6-tri-O-benzoyl-β-D-galactopyranoside. 
[α]D20 +36.5 (c 0.38, CHCl3). 
ESI-MS: m/z: Calcd for C44H44NaO15+ [M+Na]+: 835.3, found 835.3. 
1H NMR (500 MHz, CDCl3): δ = 8.09 – 8.05 (m, 2H, Ar), 8.01 – 7.95 (m, 4H, Ar), 
7.61 (t, J = 7.4 Hz, 1H, Ar), 7.57 – 7.46 (m, 4H, Ar), 7.39 (dd, J = 16.6, 8.2 Hz, 4H, 
Ar), 6.98 – 6.93 (m, 2H, Ar), 6.71 – 6.66 (m, 2H, Ar), 5.95 (dd, J = 10.6, 7.9 Hz, 1H, 
H-2), 5.35 (dd, J = 10.6, 2.9 Hz, 1H, H-3), 5.18 (d, J = 7.9 Hz, 1H, H-1), 5.09 (d, J = 
3.8 Hz, 1H, H-1’), 4.90 (dd, J = 11.4, 7.4 Hz, 1H, H-6a), 4.78 (dd, J = 11.4, 6.3 Hz, 
1H, H-6b), 4.54 (d, J = 2.8 Hz, 1H, H-4), 4.28 – 4.21 (m, 2H, H-4’, H-5), 4.12 (t, J = 
4.2 Hz, 1H, H-5’), 4.02 (dd, J = 9.9, 3.7 Hz, 1H, H-2’), 3.88 (dd, J = 9.9, 3.1 Hz, 1H, 
H-3’), 3.84 (t, J = 6.1 Hz, 2H, HCCCH2CH2O), 3.73 (s, 3H, OCH3), 3.35 (dd, J = 
11.9, 3.9 Hz, 1H, H-6’a), 3.29 (dd, J = 11.9, 5.2 Hz, 1H, H-6’b), 2.56 (td, J = 6.1, 2.0 
Hz, 2H, HCCCH2CH2O), 2.18 (t, J = 2.6 Hz, 1H, HCCCH2CH2O). 
13C NMR (126 MHz, CDCl3): δ = 166.12 (C=O), 166.04 (C=O), 165.76 (C=O), 
155.73 (Ar), 151.12 (Ar), 133.79 (Ar), 133.47 (Ar), 133.40 (Ar), 129.88 (Ar), 129.81 
(Ar), 129.73 (Ar), 129.56 (Ar), 129.18 (Ar), 128.96 (Ar), 128.68 (Ar), 128.57 (Ar), 
128.50 (Ar), 118.83 (Ar), 114.49 (Ar), 101.14 (C-1’), 100.87 (C-1), 81.90 (alkyne 
quart), 78.22 (C-3’), 74.69 (C-4), 73.73 (C-3), 72.99, 70.34 (HCCCH2CH2O), 70.05 
(C-5’), 69.54 (C-2), 68.26, 67.44 (HCCCH2CH2O), 62.79 (C-6’), 62.17 (C-6), 55.60 
(OCH3), 20.57 (HCCCH2CH2O). 
The intermediate (80 mg, 0.098 mmol) was dissolved in dry MeOH (3 mL). To the 
resulting solution, a freshly prepared 1 M NaOMe solution was added (30 µL). The 
reaction mixture was stirred for 2 h and then neutralized with Amberlyst 15, filtered 
and evaporated. The residue was chromatographed on silica (DCM/MeOH gradient) 
to yield 42 mg (85%) of 31.  
[α]D20 +13.3 (c 1.39, MeOH). 
ESI-MS: m/z: Calcd for C23H32NaO12+ [M+Na]+: 523.2, found 523.2. 
1H NMR (500 MHz, CD3OD): δ = 7.15 – 7.02 (m, 2H, Ar), 6.92 – 6.83 (m, 2H, Ar), 
5.03 (d, J = 3.9 Hz, 1H, H-1’), 4.84 (d, J = 7.6 Hz, 1H, H-1), 4.33 (t, J = 6.2 Hz, 1H, 
H-5’), 4.16 (d, J = 2.5 Hz, 1H, H-4’), 4.09 (d, J = 3.0 Hz, 1H, H-4), 3.94 – 3.87 (m, 
2H, H-2’, H-6a), 3.86 – 3.70 (m, 10H, HCCCH2CH2O, OCH3, H-2, H-6’a-b, H-5, H-
6b), 3.70 – 3.64 (m, 2H, H-3, H-3’), 2.62 – 2.47 (m, 2H, HCCCH2CH2O), 2.31 (t, J = 
2.7 Hz, 1H, HCCCH2CH2O). 
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13C NMR (126 MHz, CD3OD): δ = 156.80 (Ar), 153.00 (Ar), 119.28 (Ar), 115.55 
(Ar), 104.02 (C-1), 102.60 (C-1’), 82.18 (alkyne quart), 79.76, 79.22 (C-4), 76.30, 
74.61, 72.64, 70.69 (HCCCH2CH2O), 69.90 (C-2’), 69.25 (C-6’), 68.15 (C-4’), 62.66, 
61.01 (C-6), 56.09 (OCH3), 20.73 (HCCCH2CH2O). 
 
3-O-[2-(1-(2-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)ethyl)-1,2,3-triazol-4-
yl) ethyl]-α-D-galactopyranosyl-(14)-2,3,6-tri-O-benzoyl-β-D-galactopyranosi-
de (24g): 
Compounds 31 (8.3 mg, 0.017 mmol) and 23a (5.9 mg, 0.022 mmol) were dissolved 
in a mixture of t-BuOH (0.12 mL) and water (0.05 mL). A solution of sodium 
ascorbate in water and a solution of CuSO4 in water were successively added (0.3 and 
0.1 eq respectively). The bright yellow suspension was stirred vigorously at rt for 1 h, 
and then the mixture was chromatographed on a RP C18 column (water/ACN 
gradient) to yield 6.6 mg (51%) of 24g. 
[α]D20 +11.3 (c 0.66, MeOH). 
ESI-MS: m/z: Calcd for C34H43N6O13S+ [M+Na]+: 775.3, found 775.4. 
1H NMR (500 MHz, CD3OD): δ = 9.22 (s, 1H, Ar), 8.66 (d, J = 4.4 Hz, 1H, Ar), 8.46 
– 8.37 (m, 1H, Ar), 8.29 (d, J = 1.5 Hz, 1H, thiazole), 7.96 (s, 1H, Ar, triazole), 7.62 – 
7.52 (m, 1H, Ar), 7.13 – 7.01 (m, 2H, Ar), 6.84 (d, J = 9.0 Hz, 2H, Ar), 5.02 (d, J = 
3.9 Hz, 1H, H-1’), 4.84 (d, J = 7.6 Hz, 1H, H-1), 4.66 (t, J = 5.9 Hz, 2H, 
NCH2CH2NH), 4.29 (t, J = 6.2 Hz, 1H, H-5’), 4.14 (d, J = 2.3 Hz, 1H, H-4’), 4.08 (d, 
J = 2.9 Hz, 1H, H-4), 4.00 – 3.86 (m, 5H, OCHHCH2, H-2’, NCH2CH2NH, H-6a), 
3.85 – 3.70 (m, 9H, H-2, H-5, H-6b, H-6’a-b, OCHHCH2, OCH3), 3.66 (dd, J = 10.1, 
2.9 Hz, 1H, H-3), 3.61 (dd, J = 10.2, 3.0 Hz, 1H, H-3’), 3.01 (t, J = 6.2 Hz, 2H, 
OCH2CH2). 
13C NMR (126 MHz, CD3OD): δ = 166.12 (C=O), 163.45 (Ar), 156.75 (Ar), 153.00 
(Ar), 151.85 (Ar), 151.76 (Ar), 148.10 (Ar), 146.79 (Ar), 136.02 (Ar), 130.74 (Ar), 
126.11 (Ar), 125.76 (Ar), 124.82 (Ar), 119.21 (Ar), 115.52 (Ar), 103.95 (C-1), 102.69 
(C-1’), 101.42, 79.77 (C-3’), 79.47, 76.24, 74.65 (C-3), 72.68 (C-5’), 69.81, 69.25, 
67.72, 62.71 (C-6’), 61.12 (C-6), 56.07 (OCH3), 50.48, 40.64, 27.29 (OCH2CH2). 
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3-O-[2-(1-(3-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)propyl)-1,2,3-triazol-4-
yl) ethyl]-α-D-galactopyranosyl-(14)-2,3,6-tri-O-benzoyl-β-D-galactopyranosi-
de (24h): 
Compounds 31 (12.3 mg, 0.025 mmol) and 23b (8.5 mg, 0.029 mmol) were dissolved 
in a mixture of t-BuOH (0.12 mL) and water (0.05 mL). A solution of sodium 
ascorbate in water and a solution of CuSO4 in water were successively added (0.3 and 
0.1 eq respectively). The bright yellow suspension was stirred vigorously at rt for 1 h. 
As the azide was consumed before the alkyne, 1 mg of compound 23b was added. 
After additional 30 min the mixture was chromatographed on a RP C18 column 
(water/ACN gradient), to yield 14 mg (72%) of 24h. 
[α]D20 +12.1 (c 0.70, MeOH). 
ESI-MS: m/z: Calcd for C35H45N6O13S 789.3, found 789.4. 
1H NMR (500 MHz, CD3OD): δ = 9.26 (d, J = 1.8 Hz, 1H, Ar), 8.67 (dd, J = 4.9, 1.5 
Hz, 1H, Ar), 8.49 – 8.43 (m, 1H, Ar), 8.30 (s, 1H, thiazole), 8.01 (s, 1H, triazole), 
7.60 (dd, J = 8.0, 4.9 Hz, 1H, Ar), 7.08 – 7.00 (m, 2H, Ar), 6.86 – 6.78 (m, 2H, Ar), 
5.04 (d, J = 3.9 Hz, 1H, H-1’), 4.83 (d, J = 7.6 Hz, 1H, H-1), 4.50 (t, J = 6.8 Hz, 2H, 
NCH2CH2CH2NH), 4.31 (t, J = 6.2 Hz, 1H, H-5’), 4.15 (d, J = 2.3 Hz, 1H, H-4’), 4.09 
(d, J = 3.0 Hz, 1H, H-4), 4.02 - 3.94 (m, 2H, H-2’, OCHHCH2), 3.94 – 3.86 (m, 1H, 
H-6a), 3.83 – 3.71 (m, 9H, H-2, H-5, H-6b, H-6’ab, OCHHCH2, OCH3), 3.66 (dd, J = 
10.1, 3.0 Hz, 1H, H-3), 3.63 (dd, J = 10.2, 3.0 Hz, 1H, H-3’), 3.50 (t, J = 6.6 Hz, 2H, 
NCH2CH2CH2NH), 2.99 (t, J = 6.3 Hz, 2H, OCH2CH2), 2.27 (p, J = 6.7 Hz, 2H, 
NCH2CH2CH2NH). 
13C NMR (126 MHz, CD3OD): δ = 166.06 (Ar), 163.37 (Ar), 156.71 (Ar), 152.96 
(Ar), 152.01 (Ar), 151.83 (Ar), 148.12 (Ar), 146.73 (Ar), 136.02 (Ar), 130.76 (Ar), 
125.83 (Ar), 125.73 (Ar), 124.62 (Ar), 119.19 (Ar), 115.49 (Ar), 103.94 (C-1), 102.67 
(C-1’), 79.73 (C-3’), 79.37 (C-4), 76.22, 74.63, 72.69, 69.82, 69.13, 67.70 (C-4’), 
62.68, 61.07, 56.04 (OCH3), 37.83 (NHCH2CH2CH2), 31.10 (NHCH2CH2CH2), 27.29 
(CH2CH2O). 
 
3-O-[2-(1-(4-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)butyl)-1,2,3-triazol-4-
yl) ethyl]-α-D-galactopyranosyl-(14)-2,3,6-tri-O-benzoyl-β-D-galactopyranosi-
de (24i): 
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Compounds 31 (10.1 mg, 0.020 mmol) and 23c (9.1 mg, 0.030 mmol) were dissolved 
in a mixture of t-BuOH (0.12 mL) and water (0.05 mL). A solution of sodium 
ascorbate in water and a solution of CuSO4 in water were successively added (0.3 and 
0.1 eq respectively). The bright yellow suspension was stirred vigorously at rt for 40 
min, and then the mixture was chromatographed on a RP C18 column (water/ACN 
gradient) to yield 7.7 mg (47.5%) of 24i. 
[α]D20 +12.2 (c 0.77, MeOH). 
ESI-MS: m/z: Calcd for C36H46N6NaO13S+ [M+Na]+: 825.3, found 825.4. 
1H NMR (500 MHz, CD3OD): δ = 9.25 (s, 1H, Ar), 8.67 (d, J = 4.3 Hz, 1H, Ar), 8.46 
(dt, J = 8.0, 1.7 Hz, 1H, Ar), 8.29 (s, 1H, thiazole), 7.96 (s, 1H, triazole), 7.59 (dd, J = 
8.0, 4.9 Hz, 1H, Ar), 7.10 – 7.00 (m, 2H, Ar), 6.88 – 6.79 (m, 2H, Ar), 5.03 (d, J = 3.9 
Hz, 1H, H-1’), 4.83 (d, J = 7.6 Hz, 1H, H-1), 4.45 (t, J = 7.0 Hz, 2H, 
NCH2CH2CH2CH2NH), 4.31 (t, J = 6.1 Hz, 1H, H-5’), 4.17 (d, J = 2.4 Hz, 1H, H-4’), 
4.08 (d, J = 2.9 Hz, 1H, H-4), 4.00 (dt, J = 9.4, 6.1 Hz, 1H, OCHHCH2), 3.95 (dd, J = 
10.2, 3.9 Hz, 1H, H-2’), 3.90 (dd, J = 10.7, 6.8 Hz, 1H, H-6a), 3.84 – 3.70 (m, 9H, H-
2, H-5, H-6b, H-6’a-b, OCH3, OCHHCH2), 3.68 – 3.62 (m, 2H, H-3, H-3’), 3.48 (t, J 
= 6.9 Hz, 2H, NCH2CH2CH2CH2NH), 3.02 (t, J = 6.2 Hz, 2H, OCH2CH2), 2.06 – 1.92 
(m, 2H, NCH2CH2CH2CH2NH), 1.73 – 1.56 (m, 2H, NCH2CH2CH2CH2NH). 
13C NMR (126 MHz, CD3OD): δ = 166.10 (C=O), 163.30 (C=O), 156.75 (Ar), 152.99 
(Ar), 152.22 (Ar), 151.81 (Ar), 148.13 (Ar), 146.76 (Ar), 136.03 (Ar), 125.74 (Ar), 
125.68 (Ar), 124.38 (Ar), 119.23 (Ar), 115.52 (Ar), 103.98 (C-1), 102.69 (C-1’), 
101.41, 79.75, 79.40 (C-4), 76.25, 74.65, 72.67 (C-5’), 69.83 (C-2’), 69.15 
(OCH2CH2), 67.71 (C-4’), 62.71 (C-6’), 61.10 (C-6), 56.06 (OCH3), 50.89 
(NCH2CH2CH2CH2NH), 39.71 (NCH2CH2CH2CH2NH), 28.68 
(NCH2CH2CH2CH2NH), 27.61 (NCH2CH2CH2CH2NH), 27.31 (OCH2CH2). 
 
4-Methoxyphenyl 2,4,6-tri-O-acetyl-3-O-allyl-α-D-galactopyranosyl-(14)-2,3,6-
tri-O-benzoyl-β-D-galactopyranoside (32): Ref. [S7]. 
 
 
4-Methoxyphenyl 2,4,6-tri-O-acetyl-3-O-carbonylmethyl-α-D-galactopyranosyl-
(14)-2,3,6-tri-O-benzoyl-β-D-galactopyranoside (33): 
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To a solution of compound 32 (349 mg, 0.377 mmol) in dioxane (2.6 mL) were added 
water (0.86 mL), 2,6-lutidine (0.088 mL, 0.753 mmol), OsO4 (2.5% in t-BuOH, 0.235 
mL, 0.0190 mmol), and NaIO4 (330.2 mg, 1.544 mmol). The dense, white suspension 
was stirred at rt under argon and monitored by TLC. After 8 h, NaIO4 (110 mg 0.514 
mmol) and water (0.2 µL) were added. After overnight stirring, NaIO4 (53 mg 0.25 
mmol) was added. After further 5 h, water (20 mL) and DCM (50 mL) were added. 
The organic layer was separated, and the water layer was extracted three times with 
DCM. The combined organic layers were dried over Na2SO4, filtered, and evaporated. 
The residue was chromatographed on silica (5:2:3 PE/DCM/EtOAc  EtOAc) to 
yield 33 (246 mg, 70%). 
[α]D20 +40.4 (c 0.45, CHCl3). 
ESI-MS: m/z: Calcd for C48H48NaO19+ [M+Na]+: 951.3, found 951.4. 
1H NMR (500 MHz, CDCl3): δ = 9.63 (s, 1H, CHO), 8.09 – 8.04 (m, 2H, Ar), 7.98 – 
7.93 (m, 4H, Ar), 7.63 (t, J = 7.4 Hz, 1H, Ar), 7.55 – 7.45 (m, 4H, Ar), 7.38 (dd, J = 
14.8, 7.5 Hz, 4H, Ar), 6.99 – 6.95 (m, 2H, Ar), 6.71 – 6.66 (m, 2H, Ar), 5.95 (dd, J = 
10.6, 7.8 Hz, 1H, H-2), 5.52 (d, J = 1.9 Hz, 1H, H-4’), 5.35 (dd, J = 10.6, 2.9 Hz, 1H, 
H-3), 5.25 – 5.15 (m, 3H, H-1, H-1’, H-2’), 4.82 (dd, J = 11.3, 7.7 Hz, 1H, H-6a), 
4.59 – 4.51 (m, 2H, H-6b, H-5’), 4.49 (d, J = 2.6 Hz, 1H, H-4), 4.32 (d, J = 17.5 Hz, 
1H, HCOCHHO), 4.27 – 4.20 (m, 1H, H-5), 4.16 (d, J = 16.4 Hz, 1H, HCOCHHO), 
4.09 (dd, J = 10.5, 3.2 Hz, 1H, H-3’), 3.88 (dd, J = 10.9, 8.1 Hz, 1H, H-6’a), 3.73 (s, 
3H, ArOCH3), 3.57 (dd, J = 10.9, 5.9 Hz, 1H, H-6’b), 2.20 (s, 3H, Ac), 2.09 (s, 3H, 
Ac), 1.91 (s, 3H, Ac). 
13C NMR (126 MHz, CD3OD): δ = 199.56 (CHO), 170.77 (C=O), 170.45 (C=O), 
170.28 (C=O), 166.38 (C=O), 166.16 (C=O), 165.62 (C=O), 155.88 (Ar), 151.24 
(Ar), 133.89 (Ar), 133.68 (Ar), 133.58 (Ar), 130.02 (Ar), 129.92 (Ar), 129.83 (Ar), 
128.83 (Ar), 128.76 (Ar), 128.65 (Ar), 118.91 (Ar), 114.64 (Ar), 101.24 (C-1), 99.05 
(C-1’), 75.96 (C-4), 75.31 (HCOCH2), 74.76 (C-3’), 73.71 (C-3), 72.95 (C-5), 69.99 
(C-2’), 69.45 (C-2), 67.64 (C-5’), 66.72 (C-4’), 62.64 (C-6), 61.02 (C-6’), 55.73 
(ArOCH3), 21.10 (Ac), 20.85 (Ac), 20.72 (Ac). 
 
3-O-{2-[(4-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)butyl)amino]-ethyl}-α-D-
galactopyranosyl-(14)-2,3,6-tri-O-benzoyl-β-D-galactopyranoside (34c): 
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Compounds 32 (20 mg, 0.022 mmol) and 22c (18.5 mg, 0.067 mmol) were dissolved 
in MeOH and NaBH3CN (1 M in THF, 0.03 µL, 0.03 mmol) was added at rt with 
stirring, followed by 0.033 µL of AcOH. A mixture of products formed, among which 
also partial deprotection products. The mixture was evaporated after 1 h, and then re-
dissolved in dry MeOH (1 mL). To this solution, 1 M MeONa in MeOH was added 
until pH > 10. The mixture was stirred overnight, then neutralized with AcOH and 
evaporated. The residue was purified by column chromatography on silica 
(DCM/MeOH/water/NH4OH, 80:30:5:1). The silica was pre-washed extensively with 
this mixture before chromatography. As this procedure did not eliminate all 
impurities, the collected fractions were re-purified by RP on C18 column (water/ACN 
gradient). The product 34c was isolated in 26% overall yield (4.2 mg). 
[α]D20 +12.3 (c 0.42, MeOH). 
ESI-MS: m/z: Calcd for C34H47N4O13S+ [M]+: 751.3, found 751.4. 
1H NMR (500 MHz, CD3OD): δ = 9.36 (s, 1H, Ar), 8.89 – 8.69 (m, 1H, Ar), 8.58 (t, J 
= 8.5 Hz, 1H, Ar), 8.35 (s, 1H, thiazole), 7.73 (s, 1H, Ar), 7.10 – 7.03 (m, 2H, Ar), 
6.89 – 6.80 (m, 2H, Ar), 5.05 (d, J = 3.9 Hz, 1H, H-1’), 4.85 (d, J = 7.5 Hz, 1H, H-1), 
4.38 (t, J = 6.1 Hz, 1H, H-5’), 4.20 (d, J = 2.6 Hz, 1H, H-4’), 4.10 (d, J = 2.9 Hz, 1H, 
H-4), 4.04 – 3.94 (m, 2H, OCHHCH2, H-2’), 3.92 – 3.64 (m, 12H, H-2, H-3, H-5, H-
6a-b, H-3’, H-6’a-b, OCHHCH2, OCH3), 3.53 (t, J = 6.1 Hz, 2H, 
CONHCH2CH2CH2CH2NH), 3.31 – 3.24 (m, 2H, OCH2CH2NH), 3.22 – 3.13 (m, 2H, 
NHCH2CH2CH2CH2NH), 1.89 – 1.85 (m, 4H, NHCH2CH2CH2CH2NH). 
13C NMR (126 MHz, CD3OD): δ = 165.63 (C=O), 163.45 (C=O), 156.78 (Ar), 152.99 
(Ar), 152.16 (Ar), 150.62 (Ar), 146.98 (Ar), 137.28 (Ar), 126.25 (Ar), 119.10 (Ar), 
115.54 (Ar), 103.95 (C-1), 102.14 (C-1’), 101.40, 79.86, 78.86 (C-4), 76.37, 74.47, 
72.62, 72.14 (C-5’), 69.98 (C-2’), 68.00 (C-4’), 64.96 (OCH2CH2), 62.43 (C-6’), 
61.01 (C-6), 56.07 (OCH3), 49.00 (OCH2CH2NH), 48.40 (NHCH2CH2CH2CH2NH), 
39.42 (CONHCH2CH2CH2CH2NH), 27.76, 24.56. 
 
N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-2-(pyridin-3-yl)thiazole-4-carboxamide 
(36): 
Compound 33 (66.0 mg, 0.282 mmol) was dissolved in dry DMF (0.1 mL) and 2,2’-
(ethylenedioxy)bis(ethylamine) (0.1 mL) and the mixture was heated at 70 °C under 
argon with stirring for 45 min. The solvents were evaporated and the residue was 
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purified on silica (DCM/MeOH/H2O/NH4OH, 80:20:2.5:1) yielding 36 (50.0 mg, 
53%).  
ESI-MS: m/z: Calcd for C15H21N4O3S+ [M]+: 337.1, found 337.0. 
1H NMR (500 MHz, CD3OD): δ = 9.24 (dd, J = 2.2, 0.6 Hz, 1H, py), 8.68 (dd, J = 
4.9, 1.5 Hz, 1H, py), 8.47 – 8.42 (m, 1H, py), 8.31 (s, 1H, thiazole), 7.60 (ddd, J = 
8.0, 4.9, 0.7 Hz, 1H, py), 3.77 – 3.70 (m, 4H), 3.70 – 3.62 (m, 4H), 3.57 (t, J = 5.3 Hz, 
2H), 2.82 (t, J = 5.3 Hz, 2H). 
13C NMR (126 MHz, CD3OD): δ = 166.10 (C=O), 163.17 (Ar), 152.10 (Ar), 151.85 
(Ar), 148.05 (Ar), 135.92 (Ar), 130.71 (Ar), 125.72 (Ar), 125.69 (Ar), 72.69, 71.37, 
71.35, 70.59, 41.89 and 40.29 (CH2NH2 and CONHCH2). 
 
3-O-(1-Oxo-1-(2-(pyridin-3-yl)thiazol-4-yl)-5,8-dioxa-2,11-diazatridecan-13-yl)-α-
D-galactopyranosyl-(14)-β-D-galactopyranoside (37): 
Compounds 33 (24.8 mg, 0.027 mmol) and 36 (13.9 mg, 0.041 mmol) were dissolved 
in DCE. NaBH(OAc)3 (7.9 mg, 0.037 mmol) was added and the mixture was stirred at 
rt under argon for 2 h (TLC: 9:1 DCM/MeOH). Afterwards, the reaction mixture was 
applied to a silica column and chromatographed with DCM/MeOH gradient, to yield 
22.2 mg of protected product (67%, slightly contaminated with some byproducts), 
which was used immediately in the next step. 22 mg (0.018 mmol) of the intermediate 
were dissolved in dry MeOH (0.5 mL) under argon. To this mixture, 10 µL of 1 M 
MeONa were added with stirring. After 2 h, 10 additional µL of 1 M MeONa were 
added. After a total of 4 h reaction time, the mixture was neutralized with AcOH and 
evaporated. The residue was applied to a RP C-18 column and chromatographed 
(water/ACN + 0.1% TFA gradient) to yield 15.8 mg (97%) of 38. 
[α]D20 +9.2 (c 0.79, MeOH). 
ESI-MS: m/z: Calcd for C36H51N4O15S+ [M]+: 811.3, found 811.4. 
1H NMR (500 MHz, CD3OD): δ = 9.34 (s, 1H, Ar), 8.75 (s, 1H, Ar), 8.58 (d, J = 8.1 
Hz, 1H, Ar), 8.37 (s, 1H, thaizole), 7.73 (dd, J = 8.0, 5.1 Hz, 1H, Ar), 7.11 – 6.99 (m, 
2H, Ar), 6.90 – 6.81 (m, 2H, Ar), 5.05 (d, J = 3.9 Hz, 1H, H-1’), 4.86 (d, J = 7.5 Hz, 
1H, H-1), 4.36 (t, J = 6.1 Hz, 1H, H-5’), 4.18 (d, J = 2.6 Hz, 1H, H-4’), 4.10 (d, J = 
3.0 Hz, 1H, H-4), 4.03 – 3.98 (m, 1H, OCHHCH2), 3.97 (dd, J = 10.2, 3.9 Hz, 1H, H-
2’), 3.92 – 3.63 (m, 22H, H-2, H-3, H-3’, H-5, H-6a-b, H6’a-b, 4xOCH2, 
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pyranoseOCHHCH2, OCH3), 3.40 – 3.34 (m, 1H, pyranoseOCH2CHHNH), 3.32 – 
3.25 (m, 5H, pyranoseOCH2CHHNH, CH2NHCH2). 
13C NMR (126 MHz, CD3OD): δ = 165.55, 163.30, 156.77, 152.99, 152.18, 150.46, 
146.81, 137.56, 126.34, 119.09, 115.55, 103.94 (C-1), 102.23 (C-1’), 79.91, 79.04 (C-
4), 76.36, 74.50, 72.64, 72.21 (C-5’), 71.50, 71.38, 70.67, 69.95 (C-2’), 68.02 (C-4’), 
66.89, 64.97, 62.47 (C-6’), 61.05 (C-6), 56.07 (OCH3), 40.29. 
 
6-Azido-1-bromohexane (40): 
Preparation of the triflyl azide stock solution: To a solution of sodium azide (545 mg, 
8.38 mmol) in water (1.37 mL) was added toluene (1.37 mL). The mixture was cooled 
to 0 °C with vigorous stirring. After dropwise addition of triflyc anhydride (896 µL, 
4.19 mmol) and further vigorous stirring for 30 min at 0 °C, the temperature was 
raised to 10 °C and the biphasic mixture was stirred for another 2 h. A saturated 
aqueous solution of sodium hydrogencarbonate was added dropwise until gas 
evolution ceased. The two phases were separated and the aqueous layer was extracted 
with toluene (2 x 1.37 mL). The combined organic layers were used in the subsequent 
diazo transfer reactions. 
 
Diazo Transfer: The amine, 6-amino-1-hexanol (50 mg, 0.43 mmol), sodium 
hydrogencarbonate (143.4 mg, 1.71 mmol) and copper(II) sulfate pentahydrate (4.3 
mg, 0.02 mmol) were dissolved in water (0.6 mL). Triflic azide stock solution (2 M, 1 
mL) was added, followed by the addition of methanol (3.9 mL) to yield a 
homogeneous system. Subsequently, the blue mixture was stirred vigorously at rt for 
15 min. The solvents were removed in vacuo with a rotary evaporator keeping the 
temperature strictly below 30 °C. The residue was purified by chromatography on 
silica gel (gradient PE/EtOAc) to yield 54 mg of the azido alcohol (88%). 
The product was dissolved in DCM (1 mL) and added dropwise to a cooled solution 
(0 °C) of CBr4 (150 mg, 0.45 mmol) and PPh3 (98.9 mg, 0.38 mmol) in DCM (4 mL). 
The solution was stirred at 0 °C for 1 h, then evaporated (bath at 30 °C). The residue 
was purified on silica (PE/Et2O, gradient 5% to 15%) to yield 57 mg (73 %) of 40. 
1H NMR (500 MHz, CDCl3): δ = 3.41 (t, J = 6.7 Hz, 2H), 3.28 (t, J = 6.9 Hz, 2H), 
1.96 – 1.79 (m, 2H), 1.62 (m, 2H), 1.53 – 1.35 (m, 4H).  
13C NMR (126 MHz, CDCl3): δ = 51.33, 33.64, 32.56, 28.70, 27.69, 25.91. 
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3-O-(6-Azidohexanyl)-α-D-galactopyranosyl-(14)-β-D-galactopyranoside (41): 
Compound 16 (24 mg, 0.032 mmol) was dissolved in toluene (2 mL) and degassed 
with ultrasound under light vacuum. Bu2SnO (9 mg, 0.038 mmol) was added and the 
mixture was stirred under argon at reflux for 2 h, with azeotropic removal of water. 
The residual toluene was evaporated and the white solid was dried under high vacuum 
for 1 h. It was then dissolved in a solution of 40 (57 mg) in dry toluene (0.5 mL) 
under argon. The resulting mixture was stirred for 2 d at 75 °C under argon in a sealed 
flask. Afterwards, the solution was cooled to rt and applied to a silica column. It was 
eluted with a DCM/MeOH gradient to yield 13 mg (47%) of the 2,3,6-tri-O-benzoyl 
protected intermediate. The latter was dissolved in dry MeOH (0.5 mL). To the 
resulting solution, 5 µL of a freshly prepared solution of 1 M MeONa in MeOH were 
added. The mixture was stirred at rt under argon for 5 h, before the solvent was 
evaporated. The residue was purified on silica (DCM/MeOH gradient) to yield 13.7 
mg of 41 (85%). 
[α]D20 +12.7 (c 1.05, MeOH). 
ESI-MS: m/z: Calcd for C25H39N3NaO12+ [M+Na]+: 596.2, found 596.3. 
1H NMR (500 MHz, CDCl3): δ = 6.98 (d, J = 9.0 Hz, 2H), 6.78 (d, J = 9.1 Hz, 2H), 
5.11 (d, J = 2.5 Hz, 1H, H-1’), 4.74 (d, J = 7.5 Hz, 1H, H-1), 4.60 – 4.40 (m, 1H, H-
5’, 1 OH), 4.21 (m, 2H, 2 OH), 4.12 (s, 1H, H-4), 4.02 (m, 2H, H-4’, H-2’), 3.96 – 
3.86 (m, 2H, H-6a, H-5), 3.84 – 3.71 (m, 7H, OCH3, H-6’a, H-6b, H-2), 3.71 – 3.54 
(m, 3H, H-6’b, H-3, H-3’), 3.48 (m, 1H, OCHH(CH2)5N3), 3.32 (s, 1H, 4’-OH), 3.24 
(t, J = 6.8 Hz, 2H, O(CH2)5CH2N3), 1.64 – 1.52 (m, 4H), 1.45 – 1.31 (m, 4H). 
13C NMR (126 MHz, CDCl3): δ = 155.40 (Ar), 151.30 (Ar), 118.42 (Ar), 114.56 (Ar), 
102.60 (C-1’), 101.39 (C-1), 79.92 (C-4), 77.72 (C-3’), 73.66, 73.54, 72.00, 71.70, 
69.86 (OCH2(CH2)5N3), 68.30, 67.06, 62.32, 60.07, 55.61 (OCH3), 51.33 (CH2N3), 
29.68, 28.70, 26.48, 25.50. 
 
3-O-(6-(((2-(3-Pyridyl)-thiazol-4-yl)carbonyl)amino)-hex-6-yl-α-D-galactopyra-
nosyl-(14)-β-D-galactopyranoside (43): 
Compound 41 (13.7 mg, 0.024 mmol) was dissolved in 0.5 mL of MeOH under 
argon. To this solution, Pd/C (10%, 6 mg) was added. The mixture was hydrogenated 
(1 bar H2) for 40 min, afterwards it was diluted with MeOH and filtered through a 
PTFE filter (0.45 µm). The filtrate was concentrated under reduced pressure, to afford 
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12.7 mg of the amine compound. A mixture of HBTU (13 mg, 0.035 mmol), HOBt 
(9.4 mg, 0.061 mmol) and 42 (7.2 mg, 0.035 mmol) was dissolved in dry DMF (0.5 
mL) under argon. After shaking for 10 min, this solution was added to the amine 
compound under argon. To this solution was added DIPEA (12 µL, 0.023 mmol). 
Solvents were removed under vacuum after 1.5 h. The residue was purified on silica 
gel (DCM/MeOH gradient). The fractions containing the product were further 
purified by RP C-18 column (water/ACN gradient) to afford 43 (10 mg, 59%). 
[α]D20 +12.5 (c 0.5, MeOH). 
ESI-MS: m/z: Calcd for C34H46N3O13S+ [M+Na]+: 736.3, found 736.4. 
1H NMR (500 MHz, CD3OD): δ = 9.25 (d, J = 2.0 Hz, 1H, pyridine-H-1), 8.67 (dd, J 
= 4.9, 1.3 Hz, 1H, pyridine-H-5), 8.45 (dt, J = 8.0, 1.8 Hz, 1H, pyridine-H-3), 8.29 (s, 
1H, thiazole-CH), 7.59 (dd, J = 8.0, 4.9 Hz, 1H, pyridine-H-4), 7.13 – 7.02 (m, 2H, 2 
x phenyl-CH), 6.89 – 6.79 (m, 2H, 2 x phenyl-CH), 5.02 (d, J = 3.9 Hz, 1H, H-1’), 
4.84 (d, J = 7.6 Hz, 1H, H-1), 4.31 (t, J = 6.2 Hz, 1H, H-5’), 4.14 (d, J = 2.6 Hz, 1H, 
H-4’), 4.08 (d, J = 3.0 Hz, 1H, H-4), 3.94 – 3.86 (m, 2H, H-6a, H-2’), 3.84 – 3.69 (m, 
9H, OCH3, H-2, H-5, H-6b, H-6’a, H-6’b, OCHH(CH2)5N), 3.66 (dd, J = 10.1, 3.0 
Hz, 1H, H-3), 3.62 – 3.55 (m, 2H, H-3’, OCHH(CH2)5N), 3.46 (t, J = 7.1 Hz, 2H, 
CONH(CH2) ), 1.75 – 1.63 (m, 4H, OCH2CH2(CH2)2CH2CH2N), 1.56 – 1.40 (m, 4H, 
O(CH2)2CH2CH2(CH2)2N). 
13C NMR (126 MHz, CD3OD): δ = 166.07 (C=O), 163.17 (Ar), 156.78 (Ar), 152.99 
(Ar), 152.37 (Ar), 151.80 (Ar), 148.12 (Ar), 136.03 (Ar), 130.85 (Ar), 125.73 (Ar), 
125.53 (Ar), 119.27 (Ar), 115.52 (Ar), 104.01 (C-1), 102.70 (C-1’), 79.46, 79.19 (C-
4), 76.28, 74.64 (C-3), 72.74, 72.64, 70.71 (OCH2(CH2)5N), 69.91 (C-2’), 67.94 (C-
4’), 62.71 (C-2’), 60.98 (C-6), 56.07 (OCH3), 40.47, 30.89 
(OCH2CH2(CH2)2CH2CH2N), 30.61 (OCH2CH2(CH2)2CH2CH2N), 27.89 
(O(CH2)2CH2CH2(CH2)2N), 26.84 (O(CH2)2CH2CH2(CH2)2N). 
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Carbohydrate–Lectin Interactions: An unexpected contribution to affinity 
 
 
This paper describes the study of the interaction of PapG-II with the carbohydrate 
epitopes of sialyl galactosyl globoside (SGG), globotetraosylceramide (GbO4), and 
with the glycomimetic 4-methoxyphenyl β-galabiose (4). The SGG epitope bears a 
Neu5Ac(2-3)Gal(1-3) extension at the non-reducing end and exhibits a 5-fold 
increase in affinity in respect to the GbO4 epitope. As the additional disaccharide 
moiety lies outside the known PapG-II binding pocket, the superior binding was 
unexpected. By studying crystal structures, thermodynamic fingerprints, and solution 
conformations, an unanticipated entropy-driven contribution to the binding was 
identified.  
 
 
Contribution to the project: 
Giulio Navarra synthesized compound 4, interpreted the results from isothermal 
titration calorimetry (ITC), the crystal structures, the molecular dynamics simulation, 
and wrote the manuscript, with the exception of the supporting information on ITC, 
on protein expression, and on crystallography. 
 
 
This paper was published in ChemBioChem: 
Giulio Navarra, Pascal Zihlmann, Roman P. Jakob, K. Stangier, Roland C. Preston, 
Said Rabbani, Martin Smiesko, Bea Wagner, Timm Maier, and Beat Ernst 
 
Reprinted with permission from Navarra et al. ChemBioChem 2017, 18, 539-544.  
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Carbohydrate–Lectin Interactions: An Unexpected
Contribution to Affinity
Giulio Navarra,[a] Pascal Zihlmann,[a] Roman P. Jakob,[b] Katja Stangier,[a] Roland C. Preston,[a]
Said Rabbani,[a] Martin Smiesko,[a] Bea Wagner,[a] Timm Maier,[b] and Beat Ernst*[a]
Introduction
In numerous bacterial infections, adhesins mediate interactions
with host cells and thereby function as important virulence
factors.[1] In this process, glycans (as parts of glycoproteins or
glycolipids) on host cell surfaces function as ligands for bacteri-
al adhesins.[2,3] A classical example is the fimbrial adhesin FimH
of uropathogenic Escherichia coli (UPEC), which binds to and
infects urothelial cells, a process initiat ing urinary tract infec-
tions (UTI).[4] When UPEC strains cause infections in the upper
urinary tract, they take advantage of an additional adhesin,
PapG, which exists in three molecular variants (classes I–III)[5–9]
classified according to their slightly different agglutinat ion pat-
terns.[7,8] The PapG-II variant is of particular medical interest
because of its strong associat ion with pyelonephritis in
humans,[10–13] a potentially life-threatening disease and a fre-
quent complication during pregnancy.[14] In addition, there is
evidence of the involvement of PapG-II in bacteremia.[15] PapG-
II preferentially binds to the globoside GbO4,[16] which is pres-
ent in the human upper urinary tract. Its binding epitope is
the tetrasaccharide 1, which consists of a galabiose core
(Gala(1–4)Gal) flanked by a b(1–3)-linked N-acetyl glucosamine
residue on the nonreducing and a b(1–4)-linked glucose resi-
due on the reducing end.[11] Stapleton et al. reported increased
affinity for the natural sialosyl galactosyl globoside (SGG),
which bears the P blood group antigen Neu5Aca(2–3)Galb(1–
3)GalNAcb(1–3)Gala(1–4)Galb(1–4)Glc (SSEA4, 2).[17] Individuals
expressing SGG in the urinary tract are more susceptible to
recurrent UTI. Clinical isolates from such individuals exhibit in-
creased numbers of bacteria expressing the pap genes, which
encode PapG proteins.[17]
The current treatment of pyelonephritis with antibiotics[18]
has become increasingly inefficacious because of antibiotic re-
sistance.[18–20] Therefore, new therapeut ic options are of urgent
importance. A promising new strategy to prevent colonizat ion
of the kidneys is blocking the initial bacterial adhesion mediat-
ed by PapG-II by using soluble antagonists (antiadhesive thera-
py). As such, PapG-II antagonists are not bactericidal and there-
fore do not exert any selection pressure, and the probability of
developing resistance is minimized.[21]
Despite detailed structural knowledge of the PapG-II lectin
domain (apo form: PDB ID 1J8S; co-crystallized with epitope
1 of GbO4: PDB ID 1J8R),[22] the design of small-molecule an-
tagonists has been only partly successful. One possible reason
is the extended hydrogen-bond network that is indispensable
for binding of the central galabiose. Structural modifications
disrupted this network, thereby resulting in substantial reduc-
tion in affinity.[23–29]
The goal of the present work was to answer questions re-
garding the individual contributions to binding of the various
monosaccharide moieties of tetrasaccharide 1, hexasaccharide
2, and the p-methoxyphenyl aglycone in antagonist 4. Further-
more, the question why almost identical affinities were report-
ed for 1 and trisaccharide 3 was addressed (Scheme 1).
Uropathogenic E. coli exploit PapG-II adhesin for infecting host
cells of the kidney; the expression of PapG-II at the tip of bac-
terial pili correlates with the onset of pyelonephritis in
humans, a potentially life-threatening condition. It was envis-
aged that blocking PapG-II (and thus bacterial adhesion)
would provide a viable therapeut ic alternative to conventional
antibiotic treatment. In our search for potent PapG-II antago-
nists, we observed an increase in affinity when tetrasaccharide
1, the natural ligand of PapG-II in human kidneys, was elongat-
ed to hexasaccharide 2, even though the additional Siaa(2–
3)Gal extension is not in direct contact with the lectin. ITC
studies suggest that the increased affinity results from partial
desolvation of nonbinding regions of the hexasaccharide; this
is ultimately responsible for perturbation of the outer hydra-
tion layers. Our results are in agreement with previous obser-
vations and suggest a general mechanism for modulating car-
bohydrate–protein interactions based on nonbinding regions
of the ligand.
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